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SCIENTIFIC OPINION  
Scientific Opinion on Flavouring Group Evaluation 25, Revision 2 
(FGE.25Rev2): 
Aliphatic and aromatic hydrocarbons from chemical group 311 
EFSA Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids 
(CEF)2, 3  
European Food Safety Authority (EFSA), Parma, Italy 
ABSTRACT 
The Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids of the European 
Food Safety Authority was requested to evaluate 37 flavouring substances in the Flavouring Group 
Evaluation 25, Revision 2, using the Procedure in Commission Regulation (EC) No 1565/2000. None 
of the substances were considered to have genotoxic potential. The substances were evaluated through 
a stepwise approach (the Procedure) that integrates information on structure-activity relationships, 
intake from current uses, toxicological threshold of concern, and available data on metabolism and 
toxicity. The Panel concluded that the ten substances [FL-no: 01.001, 01.027, 01.028, 01.033, 01.034, 
01.038, 01.039, 01.046, 01.054 and 01.057] do not give rise to safety concerns at their levels of 
dietary intake, estimated on the basis of the MSDI approach. For the remaining 27 candidate 
substances [FL-no: 01.021, 01.022, 01.023, 01.030, 01.031, 01.032, 01.035, 01.036, 01.037, 01.042, 
01.043, 01.044, 01.047, 01.050, 01.051, 01.052, 01.053, 01.055, 01.056, 01.058, 01.059, 01.060, 
01.064, 01.066, 01.067, 01.070 and 10.078] no appropriate NOAEL was available and additional data 
are required. Besides the safety assessment of these flavouring substances, the specifications for the 
materials of commerce have also been considered. For five substances, the composition of the 
stereoisomeric mixture has to be specified further.  
© European Food Safety Authority, 2011 
                                                     
 
1  On request from the Commission, Question No EFSA-Q-2010-01558, adopted on 19 May 2011. 
2  Panel members Arturo Anadon, Mona-Lise Binderup, Wilfried Bursch, Laurence Castle, Riccardo Crebelli, Karl-Heinz 
Engel, Roland Franz, Nathalie Gontard, Thomas Haertle, Trine Husøy, Klaus-Dieter Jany, Catherine Leclercq, Jean Claude 
Lhuguenot, Wim Mennes, Maria Rosaria Milana, Karla Pfaff, Kettil Svensson, Fidel Toldra, Rosemary Waring, Detlef 
Wölfle. cef-unit@efsa.europa.eu   
3  Acknowledgement: The Panel wishes to thank the members of the Working Groups on Flavourings for the preparation of 
this Opinion: Ulla Beckman Sundh, Vibe Beltoft, Wilfried Bursch, Angelo Carere, Riccardo Crebelli, Karl-Heinz Engel, 
Henrik Frandsen, Rainer Gürtler, Frances Hill, Trine Husøy, John Christian Larsen, Catherine Leclercq, Pia Lund, Wim 
Mennes, Gerard Mulder, Karin Nørby, Gerard Pascal, Iona Pratt, Gerrit Speijers, Harriet Wallin and EFSA’s staff member 
Kim Rygaard Nielsen for the preparatory work on this scientific Opinion. 
 
Flavouring Group Evaluation 25, Revision 2
 
 
2 EFSA Journal 2011; 9(6):2177 
SUMMARY  
The European Food Safety Authority (EFSA) asked the Panel on Food Contact Materials, Enzymes, 
Flavourings and Processing Aids (the Panel) to advise the Commission on the implications for human 
health of chemically defined flavouring substances used in or on foodstuffs in the Member States. In 
particular, the Panel was requested to evaluate 37 flavouring substances in the Flavouring Group 
Evaluation 25, Revision 2 (FGE.25Rev2), using the Procedure as referred to in the Commission 
Regulation (EC) No 1565/2000. These 37 flavouring substances belong to chemical group 31, Annex I 
of the Commission Regulation (EC) No 1565/2000. 
The 37 candidate substances are aliphatic and aromatic hydrocarbons, which have been divided into 
eight subgroups: I) acyclic alkanes, II) acyclic alkenes, III) cyclohexene hydrocarbons, IVa) benzene 
hydrocarbons, IVb) napthalene hydrocarbons, IVc) diphenylmethane, V) bi- and tricyclic, non-
aromatic hydrocarbons and VI) macrocyclic, non-aromatic hydrocarbons. 
Several of the 37 flavouring substances possess chiral centres and/or can exist as geometrical isomers. 
For five of the flavouring substances [FL-no: 01.021, 01.027, 01.032, 01.035 and 01.078] 
the stereoisomeric composition/composition of mixture has not been specified sufficiently. 
Thirty-one of the 37 candidate substances belongs to structural class I, two belongs to structural class 
II and four to structural class III according to the decision tree approach presented by Cramer et al. 
(1978). 
Thirty-three out of the 37 candidate substances have been reported to occur naturally in a wide range 
of food items. 
In its evaluation, the Panel as a default used the “Maximised Survey-derived Daily Intake” (MSDI) 
approach to estimate the per capita intakes of the flavouring substances in Europe. However, when the 
Panel examined the information provided by the European Flavouring Industry on the use levels in 
various foods, it appeared obvious that the MSDI approach in a number of cases would grossly 
underestimate the intake by regular consumers of products flavoured at the use level reported by the 
Industry, especially in those cases where the annual production values were reported to be small. In 
consequence, the Panel had reservations about the data on use and use levels provided and the intake 
estimates obtained by the MSDI approach.  
In the absence of more precise information that would enable the Panel to make a more realistic 
estimate of the intakes of the flavouring substances, the Panel has decided also to perform an estimate 
of the daily intakes per person using a “modified Theoretical Added Maximum Daily Intake” 
(mTAMDI) approach based on the normal use levels reported by Industry. In those cases where the 
mTAMDI approach indicated that the intake of a flavouring substance might exceed its corresponding 
threshold of concern, the Panel decided not to carry out a formal safety assessment using the 
Procedure. In these cases the Panel requires more precise data on use and use levels. 
According to the default MSDI approach, 35 of the 37 flavouring substances in this group have intakes 
in Europe from 0.0012 to 28 microgram/capita/day, which are below the threshold of concern value 
for structural class I (1800 microgram/person/day), structural class II (540 microgram/person/day) and 
structural class III (90 microgram/person/day) substances. For limonene [FL-no: 01.001] and l-
limonene [FL-no: 01.046] the intakes are 4000 and 2100 microgram/capita/day, which are above the 
threshold of concern value for structural class I (1800 microgram/person/day). 
Combined intakes can be calculated for the substances in subgroup I (acyclic alkanes) and subgroup 
III (cyclohexene hydrocarbons) evaluated through the Procedure. 
For subgroup I (acyclic alkanes), the combined intake of the five candidate substances, all from 
structural class I and evaluated via the A-side of the Procedure (Annex I), is 3.0 
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microgram/capita/day, which does not exceed the threshold of 1800 microgram/person/day. There are 
no supporting substances in subgroup I. 
For subgroup III (cyclohexene hydrocarbons), the combined intake of the five candidate substances, 
all from structural class I and evaluated via the A-side of the Procedure (Annex I), is 6100 
microgram/capita/day, which exceeds the threshold of 1800 microgram/person/day. The total 
combined intake of the candidate and six supporting substances (also from structural class I) is 42000 
microgram/capita/day. This intake exceeds the threshold of 1800 microgram/person/day for a 
structural class I substance. However, limonene [FL-no: 01.001], l-limonene [FL-no: 01.046] and d-
limonene (supporting substance [FL-no: 01.045]) accounts for approximately 40000 
microgram/capita/day. The total combined intake of 42000 microgram/capita/day for the candidate 
and the supporting substances corresponds to 700 microgram/kg bw/day for a person with a body 
weight of 60 kg. Thus, based on the NOAEL for d-limonene of 215 mg/kg bw/day, a margin of safety 
of 307 can be calculated, and accordingly these substances are not expected to be of safety concern at 
the estimated level of intake. 
Data on the genotoxicity of the flavouring substances in this group are limited and the genotoxicity 
could not be assessed adequately for these substances. For one structurally related substance, 2-
methylbuta-1,3-diene, there is evidence of an in vivo genotoxic and carcinogenic potential. However, 
the Panel concluded that the available data do not preclude an evaluation of the 37 candidate 
substances using the Procedure.  
The available information on metabolism of the 37 candidate substances evaluated through the 
Procedure or the supporting substances for this FGE was very limited. Overall, only for 10 candidate 
substances it can be concluded that they will be metabolised into innocuous metabolites, [FL-no: 
01.033, 01.034, 01.038, 01.054 and 01.057] from subgroup I and [FL-no: 0.001, 01.027, 01.028, 
01.039 and 01.046] from subgroup III. For six candidate substances [FL-no: 01.037, 01.050, 01.051, 
01.053, 01.164 and 01.070] there are data, which show that they may be metabolised to toxic 
metabolites. For the remaining 21 candidate substances [FL-no: 0.021, 01.022, 01.023, 01.030, 
01.031, 01.032, 01.035, 01.036, 01.042, 01.043, 01.044, 01.047, 01.052, 01.055, 01.056, 01.058, 
01.059, 01.060, 01.066, 01.067 and 01.078], the information is too limited and it cannot be assumed 
that they are metabolised to innocuous metabolites. 
It was noted that where toxicity data were available they were consistent with the conclusions in the 
present flavouring group evaluation using the Procedure. 
It is concluded that the 10 candidate substances which are expected to be metabolised to innocuous 
substances, [FL-no: 01.033, 01.034, 01.038, 01.054 and 01.057] from subgroup I and [FL-no: 01.001, 
01.027, 01.028, 01.039 and 01.046] from subgroup III, would not give rise to safety concerns at their 
estimated intakes arising from their use as flavouring substances based on the MSDI approach. For the 
remaining 27 candidate substances, [FL-no: 01.021, 01.022, 01.023, 01.030, 01.031, 01.032, 01.035, 
01.036, 01.037, 01.042, 01.043, 01.044, 01.047, 01.050, 01.051, 01.052, 01.053, 01.055, 01.056, 
01.058, 01.059, 01.060, 01.064, 01.066, 01.067, 01.070 and 01.078], or for astructurally related 
supporting substances, no adequate NOAELs were available. Therefore, additional toxicological data 
are required. 
The mTAMDI values for the 27 candidate substances from structural class I, for which use levels have 
been provided are in the range of 3100 to 3900 microgram/person/day. For each of the two candidate 
substances from structural class II and the four candidate substances from structural class III the 
mTAMDI is 3900 microgram/person/day. These values are above the threshold for structural class I, II 
and III of 1800, 540 and 90 microgram/person/day, respectively.  
Accordingly, intake estimates according to the mTAMDI for the 33 candidate substances for which 
use levels have been provided exceed the thresholds of concern for the three structural classes, and 
more reliable exposure data are requested. On the basis of such additional data, the flavouring 
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substances should be considered using the Procedure. Subsequently, additional data might become 
necessary. For the four remaining candidate substances [FL-no: 01.001, 01.046, 01.070 and 01.078] 
use levels for food categories as outlined in Commission Regulation (EC) no 1565/2000, Annex III, 
are required. 
In order to determine whether this conclusion could be applied to the materials of commerce, it is 
necessary to consider the available specifications. Specifications including complete purity criteria and 
identity for the materials of commerce have been provided for 32 flavouring substances. For five 
substances [FL-no: 01.021, 01.027, 01.032, 01.035 and 01.078] information on stereoisomeric 
composition/composition of mixture has not been specified sufficiently. 
Thus, overall, for 27 candidate substances [FL-no: 01.021, 01.022, 01.023, 01.030, 01.031, 01.032, 
01.035, 01.036, 01.037, 01.042, 01.043, 01.044, 01.047, 01.050, 01.051, 01.052, 01.053, 01.055, 
01.056, 01.058, 01.059, 01.060, 01.064, 01.066, 01.067, 01.070 and 10.078] additional toxicity data 
are required. For four of these, [FL-no: 01.021, 01.032, 01.035 and 01.078], additional information on 
composition requested. The final evaluation of the materials of commerce cannot be performed for one 
substance [FL-no: 01.027], pending further information on composition of mixture of stereoisomers.  
For nine candidate substances [FL-no: 01.001, 01.028, 01.033, 01.034, 01.038, 01.039, 01.046, 01.054 
and 01.057] the Panel concluded that they would present no safety concern at their estimated levels of 
intake based on the MSDI approach. 
KEYWORDS 
Hydrocarbons, aliphatic, alicyclic, aromatic, flavourings, safety, FGE.25, FGE.78 
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BACKGROUND 
Regulation (EC) No 2232/96 of the European Parliament and the Council (EC, 1996a) lays down a 
Procedure for the establishment of a list of flavouring substances the use of which will be authorised 
to the exclusion of all other substances in the EU. In application of that Regulation, a Register of 
flavouring substances used in or on foodstuffs in the Member States was adopted by Commission 
Decision 1999/217/EC (EC, 1999a), as last amended by Commission Decision 2008/163/EC (EC, 
2009a). Each flavouring substance is attributed a FLAVIS-number (FL-number) and all substances are 
divided into 34 chemical groups. Substances within a group should have some metabolic and 
biological behaviour in common. 
Substances which are listed in the Register are to be evaluated according to the evaluation programme 
laid down in Commission Regulation (EC) No 1565/2000 (EC, 2000a), which is broadly based on the 
Opinion of the Scientific Committee on Food (SCF, 1999a). For the submission of data by the 
manufacturer, deadlines have been established by Commission Regulation (EC) No 622/2002 (EC, 
2002b).  
The FGE is revised to include substances for which data were submitted after the deadline as laid 
down in Commission Regulation (EC) No 622/2002 and to take into account additional information 
that has been made available since the previous Opinion on this FGE.  
The Revision also includes newly notified substances belonging to the same chemical groups 
evaluated in this FGE. 
After the completion of the evaluation programme the Union List of flavouring substances for use in 
or on foods in the EU shall be adopted (Article 5 (1) of Regulation (EC) No 2232/96) (EC, 1996a). 
HISTORY OF THE EVALUATION 
FGE Opinion 
Adopted by 
EFSA 
Link No. of 
Candidate 
Substances 
FGE.25 1 April 2008 http://www.efsa.europa.eu/EFSA/efsa_locale-
1178620753812_1211902222647.htm 
32 
FGE.25Rev1 23 September 2009 http://www.efsa.europa.eu/en/scdocs/scdoc/1334.htm 34 
FGE.25Rev2 18 May 2011  37 
 
The present Revision of FGE.25, FGE.25Rev2, includes the assessment of three additional candidate 
substances [FL-no: 01.001, 01.021 and 01.046]. No toxicity or metabolism data were provided for 
these three substances. A survey in open literature did not result in further data. 
Since the publication of FGE.25Rev1 new tonnage data for [FL-no: 01.035, 01.047 and 01.064] have 
become available (Flavour Industry, 2010a), which have been included in this revision.  
Industry has also submitted additional information on stereoisomeric composition [FL-no: 01.027, 
01.032, 01.034, 01.035, 01.050, 01.055, 01.056 and 01.060], composition of mixture [FL-no: 01.078] 
and missing ID-tests [FL-no: 01.078]. 
In the FGE.25 and FGE.25Rev1, the Panel considered that additional toxicity data were needed for 26 
of the substances evaluated through the Procedure as no adequate toxicity study from which a NOAEL 
could be established was available, neither on the candidate substances nor on supporting substances. 
Additional toxicity and genotoxicity data have now become available for the supporting substance 
beta-myrcene [FL-no: 01.008].  
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Additional genotoxicity data have also now become available for one of the 26 substances [FL-no: 
01.047] and on cedrene washed (unspecified cedrene).  
The present revision of FGE.25, FGE.25Rev2 includes the evaluation of these data submitted by the 
Industry.  
2-Methylbuta-1,3-diene [former FL-no: 01.049] was evaluated in FGE.25. For this substance the Panel 
concluded that it showed genotoxic potential in vivo and carcinogenic effects in experimental animals 
(IARC has also concluded that the substance is “possibly carcinogenic to humans” (group 2B) (IARC, 
1999a). Therefore, this substance could not be evaluated through the Procedure and could not be 
considered safe when used as a chemically defined flavouring substance. Subsequently, the substance 
has been deleted from the Register (EC, 2008a). 
TERMS OF REFERENCE 
The European Food Safety Authority (EFSA) is requested to carry out a risk assessment on flavouring 
substances in the Register prior to their authorisation and inclusion in a Union List according to 
Commission Regulation (EC) No 1565/2000 (EC, 2000a). In addition, the Commission requested 
EFSA to evaluate newly notified flavouring substances, where possible, before finalising the 
evaluation programme. 
In addition, in letter of 10 February 2010 the Commission requested EFSA to carry out a re-evaluation 
of flavouring substances α-cedrene [FL-no: 01.022], 2,6-dimethylocta-2,4,6-triene [FL-no: 01.035], 
longifolene [FL-no: 01.047] and cis-3,7-dimethyl-1,3,6-octatriene [FL-no: 01.064] based on additional 
toxicity data on β-myrcene [FL-no: 01.008]: 
“The European Commission requests the European Food Safety Authority to carry out a safety 
assessment on β-myrcene [FL-no: 01.008], α-cedrene [FL-no: 01.022], 2,6-dimethylocta-2,4,6-triene 
[FL-no: 01.035], longifolene [FL-no: 01.047] and cis-3,7-dimethyl-1,3,6-octatriene [FL-no: 01.064]    
in accordance with Commission Regulation (EC) No 1565/2000, by end 2010”.   
The deadline of the Terms of Reference was negotiated to end 2014. 
ASSESSMENT 
1. Presentation of the Substances in Flavouring Group Evaluation 25, Revision 2 
1.1. Description 
The present Flavouring Group Evaluation 25, Revision 2 (FGE.25Rev2) using the Procedure as 
referred to in the Commission Regulation (EC) No 1565/2000 (EC, 2000a) (The Procedure – shown in 
schematic form in Annex I of this FGE), deals with 37 aliphatic and aromatic hydrocarbons (candidate 
substances) from chemical group 31, Annex I of Commission Regulation (EC) No 1565/2000 (EC, 
2000a). The candidate substances in the group have been divided into eight subgroups: I) acyclic 
alkanes, II) acyclic alkenes, III) cyclohexene hydrocarbons, IVa) benzene hydrocarbons, IVb) 
naphthalene hydrocarbons, IVc) diphenylmethane, V) bi- and tricyclic, non-aromatic hydrocarbons 
and VI) macrocyclic, non-aromatic hydrocarbons. 
One flavouring substance, 2-methylbuta-1,3-diene [former FL-no: 01.049] evaluated in FGE.25 has 
been deleted from the Register of flavouring substances as it showed genotoxic potential in vivo and 
carcinogenic effects in experimental animals. Therefore this substance will not be further discussed as 
a candidate substance in the current Revision 2 of FGE.25 (FGE.25Rev2). 
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The 37 candidate substances under consideration, with their chemical Register names, FLAVIS - (FL-
), Chemical Abstract Service- (CAS-), Council of Europe- (CoE-) and Flavor and Extract 
Manufacturers Association- (FEMA-) numbers, structure and specifications, are listed in Table 1. 
A summery of the safety evaluation of the candidate substances under consideration in the present 
evaluation are listed in Table 2 and the supporting substances are listed in Table 3. 
The 37 candidate substances are closely related structurally to 19 flavouring substances (supporting 
substances) evaluated at the 63rd JECFA meeting (JECFA, 2005c) in the groups of “Aliphatic and 
alicyclic hydrocarbons” and “Aromatic hydrocarbons”. The supporting substances are listed in Table 
3. 
1.2. Stereoisomers 
It is recognised that geometrical and optical isomers of substances may have different properties. Their 
flavour may be different, they may have different chemical properties resulting in possible variability 
in their absorption, distribution, metabolism, elimination and toxicity. Thus information must be 
provided on the configuration of the flavouring substance, i.e. whether it is one of the 
geometrical/optical isomers, or a defined mixture of stereoisomers. The available specifications of 
purity will be considered in order to determine whether the safety evaluation carried out for candidate 
substances for which stereoisomers may exist can be applied to the material of commerce. Flavouring 
substances with different configurations should have individual chemical names and codes (CAS 
number, FLAVIS number etc.). 
Twenty-one of the 37 candidate substances possess chiral centres. For fifteen of these chiral 
substances the chemical names and CAS numbers specify the stereoisomers. For six of the substances 
[FL-no: 01.027, 01.034, 01.050, 01.055, 01.056 and 01.060] the stereoisomeric composition has been 
specified (EFFA, 2010a). However, for one substance [FL-no: 01.021] Industry has informed that it 
exist as a mixture of isomers (EFFA, 2011c). However, the Panel does not consider this information 
sufficient and requests data on the actual ratio (see Table 1). 
Due to the presence and the position of double bonds several of the 37 candidate substances can exist 
as geometrical isomers. For four of these flavouring substances [FL-no: 01.027, 01.032, 01.035 and 
01.078] Industry has informed that they exist as a mixture of isomers (EFFA, 2010a). However, the 
Panel does not consider this information sufficient and requests data on the actual ratios (see Table 1). 
1.3. Natural Occurrence in Food 
Thirty-three out of the 37 candidate substances have been reported to occur in various types of 
alcoholic beverages, chicken, egg (boiled), fish (raw), shrimps, guinea hen, lamb fat, cheese, milk, 
butter, various herbs, various fruits and vegetables, tea, mace and wort. Quantitative data on the 
natural occurrence in foods have been reported for 26 of these substances (TNO, 2000; TNO, 2010). 
These reports include: 
• Limonene [FL-no: 01.001]: up to 1.6 mg/kg in carrot, up to 0.3 in black currants, up to 1.4 
mg/kg in tea and very high content in citrus oil. 
• delta-Cadinene [FL-no: 01.021]: 1000 mg/kg in citrus fruits, 8000 mg/kg in ginger (EFFA, 
2005a). 
• alpha-Cedrene [FL-no: 01.022]: 0.0007 mg/kg in artichoke. 
• 1(5),11-Guaiadiene [FL-no: 01.023]: 1.5 mg/kg in mango, trace amounts in basil and in 
pepper.  
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• beta-Bisabolene [FL-no: 01.028]: 33.3 mg/kg in parsley, up to 1.18 mg/kg in carrot, 0.003 
mg/kg in artichoke, 0.0003 mg/kg in guava fruit, trace amounts in mace and in nutmeg. 
• beta-Cubebene [FL-no: 01.030]: 0.08 mg/kg in grapefruit juice, up to 0.08 mg/kg in guava 
fruit, trace amounts in mace and in nutmeg. 
• 1,2-Dihydro-1,1,6-trimethylnaphthalene [FL-no: 01.031]: 0.25 mg/kg in rum, up to 0.042 
mg/kg in white wine.  
• 2,2-Dimethylhexane [FL-no: 01.033]: up to 0.9 mg/kg in tea. 
• 2,4-Dimethylhexane [FL-no: 01.034]: up to 2 mg/kg in tea. 
• 2,6-Dimethylocta-2,4,6-triene [FL-no: 01.035]: 0.45 mg/kg in mango, 0.03 mg/kg in orange 
juice, up to 0.08 mg/kg in blackcurrants, trace amounts in sage.  
• Dodec-1-ene [FL-no: 01.037]: up to 0.4 mg/kg in butter, up to 0.01 mg/kg in loquat, up to 
0.01 mg/kg in passiflora. 
• Dodecane [FL-no: 01.038]: up to 3.5 mg/kg in butter, up to 0.1 mg/kg in passiflora, 0.1 mg/kg 
in beans, 0.1 mg/kg in cocoa, 0.1 mg/kg in tea, up to 0.1 mg/kg in lamb, 0.08 mg/kg in dill, up 
to 0.05 mg/kg in strawberry, 0.02 mg/kg in chicken, up to 0.01 mg/kg in loquat, up to 0.01 
mg/kg in papaya, 0.01 mg/kg in pea, up to 0.004 mg/kg in egg, 0.009 mg/kg in Guinea hen, 
0.0006 mg/kg in raw fish, trace amounts in liquorice. 
• delta-Elemene [FL-no: 01.039]: trace amounts in mandarin juice. 
• Germacra-1(10),4(14),5-triene [FL-no: 01.042]: 0.001 mg/kg in mandarin juice. 
• 3,7,10-Humulatriene [FL-no: 01.043]: up to 1.3 mg/kg in mango, up to 1.2 mg/kg in tea, up to 
1.05 mg/kg in guava, 0.12 mg/kg in carrot, up to 0.12 in cheese, 0.2 mg/kg in grapefruit juice, 
up to 0.09 mg/kg in blackcurrants, 0.02 mg/kg in tamarind, up to 0.01 mg/kg in orange juice, 
up to 0.0002 mg/kg in artichoke, 0.0004 mg/kg in mandarin, trace amounts in nutmeg, in 
raspberry and in celery. 
• Longifolene [FL-no: 01.047]: 0.0003 mg/kg in artichoke. 
• 2-Methylnaphthalene [FL-no: 01.051]: 0.1 mg/kg in tea, 0.08 mg/kg in capsicum, up to 0.05 
mg/kg in raspberry, up to 0.01 mg/kg in papaya, up to 0.01 mg/kg in passiflora, trace amounts 
in port wine.  
• alpha-Muurolene [FL-no: 01.052]: 7.9 mg/kg in green tea, up to 0.009 mg/kg in mango, 0.005 
mg/kg in bilberry, trace amounts in nutmeg. 
• Naphthalene [FL-no: 01.053]: 0.1 mg/kg in tea, up to 0.06 mg/kg in capsicum annum (sweet 
pepper), 0.05 mg/kg in cocoa, up to 0.035 mg/kg in cheese, 0.02 mg/kg in raw fish, 0.02 
mg/kg in beer, 0.01 mg/kg in grapefruit juice, up to 0.01 mg/kg in passiflora, up to 0.01 mg/kg 
in papaya, 0.008 mg/kg in soybean, up to 0.007 mg/kg in plumcot, 0.005 mg/kg in peanut, 
0.005 mg/kg in peas, up to 0.005 mg/kg in plum, 0.005 mg/kg in bilberry, up to 0.005 mg/kg 
in raspberry, 0.004 mg/kg in water buffalo milk, 0.003 mg/kg in beans, 0.0029 mg/kg in skim 
milk powder, 0.001 mg/kg in kiwifruit, up to 0.001 mg/kg in mango, up to 0.0005 mg/kg in 
chicken, 0.0008 mg/kg in shrimps, trace amounts in peach, trace amounts in port wine.  
• Pentadecane [FL-no: 01.054]: up to 2.3 mg/kg in butter, up to 0.4 mg/kg in mango, up to 
0.346 mg/kg in cheese, 0.1 mg/kg in chicken, 0.1 mg/kg in tea, up to 0.05 mg/kg in 
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strawberry, up to 0.03 mg/kg in raw fish, 0.029 mg/kg in Guinea hen, up to 0.02 mg/kg in egg 
(boiled), 0.014 mg/kg in milk powder, up to 0.01 mg/kg in papaya, 0.02 mg/kg in tamarind, 
0.00001 mg/kg in aubergine, trace amounts in liquorice. 
• beta-Phellandrene [FL-no: 01.055]: up to 85 mg/kg in dill, up to 0.66 mg/kg in tea, up to 0.5 
mg/kg in black currants, up to 0.4 mg/kg in mango, up to 0.1 mg/kg in papaya, 0.025 mg/kg in 
grapefruit juice, up to 0.01 mg/kg in passiflora, up to 0.005 mg/kg in plumcot, up to 0.002 
mg/kg in redcurrants, trace amounts in cinnamon, trace amounts in nectarine. 
• Tetradecane [FL-no: 01.057]: up to 1.9 mg/kg in butter, 0.3 mg/kg in liquorice, up to 0.3 
mg/kg in mango, up to 0.3 mg/kg in dill, 0.021 mg/kg in guinea hen, up to 0.15 mg/kg in 
cheese, 0.1 mg/kg in cocoa, 0.1 mg/kg in tea, 0.088 mg/kg in passiflora, up to 0.05 mg/kg in 
strawberry, up to 0.01 mg/kg in papaya, up to 0.003 mg/kg in egg, 0.001 mg/kg in milk 
0.0005 mg/kg in chicken, 0.0008 mg/kg in raw fish, trace amounts in thymus, aubergine, 
coconut and lamb. 
• 4(10)-Thujene [FL-no: 01.059]: Up to 1000 mg/kg in caraway seed (oil), up to 1.9 mg/kg in 
blackcurrant, up to 5.2 mg/kg in carrot, up to 49000 mg/kg in cardamom (oil), up to 4000 
mg/kg in coriander seed (oil), up to 4800 mg/kg in cumin seed (oil), 239000 mg/kg in pepper 
(oil) (different species), 334000 mg/kg in ginger (oil), up to 87600 mg/kg in laurel (oil), up to 
510000 mg/kg in nutmeg (oil).  
• 1,1,7-Trimethyltricyclo[2.2.1.0.(2,6)]heptane [FL-no: 01.060]: up to 50 mg/kg in pepper, trace 
amounts in cardamom. 
• cis-3,7-Dimethyl-1,3,6-octatriene [FL-no: 01.064]: up to 13.6 mg/kg in guava fruit, up to 7.5 
mg/kg in mango, 5.3 mg/kg in celery, 2.7 mg/kg in parsley, 2 mg/kg in dill, up to 0.6 mg/kg in 
tea, up to 0.5 mg/kg in papaya, up to 0.2 mg/kg in blackcurrant, 0.18 mg/kg in grapefruit, 0.05 
mg/kg in cocoa, up to 0.01 mg/kg in passiflora, trace amounts in nectarine. 
• 1-Octene [FL-no: 07.070]: up to 0.009 mg/kg in butter (1.7 mg/kg in heated butter), up to 
0.001 mg/kg in boiled egg, 0.002 mg/kg in guinea hen. 
According to TNO four of the substances, bisabola-1,8,12-triene [FL-no: 01.027], l-limonene [FL-no: 
01.046], 2-cedrene [FL-no: 01.066], and 8(14)-cedrene [FL-no: 01.067] have not been reported to 
occur naturally in any food items (TNO, 2000; TNO, 2011). 
2. Specifications 
Purity criteria for the 37 substances have been provided by the Flavour Industry (EFFA, 2005a; EFFA, 
2006o; EFFA, 2006p; Flavour Industry, 2006t; Flavour Industry, 2009t) (see Table 1). 
Judged against the requirements in Annex II of Commission Regulation (EC) No 1565/2000 (EC, 
2000a), this information is adequate for 32 candidate substances. Further information on 
stereoisomeric composition/composition of mixture is needed for five substances [FL-no: 01.021, 
01.027, 01.032, 01.035 and 01.078] (see Section 1.2 and Table 1). 
3. Intake Data 
Annual production volumes of the flavouring substances as surveyed by the Industry can be used to 
calculate the “Maximised Survey-derived Daily Intake” (MSDI) by assuming that the production 
figure only represents 60 % of the use in food due to underreporting and that 10 % of the total EU 
population are consumers (SCF, 1999a). 
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However, the Panel noted that due to year-to-year variability in production volumes, to uncertainties 
in the underreporting correction factor and to uncertainties in the percentage of consumers, the 
reliability of intake estimates on the basis of the MSDI approach is difficult to assess. 
The Panel also noted that in contrast to the generally low per capita intake figures estimated on the 
basis of this MSDI approach, in some cases the regular consumption of products flavoured at use 
levels reported by the Flavour Industry in the submissions would result in much higher intakes. In 
such cases, the human exposure thresholds below which exposures are not considered to present a 
safety concern might be exceeded. 
Considering that the MSDI model may underestimate the intake of flavouring substances by certain 
groups of consumers, the SCF recommended also taking into account the results of other intake 
assessments (SCF, 1999a). 
One of the alternatives is the “Theoretical Added Maximum Daily Intake” (TAMDI) approach, which 
is calculated on the basis of standard portions and upper use levels (SCF, 1995) for flavourable 
beverages and foods in general, with exceptional levels for particular foods. This method is regarded 
as a conservative estimate of the actual intake by most consumers because it is based on the 
assumption that the consumer regularly eats and drinks several food products containing the same 
flavouring substance at the upper use level. 
One option to modify the TAMDI approach is to base the calculation on normal rather than upper use 
levels of the flavouring substances. This modified approach is less conservative (e.g., it may 
underestimate the intake of consumers being loyal to products flavoured at the maximum use levels 
reported) (EC, 2000a). However, it is considered as a suitable tool to screen and prioritise the 
flavouring substances according to the need for refined intake data (EFSA, 2004a). 
3.1. Estimated Daily per Capita Intake (MSDI Approach) 
The intake estimation is based on the Maximised Survey-derived Daily Intake (MSDI) approach, 
which involves the acquisition of data on the amounts used in food as flavourings (SCF, 1999a). These 
data are derived from surveys on annual production volumes in Europe. These surveys were conducted 
in 1995 by the International Organization of the Flavour Industry, in which flavour manufacturers 
reported the total amount of each flavouring substance incorporated into food sold in the EU during 
the previous year (IOFI, 1995). The intake approach does not consider the possible natural occurrence 
in food. 
Average per capita intake (MSDI) is estimated on the assumption that the amount added to food is 
consumed by 10 % of the population4 (Eurostat, 1998). This is derived for candidate substances from 
estimates of annual volume of production provided by Industry and incorporates a correction factor of 
0.6 to allow for incomplete reporting (60 %) in the Industry surveys (SCF, 1999a). 
In the present FGE.25Rev2 the total annual production volume of the 37 candidate substances from 
use as flavouring substances in Europe was reported to be approximately 51000 kg (EFFA, 2005a; 
EFFA, 2005b; EFFA, 2006o; EFFA, 2006p; EFFA, 2008b; Flavour Industry, 2006t). For the 19 
supporting substances the total annual volume of production in Europe is approximately 330000 kg. d-
limonene [FL-no: 01.045] accounts for 280000 kg and 47000 kg is accounted for by seven other 
supporting substances: [FL-no: 01.003, 01.004, 01.005, 01.006, 01.007, 01.008 and 01.020] (JECFA, 
2005c).  
                                                     
 
4 EU figure 375 millions. This figure relates to EU population at the time for which production data are available, and is 
consistent (comparable) with evaluations conducted prior to the enlargement of the EU. No production data are available for 
the enlarged EU. 
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On the basis of the annual volumes of production reported for the 37 candidate substances, the MSDI 
values for each of these flavourings have been estimated (Table 2).  
Nearly 100 % of the total annual volume of production for the candidate substances is accounted for 
by two substances [FL-no: 01.001 and 01.046]. The estimated daily per capita intake from use as 
flavouring substance is 4000 and 2100 microgram, respectively. The daily per capita intakes for each 
of the remaining substances are less than 28 microgram (Table 2). 
3.2. Intake Estimated on the Basis of the Modified TAMDI (mTAMDI) 
The method for calculation of modified Theoretical Added Maximum Daily Intake (mTAMDI) values 
is based on the approach used by SCF up to 1995 (SCF, 1995). 
The assumption is that a person may consume a certain amount of flavourable foods and beverages per 
day. 
For 33 of the 37 candidate substances information on food categories and normal and maximum use 
levels5,6 were submitted by the Flavour Industry (EFFA, 2005a; EFFA, 2006o; EFFA, 2007a). Thirty-
three of the 37 candidate substances are used in flavoured food products divided into the food 
categories, outlined in Annex III of the Commission Regulation (EC) No 1565/2000 (EC, 2000a), as 
shown in Table 3.1. For three candidate substances no use levels have been submitted [FL-no: 01.001, 
01.046 and 01.070] and for one substances [FL-no: 01.078] the use levels reported have not been in 
accordance with the food categories outlined in Annex III of the above mentioned Commission 
Regulation. For this reason these substances have been included in Table 3.1 as “no data for [FL-no: 
01.001, 01.046, 01.078 and 01.070]”. For the present calculation of mTAMDI, the reported normal 
use levels were used. In the case where different use levels were reported for different food categories 
the highest reported normal use level was used. 
Table 3.1 Use of Candidate Substances 
Food 
categor
y 
Description Flavourings used* 
01.0 Dairy products, excluding products of category 2 33 
02.0 Fats and oils, and fat emulsions (type water-in-oil) 33 
03.0 Edible ices, including sherbet and sorbet 33 
04.1 Processed fruits 33 
04.2 Processed vegetables (incl. mushrooms & fungi, roots & tubers, 
pulses and legumes), and nuts & seeds 
None of the 33 
05.0 Confectionery 33 
06.0 Cereals and cereal products, incl. flours & starches from roots & 
tubers, pulses & legumes, excluding bakery 
33 
07.0 Bakery wares 33 
08.0 Meat and meat products, including poultry and game 33 
09.0 Fish and fish products, including molluscs, crustaceans and 
echinoderms  
33 
10.0 Eggs and egg products None of the 33 
11.0 Sweeteners, including honey None of the 33 
12.0 Salts, spices, soups, sauces, salads, protein products etc. 33 
13.0 Foodstuffs intended for particular nutritional uses 33 
14.1 Non-alcoholic ("soft") beverages, excl. dairy products 33 
14.2 Alcoholic beverages, incl. alcohol-free and low-alcoholic 33 
                                                     
 
5 ”Normal use” is defined as the average of reported usages and ”maximum use” is defined as the 95th percentile of reported 
usages (EFFA, 2002i). 
6 The normal and maximum use levels in different food categories (EC, 2000) have been extrapolated from figures derived 
from 12 model flavouring substances (EFFA, 2004e). 
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Table 3.1 Use of Candidate Substances 
Food 
categor
y 
Description Flavourings used* 
counterparts 
15.0 Ready-to-eat savouries 32 (except [FL-no: 01.044]) 
16.0 Composite foods (e.g. casseroles, meat pies, mincemeat) - foods that 
could not be placed in categories 1 – 15 
33 
*Information on use levels has not been provided for for of the 37 [FL-no: 01.001, 01.046, 01.070 and 01.078]. 
According to the Flavour Industry the normal use levels for the 33 candidate substances, for which use 
levels have been provided, are in the range of 2 - 20 mg/kg food, and the maximum use levels are in 
the range of 10 - 100 mg/kg (EFFA, 2002i; EFFA, 2005a; EFFA, 2006o; EFFA, 2007a) Table II.1.2, 
Annex II. 
The mTAMDI values for the 27 candidate substances from structural class I (see Section 5) and for 
which use levels were provided, are for [FL-no: 01.059] 3100 microgram/person/day, for [FL-no: 
01.044] 3500 microgram/person/day and 3900 microgram/person/day for each of the remaining 25 
candidate substances. For each of the two candidate substances from structural class II and  three 
candidate substances from structural class III (see Section 5) the mTAMDI is 3900 
microgram/person/day. 
For detailed information on use levels and intake estimations based on the mTAMDI approach, see 
Section 6 and Annex II. 
4. Absorption, Distribution, Metabolism and Elimination 
Generally, the available data indicate that the aliphatic and aromatic hydrocarbons may participate in 
similar metabolic pathways. Being lipophilic and of relatively low molecular weight, these 
hydrocarbons may be assumed to be absorbed in the gastrointestinal tract. Subsequently, they can be 
oxidised to polar oxygenated metabolites, e.g. by CYP-450 enzymes. The phase I metabolites can then 
be conjugated and excreted mainly in the urine. The candidate and supporting substances are expected 
to be metabolised either by side chain oxidation or epoxidation of the exocyclic or endocyclic double 
bonds. Alkyl oxidation initially yields hydroxylated metabolites that may be excreted in conjugated 
form or undergo further oxidation, yielding more polar metabolites, which can also be excreted. If a 
double bond is present, intermediate epoxide metabolites may be formed, which are transformed either 
by hydrolysis to yield diols or by conjugation with glutathione to yield mercapturic acid derivatives. 
For the naphthalene hydrocarbons, in addition to epoxidation, formation of reactive quinones can be 
expected. The aromatic hydrocarbons that do not contain alkyl substituents can undergo ring 
hydroxylation to form phenolic metabolites that are subsequently conjugated with sulphate or 
glucuronic acid and excreted in the urine. The saturated alkanes in this group may be anticipated to be 
metabolised via omega and omega-1, -2, -3 or -4 oxidation. Whereas omega oxidation would 
ultimately lead to the formation of carboxylic acids, the other oxidations would give rise to secondary 
alcohols and ketones. The carboxylic acids may be expected to participate in the endogenous fatty acid 
metabolism. 
However, for most of the eight subgroups (see Section 1.1 and Annex III) the information available 
was scarce and the similarity between candidate and supporting substances was limited. In addition, 
proper mass balance data were not available. The few mass balance data available indicated only slow 
elimination. For several subgroups no data were available at all. In Table 4.1 the final conclusion for 
each of the candidate substances have been presented together with a brief explanatory statement. For 
subgroup III there are only data for one supporting substance, d-limonene [FL-no: 01.045], which is 
oxidised in both side chains to yield alcohols and carboxylic acids, which may be conjugated and 
eliminated in the urine. 
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For more detailed information, see Annex III. 
Table 4.1 Can innocuous metabolites be expected to be formed based on available data? 
FL-no: Substance name Innocuous metabolites? 
Subgroup I:  ACYCLIC ALKANES 
01.033 2,2-Dimethylhexane Yes 
01.034 2,4-Dimethylhexane Yes 
01.038 Dodecane Yes 
01.050 3-Methylhexane No (potential formation of neurotoxic gamma-
diketone) 
01.054 Pentadecane Yes 
01.057 Tetradecane Yes 
Subgroup II:  ACYCLIC ALKENES 
01.032 2,3-Dihydrofarnesene No (lack of supporting data) 
01.035 2,6-Dimethylocta-2,4,6-triene No (lack of supporting data) 
01.037 Dodec-1-ene No (presence of terminal double bond which may 
give rise to reactive metabolites without 
counteracting metabolic options) 
Deleted 
from the 
Register 
2-Methylbuta-1,3-diene No (known biotransformation to reactive metabolite 
responsible for toxicity and genotoxicity) 
01.064 cis-3,7-Dimethyl-1,3,6-octatriene No (presence of terminal double bond which may 
give rise to reactive metabolites without 
counteracting metabolic options)  
01.070 1-Octene No (presence of terminal double bond which may 
give rise to reactive metabolites without 
counteracting metabolic options) 
01.078 2,4-Nonadiene No (lack of supporting data) 
Subgroup III:  CYCLOHEXENE HYDROCARBONS 
01.055 beta-Phellandrene No (lack of supporting data) 
01.027 Bisabola-1,8,12-triene Yes 
01.028 beta-Bisabolene Yes 
01.039 delta-Elemene Yes  
01.001 Limonene Yes 
01.046 l-Limonene Yes 
Subgroup IV: AROMATIC HYDROCARBONS 
Subgroup IVa:  BENZENE HYDROCARBONS 
01.031 1,2-Dihydro-1,1,6-trimethylnaphthalene No (lack of supporting data) 
01.058 1,2,3,4-Tetrahydro-1,1,6-trimethylnaphthalene No (lack of supporting dat) 
Subgroup IVb:  NAPHTHALENE HYDROCARBONS  
01.051 2-Methylnaphthalene No (known metabolism to toxic metabolites) 
01.053 Naphthalene No (known metabolism to toxic metabolites) 
Subgroup IVc: DIPHENYLMETHANE  
01.036 Diphenylmethane No (lack of supporting data) 
Subgroup V: BI- and TRICYCLIC, NON-AROMATIC HYDROCARBONS 
01.021 Delta-Cadinene No (lack of supporting data) 
01.022 alpha-Cedrene No (lack of supporting data) 
01.023 1(5),11-Guaiadiene No (lack of supporting data) 
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Table 4.1 Can innocuous metabolites be expected to be formed based on available data? 
FL-no: Substance name Innocuous metabolites? 
01.030 beta-Cubebene No (lack of supporting data) 
01.044 Isolongifolene No (lack of supporting data) 
01.047 Longifolene No (lack of supporting data) 
01.052 alpha-Muurolene No (lack of supporting data) 
01.056 alpha-Santalene No (lack of supporting data) 
01.059 4(10)-Thujene No (lack of supporting data) 
01.060 1,1,7-Trimethyltricyclo[2.2.1.0.(2.6)]heptane No (lack of supporting data) 
01.066 2-Cedrene No (lack of supporting data) 
01.067 8(14)-Cedrene No (lack of supporting data) 
Subgroup VI: MACROCYCLIC, NON-AROMATIC HYDROCARBONS 
01.042 Germacra-1(10),4(14),5-triene No (lack of supporting data) 
01.043 3,7,10-Humulatriene No (lack of supporting data) 
 
5. Application of the Procedure for the Safety Evaluation of Flavouring Substances 
The application of the Procedure is based on intakes estimated on the basis of the MSDI approach. 
Where the mTAMDI approach indicates that the intake of a flavouring substance might exceed its 
corresponding threshold of concern, a formal safety assessment is not carried out using the Procedure. 
In these cases the Panel requires more precise data on use and use levels. For comparison of the intake 
estimations based on the MSDI approach and the mTAMDI approach, see Section 6. 
For the safety evaluation of the 37 candidate substances from chemical group 31, the Procedure as 
outlined in Annex I was applied, based on the MSDI approach. The stepwise evaluations of these 37 
substances are summarised in Table 2. 
Step 1 
Thirty–one of the 37 candidate substances evaluated using the Procedure are classified into structural 
class I [FL-no: 01.001, 01.022, 01.023, 01.027, 01.028, 01.030, 01.032, 01.033, 01.034, 01.035, 
01.037, 01.038, 01.039, 01.042, 01.043, 01.044, 01.046, 01.047, 01.050, 01.052, 01.054, 01.055, 
01.056, 01.057, 01.059, 01.060, 01.064, 01.066, 01.067, 01.070 and 01.078], two into structural class 
II [FL-no: 01.031 and 01.058], and four into structural class III, [FL-no: 01.021, 01.036, 01.051 and 
01.053], according to the decision tree approach presented by Cramer et al. (Cramer et al., 1978). 
Step 2 
On the basis of the metabolism information available, five of the six candidate substances of subgroup 
I [FL-no: 01.033, 01.034, 01.038, 01.054 and 01.057] and five of the six candidate substances of 
subgroup III [FL-no: 01.001, 01.027, 01.028, 01.039 and 01.046] (see Table 4.1) may be predicted to 
be metabolised to innocuous products at the estimated levels of intake based on the MSDI approach, 
and accordingly the evaluation of these 10 substances, all belonging to structural Cramer class I, 
proceeds along the A-side of the Procedure scheme.  
The remaining candidate substance from subgroup I [FL-no: 01.050] may be biotransformed to a 
neurotoxic gamma-diketone. Three candidate substances from subgroup II [FL-no: 01.037, 01.064 and 
01.070] contain terminal double bonds in the absence of other functional groups that may provide 
alternative routes of detoxication. For the two candidate substances from subgroup IVb [FL-no: 
01.051 and 01.053] it has been shown that they may be converted to toxic metabolites. Therefore, for 
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these six substances it cannot be concluded that they will be metabolised to innocuous products, and 
accordingly they proceed along the B-side of the Procedure scheme.  
For the remaining 21 candidate substances [FL-no: 01.021, 01.022, 01.023, 01.030, 01.031, 01.032, 
01.035, 01.036, 01.042, 01.043, 01.044, 01.047, 01.052, 01.055, 01.056, 01.058, 01.059, 01.060, 
01.066, 01.067 and 01.078] there are not sufficient data available on biotransformation to conclude 
that they will be metabolised to innocuous products, and therefore their evaluation will proceed along 
the B-side of the Procedure scheme. 
Step A3 
The five candidate substances from subgroup I [FL-no: 01.033, 01.034, 01.038, 01.054 and 01.057] 
and three candidate substances from subgroup III [FL-no: 01.027, 01.028 and 01.039], proceeding via 
the A-side, have been assigned to structural class I and have estimated European daily per capita 
intakes ranging from 0.012 to 2.7 microgram (Table 6.1). These intakes are below the threshold of 
concern of 1800 microgram/person/day for structural class I. Accordingly, it is concluded that these 
eight candidate substances do not pose a safety concern as flavouring substances when used at 
estimated levels of intake, based on the MSDI approach. Two candidate substances from subgroup III 
[FL-no: 01.001and 01.046] have an estimated European daily per capita intakes of 4000 and 2100, 
respectively, which are above the threshold of concern of 1800 microgram/person/day for structural 
class I. These two candidate substances will therefore proceed to step A4 of the Procedure scheme. 
Step A4 
The candidate substances [FL-no: 01.001 and 01.046] or their metabolites are not endogenous. 
Step A5 
The two candidate substances [FL-no: 01.001 and 01.046] are supported by the substance [FL-no: 
01.045] for which an adequate carcinogenicity study is available. From this study a no observed 
adverse effect level (NOAEL) of 215 mg/kg bw/day can be derived. The estimated daily per capita 
intake is 4000 microgram for [FL-no: 01.001] and 2100 microgram for [FL-no: 01.046], 
corresponding to 0.07 mg/kg bw/day and 0.035 mg/kg bw/day at a body weight of 60 kg, respectively. 
Thus, a margin of safety of 3070 can be calculated for [FL-no: 01.001] and a margin of safety of 6140 
can be calculated for [FL-no: 01.046]. These two substances are accordingly not expected to be of 
safety concern at the estimated levels of intake. 
Step B3 
The 21 candidate substances [FL-no: 01.022, 01.023, 01.030, 01.032, 01.035, 01.037, 01.042, 01.043, 
01.044, 01.047, 01.050, 01.052, 01.055, 01.056, 01.059, 01.060, 01.064, 01.066, 01.067, 01.070 and 
01.078] proceeding via the B-side and which have been assigned to Cramer structural class I have 
estimated European daily per capita intakes between 0.0085 and 28 microgram (Table 6.1). These 
intakes are below the threshold of concern of 1800 microgram/person/day for structural class I. Two of 
the candidate substances [FL-no: 01.031 and 01.058] proceeding via the B-side and assigned to 
structural class II, have estimated European daily per capita intakes of 0.0012 and 0.12 micrograms, 
respectively. These intakes are below the threshold of concern of 540 microgram/person/day for 
structural class II. Four candidate substances [FL-no: 01.021, 01.036, 01.051 and 01.053] proceeding 
via the B-side and assigned to structural class III, have European daily per capita intakes of 0.15, 1.2, 
0.0012 and 0.013 microgram, respectively. These intakes are below the threshold of concern for 
structural class III of 90 microgram/person/day. Accordingly, these 27 substances all proceed to step 
B4 of the Procedure. 
Step B4 
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No adequate No Observed Adverse Effect Levels (NOAELs) are available for any of the 27 candidate 
substances evaluated at Step B4 [FL-no: 01.021, 01.022, 01.023, 01.030, 01.031, 01.032, 01.035, 
01.036, 01.037, 01.042, 01.043, 01.044, 01.047, 01.050, 01.051, 01.052, 01.053, 01.055, 01.056, 
01.058, 01.059, 01.060, 01.064, 01.066, 01.067, 01.070 and 01.078] or for any structurally related 
substances. Therefore, the Panel concluded that additional data are required for these 27 substances. 
6. Comparison of the Intake Estimations Based on the MSDI Approach and the mTAMDI 
Approach 
The mTAMDI values for the 27 candidate substances, for which use levels have been provided, from 
structural class I and evaluated using the Procedure range from 3100 to 3900 microgram/person/day. 
No suitable information was submitted for the four remaining substances from structural class I. Hence 
for these four substances an mTAMDI cannot be calculated. For each of the two candidate substances 
from structural class II and the four candidate substances from structural class III the mTAMDI are 
3900 microgram/person/day. The mTAMDIs values for all 33 candidate flavouring substances for 
which suitable use levels are available, are above the thresholds for structural class I, II and III of 
1800, 540 and 90 microgram/person/day, respectively.  
For comparison of the intake estimates based on the MSDI approach and the mTAMDI approach, see 
Table 6.1. 
For the 33 candidate substances, for which use levels have been provided, further information is 
required. This would include more reliable intake data and then, if required, additional toxicological 
data. For four candidate substances [FL-no: 01.001, 01.046, 01.070 and 01.078] use levels for food 
categories as outlined in Commission Regulation (EC) no 1565/2000, Annex III, are required. 
Table 6.1  Estimated intakes based on the MSDI approach and the mTAMDI approach 
FL-no EU Register name MSDI 
(μg/capita/day) 
mTAMDI 
(μg/person/day) 
Structural class Threshold of 
concern 
(µg/person/day) 
01.001 Limonene 4000  Class I 1800 
01.027 Bisabola-1,8,12-triene 0.024 3900 Class I 1800 
01.028 beta-Bisabolene 2.7 3900 Class I 1800 
01.033 2,2-Dimethylhexane 1.2 3900 Class I 1800 
01.034 2,4-Dimethylhexane 1.2 3900 Class I 1800 
01.038 Dodecane 0.012 3900 Class I 1800 
01.039 delta-Elemene 0.012 3900 Class I 1800 
01.046 l-Limonene 2100  Class I 1800 
01.054 Pentadecane 0.61 3900 Class I 1800 
01.057 Tetradecane 0.012 3900 Class I 1800 
01.022 alpha-Cedrene 0.012 3900 Class I 1800 
01.023 1(5),11-Guaiadiene 1.2 3900 Class I 1800 
01.030 beta-Cubebene 0.012 3900 Class I 1800 
01.032 2,3-Dihydrofarnesene 0.12 3900 Class I 1800 
01.035 2,6-Dimethylocta-2,4,6-triene 9.1 3900 Class I 1800 
01.037 Dodec-1-ene 0.024 3900 Class I 1800 
01.042 Germacra-1(10),4(14),5-triene 0.012 3900 Class I 1800 
01.043 3,7,10-Humulatriene 1.2 3900 Class I 1800 
01.044 Isolongifolene 0.012 3500 Class I 1800 
01.047 Longifolene 28 3900 Class I 1800 
01.050 3-Methylhexane 0.061 3900 Class I 1800 
01.052 alpha-Muurolene 0.24 3900 Class I 1800 
01.055 beta-Phellandrene 0.012 3900 Class I 1800 
01.056 alpha-Santalene 0.012 3900 Class I 1800 
01.059 4(10)-Thujene 14 3100 Class I 1800 
01.060 1,1,7-Trimethyltricyclo[2.2.1.0.(2.6)]heptane 0.012 3900 Class I 1800 
01.064 cis-3,7-Dimethyl-1,3,6-octatriene 14 3900 Class I 1800 
01.066 2-Cedrene 0.97 3900 Class I 1800 
01.067 8(14)-Cedrene 0.012 3900 Class I 1800 
01.070 1-Octene 0.0085  Class I 1800 
01.078 2,4-Nonadiene 6.1  Class I 1800 
01.031 1,2-Dihydro-1,1,6-trimethylnaphthalene 0.0012 3900 Class II 540 
01.058 1,2,3,4-Tetrahydro-1,1,6-trimethylnaphthalene 0.12 3900 Class II 540 
01.021 delta-Cadinene 0.15 3900 Class III 90 
01.036 Diphenylmethane 1.2 3900 Class III 90 
Flavouring Group Evaluation 25, Revision 2
 
 
18 EFSA Journal 2011; 9(6):2177 
Table 6.1  Estimated intakes based on the MSDI approach and the mTAMDI approach 
FL-no EU Register name MSDI 
(μg/capita/day) 
mTAMDI 
(μg/person/day) 
Structural class Threshold of 
concern 
(µg/person/day) 
01.051 2-Methylnaphthalene 0.0012 3900 Class III 90 
01.053 Naphthalene 0.013 3900 Class III 90 
 
7. Considerations of Combined Intakes from Use as Flavouring Substances 
Because of structural similarities of candidate and supporting substances, it can be anticipated that 
many of the flavourings are metabolised through the same metabolic pathways and that the 
metabolites may affect the same target organs. Further, in case of combined exposure to structurally 
related flavourings, the pathways could be overloaded. Therefore, combined intake should be 
considered. As flavourings not included in this FGE may also be metabolised through the same 
pathways, the combined intake estimates presented here are only preliminary. Currently, the combined 
intake estimates are only based on MSDI exposure estimates, although it is recognised that this may 
lead to underestimation of exposure. After completion of all FGEs, this issue should be readdressed. 
The total estimated combined daily per capita intake of structurally related flavourings is estimated by 
summing the MSDI for individual substances. 
The 27 candidate substances, for which additional data are requested, will not be included. The 
combined intakes have been calculated for the remaining candidate and supporting substances (i.e. 
five substances from subgroup I (acyclic alkanes) and five substances from subgroup III (cyclohexene 
hydrocarbons)). 
The combined intakes have been calculated on the basis of the annual production volumes from use as 
flavouring substances in Europe (EFFA, 2005a; EFFA, 2005b; EFFA, 2006o; EFFA, 2006p; Flavour 
Industry, 2006t; JECFA, 2005c). 
Subgroup I (acyclic alkanes): The combined intake of the five candidate substances, all from structural 
class I and evaluated via the A-side of the Procedure (Annex I), is 3.0 microgram/capita/day, which 
does not exceed the threshold of 1800 microgram/person/day. There are no supporting substances in 
subgroup I. 
Subgroup III (cyclohexene hydrocarbons): The combined intake of the five candidate substances, all 
from structural class I and evaluated via the A-side of the Procedure (Annex I), is 6100 
microgram/capita/day, which does exceed the threshold of 1800 microgram/person/day. The total 
combined intake of the five candidate and six supporting substances (also from structural class I) is 
approximately 42000 microgram/capita/day. This intake exceeds the threshold of 1800 
microgram/person/day for a structural class I substance. However, together, limonene [FL-no: 01.001], 
l-limonene [FL-no: 01.046] and d-limonene (supporting substance [FL-no: 01.045]) account for 
approximately 40000 microgram/capita/day. The total combined intake of 42000 
microgram/capita/day for the candidate and the supporting substances corresponds to 700 
microgram/kg bw/day for a person with a body weight of 60 kg. Thus, based on the NOAEL for d-
limonene of 215 mg/kg bw/day, a margin of safety of 307 can be calculated, and accordingly these 
substances are not expected to be of safety concern at the estimated level of intake. 
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8. Toxicity 
8.1. Acute Toxicity 
Data are available for seven candidate substances, 16 supporting substances and one structurally 
related substance (1-methyl-1,3-cyclohexadiene [FL-no: 01.077]).  Oral LD50 values in rat and mouse 
ranged from 500 - 13000 mg/kg body weight (bw).  
 
The acute toxicity data are summarised in Annex IV, Table IV.1. 
8.2. Subacute, Subchronic, Chronic and Carcinogenicity Studies 
Data are available for two candidate substances from subgroup IVb (naphthalene [FL-no: 01.053] and 
2-methyl-naphthalene [FL-no: 01.051]), for two supporting substances from subgroup II (myrcene [FL 
no: 01.008] and undeca-1,3,5-triene [FL no: 01.061], for one supporting substance from subgroup III 
(d-limonene [FL no: 01.045]), one supporting substance for subgroup IVb (1-naphthalene [FL no: 
01.014]), for two supporting substances for subgroup V (pinene [FL no: 01.003] and camphene [FL 
no: 01.009]) (see also Table IV.2). In the text below the relevant studies are discussed.  
Subgroup II 
Myrcene [01.008] 
 
Mice, 90 day study (NTP, 2010b) 
Male and female B6C3F1 mice (10/sex/group) were administered 0, 250, 500, 1000, 2000 or 4000 
mg/kg bw of beta-myrcene by gavage 5 days a week for 14 weeks. Body weights and clinical 
observations were recorded weekly. Blood was collected from mice surviving to the end of the study 
for haematological analyses and micronuclei evaluation. Sperm morphology and vaginal cytology 
evaluations were conducted at the end of the study on animals in the control and three lowest dose 
groups. At necropsy, organ weights were measured and complete histopathological examination was 
performed on animals from the dose groups 0, 1000, 2000 and 4000 mg/kg bw, and all animals that 
died early.    
All animals in the 4000 mg/kg bw group died within the first three days while 9 of 10 males and 8 of 
10 females in the 2000 mg/kg bw group died prior to week 5.  In animals that died prior to study 
termination, clinical signs included lethargy, abnormal breathing and/or thin appearance. The final 
mean body weights and body weight gain of the 1000 mg/kg bw  males and 500 mg/kg bw  females 
were significantly less than those of vehicle controls. Because of the low survival in the two top doses, 
further results are not reported for those doses. 
A significant, approximately 15 - 20 % decrease in hematocrit, haemoglobin and erythrocyte count 
values was observed in the 1000 mg/kg bw dose group in both females and males at week 14. A dose-
dependent significant increase in the relative liver weight (approximately 7 %, 6 % and 17 %) were 
observed for all doses in male mice, and a significant increase in absolute liver weight were observed 
for the low dose males only. In female mice a dose-dependent significant increase in relative kidney 
weight was observed at all doses (approximately 14 %, 12 % and 22 %), with a significant increase in 
absolute kidney weight in the 1000 mg/kg bw dose group only. Also for female mice, dose-dependent 
increases in absolute and relative liver weight (approximately  8 %, 17 % and 26 %) were observed, 
but the increase reached statistical significance only at 500 and 1000 mg/kg bw. There were no 
significant changes seen in the weights of the reproductive organs, in the sperm parameters, or in 
oestrous cyclicity at any dose level. No significant histopathological changes in other organs 
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examined, including kidney, were observed in mice receiving up to 1000 mg/kg bw beta-myrcene for 
14 weeks.  
As a significant dose-dependent increase in the relative kidney weight was observed for female mice at 
all treatment doses, no NOAEL for this study could be allocated. 
Rats, 90-day study (NTP, 2010b) 
Male and female F344N Fisher rats (10/sex/group) were administered 0, 250, 500, 1000, 2000 or 4000 
mg/kg bw of beta-myrcene by gavage 5 days a week for 14 weeks. Body weights and clinical 
observations were recorded weekly. Blood was collected from rats surviving to the end of the study 
for clinical chemistry and haematological analyses. Sperm morphology and vaginal cytology 
evaluations were conducted at the end of the study on animals in the control and three lowest dose 
groups. At necropsy, organ weights were measured and complete histopathological examination was 
performed on animals from the dose groups 0, 2000 and 4000 mg/kg bw, and all animals that died 
early. Tissues were examined in the lower dose groups to a no-effect level, including renal pathology 
in all dose groups. Additionally sections of kidney from both sexes were stained using the Mallory-
Heidenhain technique for investigation of hyaline droplet formation (indicative of development of 
alpha-2µ-globulin).  
All animals in the group receiving 4000 mg/kg bw beta-myrcene died within the first week of the 
study, except for one male that died at day 11. One male receiving 500 mg/kg bw, one male and one 
female receiving 1000 mg/kg bw and two males and four females receiving 2000 mg/kg bw died 
before the end of the study. Final mean body weight and mean body weight gains of males and 
females administered 500 mg/kg bw or more were significantly less than those of vehicle control. At 
termination at week 14, dose-related decreases in plasma creatinine concentration in both males and 
females were observed, statistically significant at 500 mg/kg bw and above in males and at 250 mg/kg 
bw and above in females. These decreases were suggested by the authors to be associated with the 
decreased body weight gains observed in treated rats. No other consistent changes in clinical 
chemistry parameters were found. 
Absolute kidney and liver weights were significantly increased in both male and female rats receiving 
beta-myrcene. Also a dose-dependent increase in the relative liver and kidney weights were observed 
for males (25 - 150 % in kidney, 13 - 46 % in liver) and females (27 - 100 % in kidney, 13 - 67 % in 
liver). Microscopically, the incidence of renal tubular necrosis was significantly increased in all dosed 
groups of males and females, with increasing severity from minimal to moderate related to dose. Both 
control and treated rats showed development of chronic progressive nephropathy (CPN), although the 
incidence was higher in treated rats. Treatment-related increases in the incidences and severity of 
hyaline droplet accumulation were found in the 250, 500 and 1000 mg/kg bw males, accompanied by 
granular casts in the outer medulla of the kidney. Hyaline droplet formation was not observed in the 
2000 mg/kg bw males, although the animals showed a high incidence of renal tubular necrosis, 
nephrosis and CPN. No evidence of hyaline droplet accumulation was found in female rats, however 
treated females showed both nephrosis and CPN. A significant increase in nephrosis was observed in 
the 1000 and 2000 mg/kg bw dose groups of both males and females, with a dose-related increase in 
severity from minimal to moderate. Nephrosis is an uncommon lesion defined as renal tubule 
epithelial degeneration and regeneration. 
A dose-related effect of beta-myrcene in the nose was observed in both sexes as degeneration of the 
olfactory epithelium and necrosis of the respiratory epithelium (significant only at 2000 mg/kg bw) 
accompanied by chronic inflammatory change (significant at 1000 and 2000 mg/kg bw). 
The incidence of splenic atrophy were significantly increased in both sexes receiving 2000 mg/kg bw, 
accompanied by thymic necrosis in one male and three females. In the mesenteric lymph node, the 
incidence of atrophy were increased in males receiving 2000 mg/kg bw and females receiving 1000 or 
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2000 mg/kg bw. The lymphoid changes in these organs were considered by the authors to be 
secondary to morbidity rather than a direct toxic effect of beta-myrcene. 
It has been argued that increased hyaline droplet accumulation in male rats is characteristic of alpha-
2µ-globulin nephropathy (Hard et al., 1993), which is a male rat specific effect with little relevance for 
humans. The evidence provided for the mechanistic background of the hyaline droplet formation was 
considered too limited to completely disregard the nephrotoxic effects in male rats as irrelevant for 
humans. Involvement of alpha-2µ-globulin accumulation (e.g. by immunohistochemical techniques) 
was not demonstrated. In addition, also renal toxicity was observed in the female animals. Therfore, 
based on the presence of renal tubular nephrosis and necrosis in all test groups, a NOAEL could not be 
assigned. 
Mice, 2-year carcinogenicity study (NTP, 2010b) 
Groups of B6C3F1 mice (50/sex/group) were administered 0, 250, 500 or 1000 mg beta-myrcene/kg 
bw per day in corn oil by gavage once per day, five days a week for 104 (females) weeks or 105 
weeks (males). The animals were observed twice per day and weighed once per week for 12 weeks 
and once per month thereafter. Complete necropsies and microscopic examination were performed on 
all animals. Histological examinations were performed on all animals and tissues from all major 
organs were examined.   
Mean body weights of males receiving 1000 mg/kg bw and females receiving 500 or 1000 mg/kg bw 
were less than those of the vehicle control. Survival of the high-dose group was significantly reduced 
for both males and females. Due to the high mortality in the 1000 mg/kg bw dose group, the results 
from this group are not described further. 
In the liver there was an increase in hepatocellular carcinoma in both males and females, with a 
significant increase in incidence in males at the 500 mg/kg bw dose level (incidence 1 in controls, 4 in 
the 250 mg/kg bw group and 9 in the 500 mg/kg bw group) and females at 250 mg/kg bw, but not at 
500 mg/kg bw. Males and to a lesser extent females showed an increase in hepatocellular adenoma in 
the liver at both 250 and 500 mg/kg bw. Liver hypertrophy was observed to increase with dose both in 
incidence and severity, reaching statistical significance only at 500 mg/kg bw in both males and 
females. Eosinophilic foci and cytoplasmic vacuolization were noted in both male and female 
treatment groups.  
Treatment-related changes in other organs included increases in hyperplasia, inflammation, necrosis 
and ulcer of the forestomach, which were most likely attributable to gavage administration of an 
irritant substance. Bone marrow atrophy and mandibular and mesenteric lymph node atrophy was 
observed in both males and females at the 500 mg/kg bw dose. In addition, male mice showed atrophy 
of the spleen at the 500 mg/kg bw dose. 
Taking into account the high sensitivity of this mice strain to tumour development in the liver, these 
effects were not regarded relevant to humans. A NOAEL of 250 mg/kg bw for beta-myrcene was 
allocated, based on the increase in bone marrow atrophy and lymph node atrophy observed in both 
males and females at 500 mg/kg bw dose. 
Rats, two-year carcinogenicity study (NTP, 2010b) 
A chronic two-year bioassay on beta-myrcene using the standard NTP protocol with F344/N rats was 
conducted. Doses were determined from the results of the prior 13-week subchronic study. Groups of 
F344/N rats (50/sex/group) were administered 0, 250, 500 or 1000 mg beta-myrcene/kg bw per day in 
corn oil by gavage once per day, five days a week for 104 weeks. The animals were observed twice 
per day and weighed once per week for 12 weeks and once per month thereafter. Complete necropsies 
and microscopic examination were performed on all animals. Histological examinations were 
performed on all animals and tissues from all major organs were examined.   
Flavouring Group Evaluation 25, Revision 2
 
 
22 EFSA Journal 2011; 9(6):2177 
Survival rates of females were comparable across all control and treatment groups. Survival of males 
in the low- and mid-dose groups was similar to that in the controls. However, no males in the high-
dose group survived past 83 weeks of the study, due to renal toxicity. Body weight gain was 
significantly reduced in high-dose males and females, while the mean body weight of the 500 mg/kg 
females were less than those of the vehicle controls during much of the study but were similar by the 
end of the study. Due to the high mortality of males in the 1000 mg/kg bw group, the data from this 
dose group are not presented further.  
The incidences of renal tubular adenoma and of renal tubule adenoma or carcinoma (combined) 
showed a significant and dose-dependent increase in the 250 and 500 mg/kg bw males.  Two renal 
tubule adenomas occurred in the 1000 mg/kg bw females, the incidence being higher than the 
historical control mean for the laboratory. In males high increase in both the incidence and severity of 
renal tubular nephrosis were observed, already at the lowest dose, with 84 and 92 % incidence at 250 
and 500 mg/kg bw, respectively. A significant but not dose related increase in papilla mineralisation, 
epithelial hyperplasia and inflammation was seen in the dose groups 250 and 500 mg/kg bw. In female 
rats a dose-dependent increase in nephropathy (CPN) were observed for the doses 250, 500 and 1000 
mg/kg bw and a dose-dependent increase in the incidence and severity of renal tubule nephrosis at the 
doses 500 and 1000 mg/kg bw. In addition a non-dose related significant increase in renal tubular 
hyperplasia was reported at the doses (250, 500, 1000 mg/kg bw). Nephrosis, observed both in male 
and female rats, was reported by the authors to be an uncommon lesion defined as renal tubule 
epithelial degeneration and regeneration. This indicates that beta-myrcene might cause nephrotoxicity 
by a mechanism other than, or in addition to, alpha-2µ-globulin nephropathy. The observation of renal 
neoplasms in female rats also suggests a mechanism of carcinogenesis that may be related to nephrosis 
and is distinct from the alpha-2µ-globulin mechanism. 
Other histopathological changes seen in the study included chronic active inflammation in the nose 
and forestomach, suggesting that the substance is an irritant. In females, the incidence of thyroid gland 
C-cell adenomas was significantly increased in the 250 mg/kg bw group, but the incidence did not 
increase with increasing dose. In the lung, the incidence of alveolar/bronchiolar adenoma in the 250 
mg/kg bw group exceeded the control means, but was not observed at higher doses. 
Due to the observation of renal tubular adenomas and carcinomas in all dose groups in male rats, 
accompanied by an increased incidence and severity of nephrosis in both sexes, a NOAEL for beta-
myrcene from this study could not be allocated. 
Overall conclusion for the NTP study on beta-myrcene 
No overall NOAEL from the NTP study on beta-myrcene could be allocated due to the observation of 
renal toxicity in male and female rats at all dose groups. The Panel has considered deriving a BMDL 
from the NTP study of myrcene. However, a BMDL from this study could not be derived because of a 
lack of dose-response since nearly 100 % incidence of nephrosis was observed in rats already at the 
lowest dose of beta-myrcene. 
Subgroup III 
d-Limonene [FL-no: 01.045]: 
The Joint FAO/WHO Expert Committee on Food Additives (JECFA) evaluated the supporting 
substance d-limonene as an additive in its forty-first meeting in 1993, and withdrew the previous ADI 
for d-limonene and allocated an ADI “not specified” (JECFA, 1993a). This assessment was mainly 
based on an NTP study with d-limonene from 1990 (NTP 1990e). In the carcinogenicity study, F344 
rats (n = 50/dose/sex) were treated with 0, 75 and 150 mg/kg d-limonene (males) and 0, 300 and 600 
mg/kg (females) by gavage in corn oil for five days a week. B6C3F1 mice (n = 50/dose/sex) were 
treated with 0, 250 and 500 mg/kg d-limonene (males) and 0, 500 and 1000 mg/kg (females) in corn 
oil by gavage for five days a week. In the high dose female rats, the survival was reduced. No effect 
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on survival or any other toxic effect was observed in the females of the low dose group. The major 
toxicological effect in the male rats was found in the kidneys where a dose dependent increase in both 
renal mineralization and epithelial hyperplasia, and a dose-dependent increase in renal tubular cell 
adenomas and adenocarcinomas was observed. These effects were accompanied with dose related 
increase in alpha-2µ-globulin in the kidney of male rats. No increase in  alpha-2µ-globulin, kidney 
nephropathy or renal adenomas or carcinomas was found in female rats. Therefore, the toxicological 
effects seen in the male rat kidneys are due to alpha-2µ-globulin accumulation related nephropathy 
specifically seen in male rats, which is not relevant for humans (Hard et al., 1993). A reduction in the 
mean body weights at the high dose group was observed for male and female rats (4 - 7 %) and high 
dose female mice (5 - 15 %). For the male rats this reduction in mean body weight may have been 
linked to the toxicity in the kidneys. Based on the decreased body weights in female mice, a NOAEL 
of 500 mg/kg bw/day (5 days/week) could be derived, but considering the decrease in survival in the 
female rats exposed at 600 mg/kg bw/day (5 days/week) an overall NOAEL of 300 mg/kg bw/day (5 
days/week) should be derived from these NTP studies. This would correspond to 215 mg/kg bw/day 
for daily exposure.  
Subgroup IVb  
Naphthalene [FL-no: 01.053]: 
For naphthalene [FL-no: 01.053] two unpublished 13 week oral studies on rats and mice were only 
available as summaries, referred to in US EPA (1998). Since the original data were not available it was 
not possible to evaluate the quality of the study. Groups of 20 rats, male and female, were given doses 
of 0, 25, 50, 100, 200 or 400 mg naphthalene/kg bw by gavage five days a week for 13 weeks. The 
NOAEL in this study was 100 mg/kg bw based on mean terminal bw decreases. Other findings were 
low incidence of lesions in exposed male kidneys and female thymuses. In the mouse study groups of 
10 male and 10 female mice were given doses of 0, 12.5, 25, 50, 100 or 200 mg/kg bw following the 
same design as the rat study. Transient signs of toxicity occurred in the 200 mg/kg groups. No 
exposure-related lesions were observed in any organs examined. The authors considered the highest 
dose level to be a NOAEL, whereas the EPA judged the highest dose level to be a Lowest Observed 
Adverse Effect Level (LOAEL) for transient signs of toxicity.  
Naphthalene [FL-no: 01.053] was given six times per week in food to 28 rats at a dose level varying 
between 10 and 20 mg/rat/day. Treatment was stopped after 700 days after reaching a total dose of 10 
g/rat. Rats were observed until spontaneous death. The conclusion by the author was that naphthalene 
did not cause cancer in the study. It is however not possible to draw conclusions on carcinogenicity or 
chronic toxicity from the study since it is deficient in design and poorly reported (Schmähl, 1955).  
Groups of male (76 - 112) and female (40 - 76) mice were given naphthalene [FL-no: 01.053] by 
gavage at dose levels of 0, 5.3, 53 or 133 mg/kg bw/day for 90 consecutive days. The study identified 
a LOAEL of 133 mg/kg bw/day and a NOAEL of 53 mg/kg bw/day based upon the significant 
decreases in absolute weight of brain, liver and spleen and relative weight of spleen in female mice. 
Histopathology was not conducted in this study (Shopp et al., 1984).  
Naphthalene [FL-no: 01.053] was studied in a two-year NTP inhalation study in B6C3F1 mice. The 
result showed no evidence of carcinogenic activity in male mice exposed to naphthalene, but some 
evidence of carcinogenic activity in female mice. Groups of male and female mice were exposed to 0 
(75/group), 10 (75/group) or 30 ppm (150/group) naphthalene for six hours daily, five days/week for 
105 weeks. No increased tumour incidence related to exposure was observed in male mice, but in 
females the incidence of pulmonary alveolar/bronchiolar adenomas was significantly greater in the 
high-dose group than in controls. In both male and female mice exposure to naphthalene caused 
increased incidences and severity of chronic inflammation, metaplasia of the olfactory epithelium and 
hyperplasia of the respiratory epithelium in the nose and chronic inflammation in the lungs (NTP, 
1992g). 
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In a two-year NTP inhalation study in F344/N rats on the toxicology and carcinogenesis of 
naphthalene [FL-no: 01.053] it was concluded by NTP that there was clear evidence of carcinogenic 
activity based on increased incidences of respiratory epithelial adenoma and olfactory epithelial 
neuroblastoma of the nose. Groups of 49 male and female rats were exposed to naphthalene by 
inhalation at concentrations of 0, 10, 30 or 60 ppm for six hours plus 12 minutes per day five days per 
week for 105 weeks. The highest exposure concentration is the maximum without naphthalene 
condensation. Additional groups of nine male and female rats were exposed to 10, 30 or 60 ppm for up 
to 18 months for evaluation of toxicokinetic parameters. At the exposure concentrations in the study 
approximately 20 - 30 % of the inhaled dose was metabolised by the rats. Naphthalene that was not 
absorbed during exposure was presumed to be exhaled. The daily doses were estimated to be 0, 3.6 - 
3.9, 10.7 - 11.4 and 20.1 - 20.7 mg/kg bw. Survival of all exposed groups was similar to that of 
controls. Mean body weights of exposed animals were less than those of controls. Incidences of 
adenoma of the respiratory epithelium were associated with exposure and increased with dose, as did 
incidences of neuroblastoma of the olfactory epithelium. Increased incidences of non-neoplastic 
lesions of the nose associated with exposure to naphtalene included atypical hyperplasia, atrophy, 
chronic inflammation, hyaline degradation of epithelium, hyperplasia, squamous metaplasia, goblet 
hyperplasia of respiratory epithelium and glandular hyperplasia and squamous metaplasia. There were 
no ocular abnormalities in the rats, although naphthalene is a known ocular irritant. Unlike mice, 
naphthalene was not carcinogenic in the rat lung. Higher rates of metabolism in the mouse lung 
compared to the rat lung may have been a contributing factor to this species difference in response 
(NTP, 2000d). 
Conclusion on carcinogenicity for naphthalene 
The Panel agreed with the European Union Risk Assessment Report (EU-RAR, 2003) in its evaluation 
of the long-term carcinogenicity studies on naphthalene. It was concluded that overall the balance of 
evidence indicates that naphthalene is not genotoxic. In the two-year rat study, inhalation of 
naphthalene produced an increase in the incidence of respiratory epithelial adenomas and olfactory 
epithelial neuroblastomas in both males and females. All these tumours occurred at sites where dose-
related non-neoplastic inflammatory changes in the nose and respiratory epithelium also occurred. In 
view of the negative results obtained in the in vivo genotoxicity studies (see Section 8.4), these 
tumours are considered to arise via a non-genotoxic, thresholded mechanism. In mice an increase in 
the incidence of benign alveolar/bronchiolar adenomas in females was observed after inhalation of 
naphthalene. These tumours are similarly considered to arise via a non-genotoxic procedure, and are 
unlikely to be of relevance to human health due to the well-known species differences in pulmonary 
metabolism, mouse lung preparations being able to metabolise naphthalene at a substantially greater 
rate (up to 100-fold) than those from hamster, rat or monkey. Although the significance of these 
inhalation studies for the evaluation of naphthalene used as a flavouring substance in food is 
questionable, the Panel noted that they did not provide a NOAEL for the non-neoplastic toxic effects 
on the olfactory and respiratory tissues preceding the tumour formation. 
2-Methylnaphthalene [FL-no: 01.051]: 
In a valid study by Murata et al. (1997) groups of 50 male and 50 female mice were fed diets 
containing 0, 0.075 % or 0.15 % 2-methylnaphthalene [FL-no: 01.051] for 81 weeks. The doses were 
calculated to correspond to 50 - 54 and 108 - 114 mg/kg bw/day, respectively. Pulmonary alveolar 
proteinosis developed in all treated animals differing significantly from controls. No tumours were 
seen. No NOAEL could be derived from this study (Murata et al., 1997). 
Cutaneous application of methylnaphthalene, a mixture of 1-methylnaphthalene and 2-
methylnaphthalene in acetone, at doses of 29.7 or 118.8 mg/kg bw painted on the shaved backs of 
B6C3F1 mice twice a week for life was followed by lesions in the lungs. Control mice received 
acetone in the same manner. The lesions were diagnosed as endogenous lipid pneumonia. Frequency 
of pneumonia was 0/4 control, 3/11 low dose and 31/32 high dose animals (Emi and Konishi, 1985). 
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The results suggest that lipid pneumonia could result from systemic administration, and that the lung 
may be a site for naphthalene toxicity in mice as is discussed in the NTP studies reported above. 
Conclusion on carcinogenicity for 2-methylnaphthalene 
The data available, principally from a valid 81-week feeding study in mice, do not indicate that 2-
methylnaphthalene [FL-no: 01.051] is carcinogenic. 
The toxicity data are summarised in Annex IV, Table IV.2. 
8.3. Developmental / Reproductive Toxicity Studies 
Developmental and reproductive studies are available for one candidate substance, naphthalene [FL-
no: 01.053] (subgroup IVb). Studies have been performed on mice, rats and rabbits. Pregnant mice 
were given 0 or 300 mg naphthalene/kg/day on gestation days 7 - 14. The conclusion was drawn that 
naphthalene toxicity is manifest before a high level of developmental toxicity occurs. The study does 
not assess skeletal or visceral foetal development and it is not possible to derive a NOAEL from the 
study (Booth et al., 1983; Plasterer et al., 1985).  
Groups of 25 - 26 pregnant rats were administered naphthalene [FL-no: 01.053] by gavage at dose 
levels of 0, 50, 150 or 450 mg/kg bw on gestational days 6 - 15. Clinical signs of toxicity were 
observed in all dams, but they subsided in the two lowest dose groups. Decreased body weight and 
body weight gain were observed in the two highest dose groups. Foetal growth, viability and 
morphological development were not significantly affected by treatment. There was no significant 
treatment related effect on implantation, foetal survival or resorption. The authors concluded that the 
lowest dose level was a LOAEL for maternal toxicity and that 450 mg/kg bw was a NOAEL for foetal 
developmental toxicity (Navarro et al., 1991).  
Groups of 25 - 27 pregnant rabbits were administered naphthalene [FL-no: 01.053] by gavage at dose 
levels of 0, 20, 80 or 120 mg/kg bw on gestational days 6 - 19. No treatment-related signs of maternal 
toxicity were observed. No statistically significant differences were found between control and treated 
groups in average live litter size, foetal body weight or incidence of malformations. The 
developmental NOAEL was considered to be 120 mg/kg bw/day in this study.  
Groups of 18 pregnant rabbits were given naphthalene [FL-no: 01.053] by gavage at doses of 0, 40, 
200 or 400 mg/kg bw on gestational days 6 - 18. Treatment-related clinical signs were observed in a 
dose-related manner. Maternal NOAEL was not determined. No statistically significant changes were 
apparent in the mean number of corpora lutea, foetal body weights, viable foetuses, total 
implantations, post-implantational loss or foetal sex distribution when comparing control or treatment 
groups. No treatment-related effects were found on examining foetuses for visceral and skeletal 
abnormalities. Foetal developmental NOAEL was determined as 400 mg/kg bw (Naismith & 
Matthews, 1986). 
Conclusion 
In the tested animal species, mice, rats and rabbits, clinical symptoms of maternal toxicity appeared 
before signs of reproductive or developmental toxicity were apparent. Developmental NOAELs varied 
between 120 mg/kg bw/day (rabbit) and 450 mg/kg bw/day (rat, rabbit).  
The developmental/reproductive toxicity data are summarised in Annex IV, Table IV.3. 
8.4. Genotoxicity Studies 
Data from in vitro tests are available for six candidate substances, subgroup I: [FL-no: 01.038] and 
[FL-no: 01.057]; subgroup II: [FL-no: 01.037]; subgroup IVb: [FL-no: 01.051 and 01.053]; subgroup 
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V7: [FL-no: 01.047] and 11 supporting substances, one from subgroup II, four from subgroup III, one 
from subgroup IVb, five from subgroup V (for one of these [FL-no: 01.004] also data for separate 
stereoisomers were available (+ and -)-alpha-pinene (pin-2(3)-ene)(isomer of [FL-no: 01.004]), and 
one structurally related substance (2-methylbuta-1,3-diene (isoprene)) from subgroup II. Data for two 
of the candidate substances [FL-no: 01.051 and 01.053] (subgroup IVb), data for four supporting 
substances [FL-no: 01.008] (subgroup II), [FL-no: 01.019] (subgroup III), [FL-no: 01.014] (subgroup 
IVb), [FL-no: 01.004] (subgroup V) and data for the structurally related substance from subgroup II 
are considered valid.  
Data from in vivo tests are available for one candidate substance, subgroup IVb: [FL-no: 01.053], for 
two supporting substances (one from subgroup II and one from subgroup III) and for one substance 
structurally related to subgroup II (2-methylbuta-1,3-diene). 
There are no data available on candidate or supporting substances from subgroups IVa, IVc and VI. 
Candidate substances 
Subgroup I 
The two candidate substances [FL-no: 01.038 and 01.057] tested in vitro for bacterial gene mutations 
gave negative results in bacterial reverse gene mutation tests and for mammalian cell gene mutations.  
Subgroup II 
For the six candidate substances in subgroup II [FL-no: 01.032, 01.035, 01.037, 01.064, 01.070 and 
01.078] there are, except for one negative bacterial reverse gene mutation test (“Ames test”), no 
genotoxicity data available.  
The available in vivo studies on the structurally related substance 2-methylbuta-1,3-diene (isoprene) 
reported a negative result in a valid chromosomal aberration assay in the bone marrow of mice after 12 
days of inhalatory exposure to isoprene. However, isoprene induced sister chromatid exchanges (SCE) 
in the bone marrow and micronuclei in peripheral blood cells of mice after 12 days of inhalatory 
exposure in two valid studies carried out within NTP. Induction of micronuclei in peripheral blood 
cells of mice has also been reported after inhalatory exposure for 13 weeks. In contrast, inhalatory 
exposure of isoprene to male and female rats for four weeks did not result in an increase in the 
frequency of micronuclei in the lung fibroblasts. The validity of the latter two studies cannot be 
evaluated due to limited details available. Isoprene has been reported to bind covalently to 
haemoglobin in vivo (IARC, 1999a). 
The genotoxic and carcinogenic potential of isoprene has been evaluated by IARC (1999a). It was 
concluded that there is sufficient evidence of carcinogenicity in experimental mammalians and that 
isoprene is ‘possibly carcinogenic to humans’ (Group 2B) (IARC, 1999a). Isoprene has been classified 
in the EU as a ‘Muta. Cat. 3; R68’ and ‘Carc. Cat. 2; R45’ (ECB, 2005). 
The available data on in vivo genotoxicity of 2-methylbuta-1,3-diene (synonym: isoprene) indicate a 
genotoxic potential of the substance. In the light of the evidence of carcinogenic activity of isoprene in 
rats and mice (NTP, 1999d) and the genotoxic effects of isoprene in mice and the fact that the 
structurally related substance 1,3-butadiene is classified as a genotoxic carcinogen, the Panel 
concluded that there is reason for concern with respect to genotoxicity and carcinogenicity of isoprene. 
This substance has been deleted from the Register. 
                                                     
 
7 An Ames test with cedrene washed (unspecified cedrene) was also submitted, but an adequate identification of the 
substance studied was not possible. Therefore the study is not further discussed. 
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For the supporting substances beta-myrcene, several in vitro genotoxicity tests and three in vivo 
genotoxicity studies were available. All the in vitro genotoxicity tests on beta-myrcene were negative. 
Two micronucleous tests on peripheral blood cells and one chromosomal aberration assay with beta-
myrcene gave negative results. 
Conclusion on Genotoxicity for subgroup II 
The structurally related substance myrcene [FL-no: 01.008] has like former Register substance 2-
methyl-1,3-butadiene (isoprene), two conjugated terminal double bonds, but has, similar to candidate 
substance [Fl no: 01.064], a longer chain length, with 10 carbon atoms. In contrast to isoprene, the 
candidate substances in subgroup II do not contain conjugated terminal double bonds, except [FL-no: 
01.064], which, however, are very structurally related to myrcene [FL-no: 01.008]. Therefore, the 
Panel considers myrcene a better supporting substance for the substances in group II than isoprene. 
The genotoxicity data available on myrcene do not give rise to concern with respect to genotoxicity. 
Therefore, the Panel has not concern for genotoxicity for the 6 substances in subgroup II. 
Subgroup III 
For the six candidate substances in subgroup III no genotoxicity studies were available. For the four 
supporting substances, d-limonene [FL-no: 01.045], gamma-terpinene [FL-no: 01.020], alpha-
terpinene [FL-no: 01.019] and alpha-phellandrene [FL-no: 01.006], several in vitro studies on 
genotoxicity were available and they were all negative. Also two in vivo Comet assay with d-limonene 
and a study with d-limonene in BigBlueTM rats were found negative. Therefore, the Panel has no 
concern for genotoxicity for the substances in subgroup III. 
Subgroup IVb 
Naphthalene 
Naphthalene [FL-no: 01.053], which was negative in all bacterial gene mutation tests (Ames tests, Rec 
assay, Inductest) and in a unscheduled DNA synthesis (UDS) test in primary rat hepatocytes, gave a 
weakly positive result in a valid sister chromatid exchange (SCE) test both in the presence and absence 
of metabolic activation and a positive result in a valid chromosomal aberration test in the presence of 
S9. A positive result was also reported in a mammalian cell gene mutation test (mouse lymphoma 
assay). However, the validity of this study cannot be evaluated.  
The available in vivo studies on the candidate substance naphthalene [FL-no: 01.053] reported 
negative results in a valid UDS test and in two micronucleus tests, for one of which the validity cannot 
be evaluated due to insufficiently reported experimental details.  
The genotoxicity of naphthalene [FL-no: 01.053] has been evaluated by international expert bodies 
(WHO, 1998; EU-RAR, 2003; US ATSDR, 2005). Results of the in vitro genotoxicity studies that 
were evaluated are in line with the data summarised in the present evaluation. Negative results were 
reported for all the evaluated bacterial gene mutation tests (Ames tests, Rec assays, Inductests/SOS 
response tests). For in vitro mammalian gene mutation, cytogenetic, or DNA damage assays, equally 
mixed results were reported as in the present evaluation. In addition to the studies cited in the present 
evaluation, negative results were reported for mutations at the hprt and tk locus in a human B-
lymphoblastoid cell line (Sasaki et al., 1997) and for single-strand breaks in an alkaline elution test 
with rat hepatocytes (Sina et al., 1983) as well as for some other less relevant endpoints (different cell 
transformation assays). Positive results were reported for naphthalene in a non-standard chromosomal 
aberration assay (Gollahon, 1991) and for the naphthalene metabolites 1,2- and 1,4-naphthoquinone in 
a SCE test (Wilson et al., 1996). For in vivo genotoxicity, besides the negative results from studies 
examining commonly accepted endpoints (micronuclei formation in mouse bone marrow, DNA single 
strand breaks and UDS in rat hepatocytes) as reported in the present evaluation, some positive results 
were reported for somatic mutations in D. melanogaster (Delgado-Rodriques et al., 1995), micronuclei 
in salamander larvae erythrocytes (Djomo et al., 1995), and DNA fragmentation in liver and brain 
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tissue from mice and rats orally exposed to naphthalene (Bagchi et al., 2000). However, DNA 
fragmentation per se cannot be considered a specific endpoint of genotoxicity, being rather an 
indicator of cytotoxicity, in this case due to oxidative stress. Therefore, the study by Bagchi et al. 
(2000) has no relevance for the evaluation of the genotoxic potential of naphthalene. WHO (1998) 
noted that naphthalene was inactive in all short-term mutagenicity tests evaluated by IARC in 1983 
(WHO, 1998). US ATSDR (2005) concluded that the available data suggest that genotoxic action by 
the naphthalene metabolite, 1,2-naphthoquinone, is plausible and that the mutagenic/genotoxic 
potential of naphthalene and its metabolites may be weak (US ATSDR, 2005). In the EU-RAR (2003) 
it was concluded that overall, the balance of evidence indicates that naphthalene is not genotoxic (EU-
RAR, 2003). 
2-Methylnaphthalene 
The weak increases of chromosome aberrations (chromatid breaks only at the highest concentration) 
and of the SCE in cultured human lymphocytes in the presence of S9 are of doubtful relevance (Kulka 
et al., 1988). According to the authors, these effects do not indicate that 2-methylnaphthalene is a 
potentially genotoxic substance. 
The genotoxicity of 2-methylnaphthalene has been evaluated by international expert bodies (EFSA, 
2004e; US ATSDR, 2005). Results of the in vitro genotoxicity studies that were evaluated are in line 
with the data summarised in the present evaluation. Negative results were reported for all the 
evaluated bacterial gene mutation tests (Ames tests, Rec assays, Inductests/SOS response tests). 
The supporting substance, 1-methylnaphthalene, gave a weak increase, of doubtful biological 
relevance, of SCE in cultured human lymphocytes in the presence of S9 (Kulka et al., 1988). This 
effect was interpreted by the authors not to be an indication of genotoxic potential. Furthermore, 1-
methylnaphthalene gave negative results in two bacterial reverse gene mutation tests (Florin et al., 
1980; Kaden et al., 1979); and in a chromosomal aberration assay in human lymphocytes (Kulka et al., 
1988). 
Conclusion on genotoxicity for subgroup IVb 
For naphthalene there is indication of in vitro genotoxicity especially at chromosome level. However, 
this genotoxic activity is not expressed in valid in vivo assays covering different end-points (e.g. 
micronucleus, UDS and DNA single strand breaks). 
The available data on 2-methylnaphthalene, limited to the in vitro data referred to in the present 
evaluation, were considered not to give evidence for a genotoxic activity.  
The Panel concluded that the available genotoxicity data on naphthalene and 2-methylnaphthalene do 
not preclude an evaluation of this substance through the Procedure. 
Subgroup V 
One candidate substances longifolene [FL-no: 01.047] was tested in vitro for bacterial reverse gene 
mutations and gave negative results. 
For all genotoxicity studies on supporting substances, only negative results were reported in the 
available studies except for delta-3-carene (see Table IV.4). Delta-3-carene was studied individually as 
a component in wood fumes and wood fume condensates (Kurttio et al., 1990). It was reported to be 
positive in TA100 and TA102 strains in an insufficiently reported bacterial reverse gene mutation test 
in the absence of metabolic activation at high concentrations only, while it was negative in the 
presence of metabolic activation. 
Altogether, the Panel has no concern for genotoxicity for the substances in subgroup V. 
Flavouring Group Evaluation 25, Revision 2
 
 
29 EFSA Journal 2011; 9(6):2177 
Genotoxicity data are summarised in Annex IV, Table IV.4 and IV.5. 
Overall conclusion on genotoxicity:  
Data on the genotoxicity of the flavouring substances in this group are limited and the genotoxicity 
could not be assessed adequately for these substances. However, the Panel concluded that the available 
data do not preclude evaluating the 37 candidate substances using the Procedure. 
9. Conclusions 
The present revision of FGE.25, Revision 2 includes the assessment of three additional candidate 
substances [FL-no: 01.001, 01.021 and 01.046] compared to FGE.25Rev1. The FGE.25Rev2 deals 
with 37 flavouring substances in total. 
In the previous version of the present FGE, the Panel considered that additional toxicity data were 
needed for 26 of the substances evaluated through the Procedure as no adequate toxicity study from 
which a NOAEL could be established was available, neither on the candidate substances nor on 
supporting substances. Additional toxicity data have now become available for the structurally related 
substance beta-myrcene [FL-no: 01.008]. 
However, no overall NOAEL from the NTP study on beta-myrcene could be allocated due to the 
observation renal toxicity in male and female rats at all dose groups. Therefore, additional 
toxicological data are still required. 
The 37 candidate substances are aliphatic and aromatic hydrocarbons from chemical group 31, which 
have been divided into eight subgroups: I) acyclic alkanes, II) acyclic alkenes, III) cyclohexene 
hydrocarbons, IVa) benzene hydrocarbons, IVb) napthalene hydrocarbons, IVc) diphenylmethane, V) 
bi- and tricyclic, non-aromatic hydrocarbons and VI) macrocyclic, non-aromatic hydrocarbons. 
Several of the 37 flavouring substances possess chiral centres and/or can exist as geometrical 
isomers. For five of the flavouring substances [FL-no: 01.021, 01.027, 01.032, 01.035 and 
01.078] the stereoisomeric composition/composition of mixture has not been specified 
sufficiently.  
Of the 37 candidate substances 31 are classified into structural class I [FL-no: 01.001, 01.022, 01.023, 
01.027, 01.028, 01.030, 01.032, 01.033, 01.034, 01.035, 01.037, 01.038, 01.039, 01.042, 01.043, 
01.044, 01.046, 01.047, 01.050, 01.052, 01.054, 01.055, 01.056, 01.057, 01.059, 01.060, 01.064, 
01.066, 01.067, 01.070 and 01.078], two into structural class II [FL-no: 01.031 and 01.058], and four 
into structural class III [FL-no: 01.021, 01.036, 01.051 and 01.053], according to the decision tree 
approach presented by Cramer et al. (1978). 
Thirty-three out of the 37 candidate substances have been reported to occur naturally in a wide range 
of food items. 
According to the default MSDI approach, 35 of the 37 flavouring substances in this group have intakes 
in Europe from 0.0012 to 28 microgram/capita/day, which are below the threshold of concern value 
for structural class I (1800 microgram/person/day), structural class II (540 microgram/person/day) and 
structural class III (90 microgram/person/day) substances. For limonene [FL-no: 01.001] and l-
limonene [FL-no: 01.046] the intakes are 4000 and 2100 microgram/capita/day, which are above the 
threshold of concern value for structural class I (1800 microgram/person/day). 
Combined intakes can be calculated for the substances in subgroup I (acyclic alkanes) and subgroup 
III (cyclohexene hydrocarbons) evaluated through the Procedure. 
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For subgroup I (acyclic alkanes): The combined intake of the five candidate substances, all from 
structural class I and evaluated via the A-side of the Procedure (Annex I), is 3.0 
microgram/capita/day, which does not exceed the threshold of 1800 microgram/person/day. There are 
no supporting substances in subgroup I. 
For subgroup III (cyclohexene hydrocarbons): The combined intake of the five candidate substances, 
all from structural class I and evaluated via the A-side of the Procedure (Annex I), is 6100 
microgram/capita/day, which exceeds the threshold of 1800 microgram/person/day. The total 
combined intake of the candidate and six supporting substances (also from structural class I) is 42000 
microgram/capita/day. This intake exceeds the threshold of 1800 microgram/person/day for a 
structural class I substance. However, limonene [FL-no: 01.001], l-limonene [FL-no: 01.046] and d-
limonene (supporting substance [FL-no: 01.045]) accounts for approximately 40000 
microgram/capita/day. The total combined intake of 42000 microgram/capita/day for the candidate 
and the supporting substances corresponds to 700 microgram/kg bw/day for a person with a body 
weight of 60 kg. Thus, based on the NOAEL for d-limonene of 215 mg/kg bw/day, a margin of safety 
of 307 can be calculated, and accordingly these substances are not expected to be of safety concern at 
the estimated level of intake.  
Data on the genotoxicity of the flavouring substances in this group are limited and the genotoxicity 
could not be assessed adequately for these substances. For one structurally related substance, 2-
methylbuta-1,3-diene, there is evidence of an in vivo genotoxic and carcinogenic potential. However, 
the Panel concluded that the available data do not preclude an evaluation of the 37 candidate 
substances using the Procedure.  
The available information on metabolism of the 37 candidate substances evaluated through the 
Procedure or the supporting substances for this FGE was very limited. Overall, only for the following 
10 candidate substances it can be concluded that they will be metabolised into innocuous metabolites, 
[FL-no: 01.033, 01.034, 01.038, 01.054 and 01.057] from subgroup I and [FL-no: 0.001, 01.027, 
01.028, 01.039 and 01.046] from subgroup III. For six candidate substances there are data, which 
show that they may be metabolised to toxic metabolites [FL-no: 01.037, 01.050, 01.051, 01.053, 
01.164 and 01.070]. For the remaining 21 candidate substances [FL-no: 0.021, 01.022, 01.023, 01.030, 
01.031, 01.032, 01.035, 01.036, 01.042, 01.043, 01.044, 01.047, 01.052, 01.055, 01.056, 01.058, 
01.059, 01.060, 01.066, 01.067 and 01.078], the information is too limited and it cannot be assumed 
that they are metabolised to innocuous metabolites. 
It was noted that where toxicity data were available they were consistent with the conclusions in the 
present flavouring group evaluation using the Procedure. 
It is concluded that the 10 candidate substances which are expected to be metabolised to innocuous 
substances, [FL-no: 01.033, 01.034, 01.038, 01.054 and 01.057] from subgroup I and [FL-no: 01.001, 
01.027, 01.028, 01.039 and 01.046] from subgroup III, would not give rise to safety concerns at their 
estimated intakes arising from their use as flavouring substances based on the MSDI approach. For the 
remaining 27 candidate substances, [FL-no: 01.021, 01.022, 01.023, 01.030, 01.031, 01.032, 01.035, 
01.036, 01.037, 01.042, 01.043, 01.044, 01.047, 01.050, 01.051, 01.052, 01.053, 01.055, 01.056, 
01.058, 01.059, 01.060, 01.064, 01.066, 01.067, 01.070 and 01.078] or for structurally related 
supporting substances, no adequate NOAELs were available. Therefore, additional toxicological data 
are required. 
The mTAMDI values for the 27 candidate substances from structural class I, for which use levels have 
been provided are in the range of 3100 to 3900 microgram/person/day. For each of the two candidate 
substances from structural class II and the four candidate substances from structural class III the 
mTAMDI is 3900 microgram/person/day. These values are above the threshold for structural class I, II 
and III of 1800, 540 and 90 microgram/person/day, respectively.  
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Accordingly, intake estimates according to the mTAMDI for the 33 candidate substances for which 
use levels have been provided exceed the thresholds of concern for the three structural classes, and 
more reliable exposure data are requested. On the basis of such additional data, the flavouring 
substances should be considered using the Procedure. Subsequently, additional data might become 
necessary. For the four remaining candidate substances [FL-no: 01.001, 01.046, 01.070 and 01.078] 
use levels for food categories as outlined in Commission Regulation (EC) no 1565/2000, Annex III, 
are required. 
In order to determine whether this conclusion could be applied to the materials of commerce, it is 
necessary to consider the available specifications. Specifications including complete purity criteria and 
identity for the materials of commerce have been provided for 32 flavouring substances. For five 
substances [FL-no: 01.021, 01.027, 01.032, 01.035 and 01.078] information on stereoisomeric 
composition/composition of mixture has not been specified sufficiently. 
Thus, overall, for 27 candidate substances [FL-no: 01.021, 01.022, 01.023, 01.030, 01.031, 01.032, 
01.035, 01.036, 01.037, 01.042, 01.043, 01.044, 01.047, 01.050, 01.051, 01.052, 01.053, 01.055, 
01.056, 01.058, 01.059, 01.060, 01.064, 01.066, 01.067, 01.070 and 10.078] additional toxicity data 
are required. For four of these, [FL-no: 01.021, 01.032, 01.035 and 01.078], additional information on 
composition requested. The final evaluation of the materials of commerce cannot be performed for one 
substance [FL-no: 01.027], pending further information on composition of mixture of stereoisomers.  
For nine candidate substances [FL-no: 01.001, 01.028, 01.033, 01.034, 01.038, 01.039, 01.046, 01.054 
and 01.057] the Panel concluded that they would present no safety concern at their estimated levels of 
intake based on the MSDI approach. 
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TABLE 1: SPECIFICATION SUMMARY OF THE SUBSTANCES IN THE FLAVOURING GROUP EVALUATION 25, REVISION 2 
Table 1: Specification Summary of the Substances in the Flavouring Group Evaluation 25, Revision 2 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
Phys.form 
Mol.formula 
Mol.weight 
Solubility 1) 
Solubility in ethanol 
2) 
Boiling point, °C 
3) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. 
Index 4) 
Spec.gravity 
5) 
Specification comments 
01.001 
 
Limonene 2633 
491 
138-86-3 
Liquid 
C10H16 
136.23 
Insoluble 
Soluble 
178 
 
MS 
95 % 
1.4760-
1.4820 
0.843-0.851 
 
With respect to specific 
gravity it is noted that 
limonene and l-limonene are 
submitted by different 
applicants. 
01.021 
 
delta-Cadinene 
 
 
10982 
29350-73-0 
Liquid 
C15H24 
204.36 
 
Freely soluble 
286 
 
MS 
95 % 
1.497-1.503 
0.917-0.923 
 
Mixture of beta-Cadinene 
(CAS-no 523-47-7) and 
mainly the racematic. 
mixture (+)-delta-Cadinene 
(CAS-no 483-76-1) and (-)-
delta-Cadinene (CAS-no 
60305-17-1), and some 
alpha-, gamma- and epsilon 
isomers (EFFA, 2011c). 
Composition of the 
stereosomeric mixture to be 
specified. 
 
01.022 
 
alpha-Cedrene H
H
 
10985 
469-61-4 
Liquid 
C15H24 
204.35 
Practically insoluble 
or insoluble 
Freely soluble 
119 (13 hPa) 
 
MS 
95 % 
1.500-1.506 
0.932-0.938 
 
 
01.023 
 
1(5),11-Guaiadiene  
11003 
3691-12-1 
Liquid 
C15H24 
204.35 
Practically insoluble 
or insoluble 
Freely soluble 
78 (3 hPa) 
 
MS 
95 % 
1.493-1.499 
0.897-0.903 
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Table 1: Specification Summary of the Substances in the Flavouring Group Evaluation 25, Revision 2 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
Phys.form 
Mol.formula 
Mol.weight 
Solubility 1) 
Solubility in ethanol 
2) 
Boiling point, °C 
3) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. 
Index 4) 
Spec.gravity 
5) 
Specification comments 
01.027 
 
Bisabola-1,8,12-triene  
 
17627-44-0 
Liquid 
C15H24 
204.35 
Practically insoluble 
or insoluble 
Freely soluble 
99 (5 hPa) 
 
MS 
95 % 
1.483-1.489 
0.912-0.918 
 
Racemate of (R)- and (S)-
isomers, mixture of (E)- and 
(Z)-isomers (EFFA, 2010a). 
CASrn in Register refers to 
the racemate. Composition 
of stereoisomeric mixture to 
be specified. 
01.028 
 
beta-Bisabolene  
 
495-61-4 
Liquid 
C15H24 
204.35 
Practically insoluble 
or insoluble 
Freely soluble 
130 (13 hPa) 
 
MS 
95 % 
1.489-1.495 
0.879-0.885 
 
 
01.030 
 
beta-Cubebene  
10989 
13744-15-5 
Solid 
C15H24 
204.35 
Practically insoluble 
or insoluble 
Freely soluble 
284 
60 
MS 
95 % 
n.a. 
n.a. 
 
 
01.031 
 
1,2-Dihydro-1,1,6-
trimethylnaphthalene 
 
 
30364-38-6 
Liquid 
C13H16 
172.27 
Practically insoluble 
or insoluble 
Freely soluble 
115 (24 hPa) 
 
MS 
95 % 
1.542-1.548 
0.942-0.948 
 
 
01.032 
 
2,3-Dihydrofarnesene  
 
7681-88-1 
Liquid 
C15H26 
206.37 
Practically insoluble 
or insoluble 
Freely soluble 
130 (15 hPa) 
 
NMR 
95 % 
1.468-1.474 
0.817-0.823 
 
Mixtures of (E)- and (Z)- 
isomers (EFFA, 2010a). 
CASrn in Register does not 
specify stereoisomeric 
composition. Composition 
of the stereoisomeric 
mixture to be specified. 
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Table 1: Specification Summary of the Substances in the Flavouring Group Evaluation 25, Revision 2 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
Phys.form 
Mol.formula 
Mol.weight 
Solubility 1) 
Solubility in ethanol 
2) 
Boiling point, °C 
3) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. 
Index 4) 
Spec.gravity 
5) 
Specification comments 
01.033 
 
2,2-Dimethylhexane 
 
 
 
590-73-8 
Liquid 
C8H18 
114.23 
Practically insoluble 
or insoluble 
Freely soluble 
107 
 
MS 
95 % 
1.390-1.396 
0.693-0.699 
 
 
01.034 
 
2,4-Dimethylhexane 
 
 
 
589-43-5 
Liquid 
C8H18 
114.23 
Practically insoluble 
or insoluble 
Freely soluble 
109 
 
MS 
95 % 
1.390-1.396 
0.697-0.703 
 
Racemate (EFFA, 2010a). 
01.035 
 
2,6-Dimethylocta-2,4,6-triene  
 
673-84-7 
Liquid 
C10H16 
136.24 
Practically insoluble 
or insoluble 
Freely soluble 
75 (13 hPa) 
 
MS 
95 % 
1.539-1.545 
0.809-0.815 
 
Mixtures of (E)- and (Z)- 
isomers (EFFA, 2010a). 
CASrn in Register does not 
specify stereoisomeric 
composition. Composition 
of the stereoisomeric 
mixture to be specified. 
01.036 
 
Diphenylmethane  
11847 
101-81-5 
Solid 
C13H12 
168.24 
Practically insoluble 
or insoluble 
Freely soluble 
262 
27 
MS 
95 % 
n.a. 
n.a. 
 
 
01.037 
 
Dodec-1-ene 
 
 
10992 
112-41-4 
Liquid 
C12H24 
168.23 
Practically insoluble 
or insoluble 
Freely soluble 
213 
 
MS 
95 % 
1.425-1.431 
0.755-0.761 
 
 
01.038 
 
Dodecane   
 
112-40-3 
Liquid 
C12H26 
170.34 
Practically insoluble 
or insoluble 
Freely soluble 
216 
 
MS 
95 % 
1.417-1.423 
0.746-0.752 
 
 
01.039 
 
delta-Elemene  
10996 
20307-84-0 
Liquid 
C15H24 
204.35 
Practically insoluble 
or insoluble 
Freely soluble 
107 (13 hPa) 
 
MS 
95 % 
1.480-1.486 
0.856-0.862 
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Table 1: Specification Summary of the Substances in the Flavouring Group Evaluation 25, Revision 2 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
Phys.form 
Mol.formula 
Mol.weight 
Solubility 1) 
Solubility in ethanol 
2) 
Boiling point, °C 
3) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. 
Index 4) 
Spec.gravity 
5) 
Specification comments 
01.042 
 
Germacra-1(10),4(14),5-triene  
 
23986-74-5 
Liquid 
C15H24 
204.35 
Practically insoluble 
or insoluble 
Freely soluble 
308 
 
MS 
95 % 
1.507-1.513 
0.896-0.892 
 
 
01.043 
 
3,7,10-Humulatriene  
11004 
6753-98-6 
Liquid 
C15H24 
204.35 
Practically insoluble 
or insoluble 
Freely soluble 
123 (13 hPa) 
 
MS 
95 % 
1.499-1.505 
0.889-0.895 
 
 
01.044 
 
Isolongifolene  
 
1135-66-6 
Liquid 
C15H24 
204.35 
Practically insoluble 
or insoluble 
Freely soluble 
120 (16 hPa) 
 
MS 
95 % 
1.495-1.501 
0.926-0.932 
 
 
01.046 
 
l-Limonene 2633 
491 
5989-54-8 
Liquid 
C10H16 
136.23 
Insoluble 
Soluble 
177 
 
MS 
95 % 
1.469 - 1.473 
0.837 - 0.841 
 
With respect to specific 
gravity it is noted that 
limonene and l-limonene are 
submitted by different 
applicants. 
01.047 
 
Longifolene 
H
H
H
 
 
475-20-7 
Liquid 
C15H24 
204.35 
Practically insoluble 
or insoluble 
Freely soluble 
115 (13 hPa) 
 
MS 
95 % 
1.498-1.504 
0.929-0.935 
 
 
01.050 
 
3-Methylhexane 
 
 
 
589-34-4 
Liquid 
C7H16 
100.20 
Practically insoluble 
or insoluble 
Freely soluble 
92 
 
MS 
95 % 
1.385-1.391 
0.684-0.690 
 
Racemate (EFFA, 2010a). 
01.051 
 
2-Methylnaphthalene  
11010 
91-57-6 
Solid 
C11H10 
142.20 
Practically insoluble 
or insoluble 
Freely soluble 
241 
35 
MS 
95 % 
n.a. 
n.a. 
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Table 1: Specification Summary of the Substances in the Flavouring Group Evaluation 25, Revision 2 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
Phys.form 
Mol.formula 
Mol.weight 
Solubility 1) 
Solubility in ethanol 
2) 
Boiling point, °C 
3) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. 
Index 4) 
Spec.gravity 
5) 
Specification comments 
01.052 
 
alpha-Muurolene  
11011 
10208-80-7 
Liquid 
C15H24 
204.35 
Practically insoluble 
or insoluble 
Freely soluble 
118 (17 hPa) 
 
MS 
95 % 
1.502-1.508 
0.911-0.917 
 
 
01.053 
 
Naphthalene  
11014 
91-20-3 
Solid 
C10H8 
128.17 
Practically insoluble 
or insoluble 
Freely soluble 
218 
80 
MS 
95 % 
n.a. 
n.a. 
 
 
01.054 
 
Pentadecane  
 
629-62-9 
Liquid 
C15H32 
212.42 
Practically insoluble 
or insoluble 
Freely soluble 
270 
10 
MS 
95 % 
1.428-1.434 
0.765-0.771 
 
 
01.055 
 
beta-Phellandrene  
11017 
555-10-2 
Liquid 
C10H16 
136.24 
Practically insoluble 
or insoluble 
Freely soluble 
174 
 
MS 
95 % 
1.476-1.482 
0.839-0.845 
 
Racemate (EFFA, 2010a). 
01.056 
 
alpha-Santalene  
 
512-61-8 
Liquid 
C15H24 
204.35 
Practically insoluble 
or insoluble 
Freely soluble 
112 (9 hPa) 
 
MS 
95 % 
1.480-1.486 
0.895-0.901 
 
Register name to be changed 
to (-)-alpha-Santalene 
(EFFA, 2010a). 
01.057 
 
Tetradecane  
 
629-59-4 
Liquid 
C14H30 
198.39 
Practically insoluble 
or insoluble 
Freely soluble 
252 
5 
MS 
95 % 
1.422-1.428 
0.759-0.765 
 
 
01.058 
 
1,2,3,4-Tetrahydro-1,1,6-
trimethylnaphthalene 
 
 
475-03-6 
Liquid 
C13H18 
174.29 
Practically insoluble 
or insoluble 
Freely soluble 
245 
 
MS 
95 % 
1.519-1.525 
0.932-0.938 
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Table 1: Specification Summary of the Substances in the Flavouring Group Evaluation 25, Revision 2 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
Phys.form 
Mol.formula 
Mol.weight 
Solubility 1) 
Solubility in ethanol 
2) 
Boiling point, °C 
3) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. 
Index 4) 
Spec.gravity 
5) 
Specification comments 
01.059 
 
4(10)-Thujene 
 
 
11018 
3387-41-5 
Liquid 
C10H16 
136.24 
Practically insoluble 
or insoluble 
Freely soluble 
165 
 
MS 
95 % 
1.463-1.469 
0.840-0.846 
 
Assay value: 70 % 4(10)-
thujene, 6 % alpha-pinene, 
19 % beta-pinene, 1 % 
myrcene, < 4 % not 
identified (EFFA). 
01.060 
 
1,1,7-
Trimethyltricyclo[2.2.1.0.(2.6)]hept
ane 
 
 
 
508-32-7 
Solid 
C10H16 
136.24 
Practically insoluble 
or insoluble 
Freely soluble 
152 
66 
MS 
95 % 
n.a. 
n.a. 
 
Racemate (EFFA, 2010a). 
01.064 
 
cis-3,7-Dimethyl-1,3,6-octatriene 
 
 
 
3338-55-4 
Liquid 
C10H16 
136.24 
Practically insoluble 
or insoluble 
Freely soluble 
177 
 
MS 
95 % 
1.483-1.489 
0.796-0.802 
 
Synonym: cis-beta-ocimene. 
01.066 
 
2-Cedrene H
H
 
 
 
Liquid 
C15H24 
204.35 
Practically insoluble 
or insoluble 
Freely soluble 
82 (11 hPa) 
 
MS 
95 % 
1.495-1.501 
0.928-0.934 
 
CASrn 35944-22-0 to be 
introduced in the Register. 
01.067 
 
8(14)-Cedrene HH  
 
 
Liquid 
C15H24 
204.35 
Practically insoluble 
or insoluble 
Freely soluble 
118 (13 hPa) 
 
MS 
95 % 
1.498-1.504 
0.930-0.936 
 
CASrn 22567-43-7 or 
35964-52-4 to be clarified. 
01.070 
 
1-Octene  4293 
 
111-66-0 
Liquid 
C8H16 
112.22 
Insoluble 
Soluble 
121 
 
IR NMR MS 
97 % 
1.410-1.416 
0.718-0.722 
 
 
01.078 
 
2,4-Nonadiene 
 
4292 
 
56700-78-8 
Liquid 
C9H16 
124.23 
Insoluble 
Slightly soluble 
155 
 
MS 
79 % 
1.446 
0.755 
 
Mixture of isomers:  
(2E,4E)-nonadiene: 79 % 
(1E,3E)-nonadiene: 9.7 % 
(1E,3Z)-nonadiene:: 1.1% 
Other isomers including 
(2E,4Z)-nonadien: 9.3 %. 
 
Minimum assay 79 % 
(EFFA, 2010a). 
Compostion of the mixture 
to be specified further. 
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1) Solubility in water, if not otherwise stated. 
2) Solubility in 95 %  ethanol, if not otherwise stated. 
3) At 1013.25 hPa, if not otherwise stated. 
4) At 20°C, if not otherwise stated. 
5) At 25°C, if not otherwise stated. 
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TABLE 2: SUMMARY OF SAFETY EVALUATION APPLYING THE PROCEDURE (BASED ON INTAKES CALCULATED BY THE MSDI APPROACH) 
Table 2: Summary of Safety Evaluation Applying the Procedure (based on intakes calculated by the MSDI approach) 
FL-no EU Register name Structural formula MSDI 1) 
(μg/capita/day
) 
Class 2) 
Evaluation procedure path 
3) 
Outcome on the named 
compound 
[ 4) or 5] 
Outcome on the 
material of 
commerce [6), 7), 
or 8)] 
Evaluation remarks 
01.001 
 
Limonene 
 
4000 
 
Class I 
A3: Intake above threshold; 
A5:Adequate NOAEL exist 
4) 6)  
01.027 
 
Bisabola-1,8,12-triene 0.024 
 
Class I 
A3: Intake below threshold 
4) 7)  
01.028 
 
beta-Bisabolene 2.7 
 
Class I 
A3: Intake below threshold 
4) 6)  
01.033 
 
2,2-Dimethylhexane 1.2 
 
Class I 
A3: Intake below threshold 
4) 6)  
01.034 
 
2,4-Dimethylhexane 1.2 
 
Class I 
A3: Intake below threshold 
4) 6)  
01.038 
 
Dodecane  0.012 
 
Class I 
A3: Intake below threshold 
4) 6)  
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Table 2: Summary of Safety Evaluation Applying the Procedure (based on intakes calculated by the MSDI approach) 
FL-no EU Register name Structural formula MSDI 1) 
(μg/capita/day
) 
Class 2) 
Evaluation procedure path 
3) 
Outcome on the named 
compound 
[ 4) or 5] 
Outcome on the 
material of 
commerce [6), 7), 
or 8)] 
Evaluation remarks 
01.039 
 
delta-Elemene 0.012 
 
Class I 
A3: Intake below threshold 
4) 6)  
01.046 
 
l-Limonene 
 
2100 
 
Class I 
A3: Intake above threshold 
A5:Adequate NOAEL exist 
4) 6)  
01.054 
 
Pentadecane 0.61 
 
Class I 
A3: Intake below threshold 
4) 6)  
01.057 
 
Tetradecane  0.012 
 
Class I 
A3: Intake below threshold 
4) 6)  
01.022 
 
alpha-Cedrene H
H
0.012 
 
Class I 
B3: Intake below threshold, 
B4: No adequate NOAEL 
Additional data required   
01.023 
 
1(5),11-Guaiadiene 1.2 
 
Class I 
B3: Intake below threshold, 
B4: No adequate NOAEL 
Additional data required   
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Table 2: Summary of Safety Evaluation Applying the Procedure (based on intakes calculated by the MSDI approach) 
FL-no EU Register name Structural formula MSDI 1) 
(μg/capita/day
) 
Class 2) 
Evaluation procedure path 
3) 
Outcome on the named 
compound 
[ 4) or 5] 
Outcome on the 
material of 
commerce [6), 7), 
or 8)] 
Evaluation remarks 
01.030 
 
beta-Cubebene 0.012 
 
Class I 
B3: Intake below threshold, 
B4: No adequate NOAEL 
Additional data required   
01.032 
 
2,3-Dihydrofarnesene 0.12 
 
Class I 
B3: Intake below threshold, 
B4: No adequate NOAEL 
Additional data required   
01.035 
 
2,6-Dimethylocta-2,4,6-triene 
 
9.1 
 
Class I 
B3: Intake below threshold, 
B4: No adequate NOAEL 
Additional data required   
01.037 
 
Dodec-1-ene 
 
0.024 
 
Class I 
B3: Intake below threshold, 
B4: No adequate NOAEL 
Additional data required   
01.042 
 
Germacra-1(10),4(14),5-triene 0.012 
 
Class I 
B3: Intake below threshold, 
B4: No adequate NOAEL 
Additional data required   
01.043 
 
3,7,10-Humulatriene 1.2 
 
Class I 
B3: Intake below threshold, 
B4: No adequate NOAEL 
Additional data required   
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Table 2: Summary of Safety Evaluation Applying the Procedure (based on intakes calculated by the MSDI approach) 
FL-no EU Register name Structural formula MSDI 1) 
(μg/capita/day
) 
Class 2) 
Evaluation procedure path 
3) 
Outcome on the named 
compound 
[ 4) or 5] 
Outcome on the 
material of 
commerce [6), 7), 
or 8)] 
Evaluation remarks 
01.044 
 
Isolongifolene 0.012 
 
Class I 
B3: Intake below threshold, 
B4: No adequate NOAEL 
Additional data required   
01.047 
 
Longifolene 
H
H
H
28 
 
Class I 
B3: Intake below threshold, 
B4: No adequate NOAEL 
Additional data required   
01.050 
 
3-Methylhexane 0.061 
 
Class I 
B3: Intake below threshold, 
B4: No adequate NOAEL 
Additional data required   
01.052 
 
alpha-Muurolene 0.24 
 
Class I 
B3: Intake below threshold, 
B4: No adequate NOAEL 
Additional data required   
01.055 
 
beta-Phellandrene 
 
0.012 
 
Class I 
B3: Intake below threshold, 
B4: No adequate NOAEL 
Additional data required   
01.056 
 
alpha-Santalene 0.012 
 
Class I 
B3: Intake below threshold, 
B4: No adequate NOAEL 
Additional data required   
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Table 2: Summary of Safety Evaluation Applying the Procedure (based on intakes calculated by the MSDI approach) 
FL-no EU Register name Structural formula MSDI 1) 
(μg/capita/day
) 
Class 2) 
Evaluation procedure path 
3) 
Outcome on the named 
compound 
[ 4) or 5] 
Outcome on the 
material of 
commerce [6), 7), 
or 8)] 
Evaluation remarks 
01.059 
 
4(10)-Thujene 
 
14 
 
Class I 
B3: Intake below threshold, 
B4: No adequate NOAEL 
Additional data required   
01.060 
 
1,1,7-
Trimethyltricyclo[2.2.1.0.(2.6)]h
eptane 
0.012 
 
Class I 
B3: Intake below threshold, 
B4: No adequate NOAEL 
Additional data required   
01.064 
 
cis-3,7-Dimethyl-1,3,6-octatriene 
 
14 
 
Class I 
B3: Intake below threshold, 
B4: No adequate NOAEL 
Additional data required   
01.066 
 
2-Cedrene H
H
0.97 
 
Class I 
B3: Intake below threshold, 
B4: No adequate NOAEL 
Additional data required   
01.067 
 
8(14)-Cedrene HH 0.012 
 
Class I 
B3: Intake below threshold, 
B4: No adequate NOAEL 
Additional data required   
01.070 
 
1-Octene  0.0085 
 
Class I 
B3: Intake below threshold, 
B4: No adequate NOAEL 
Additional data required   
01.078 
 
2,4-Nonadiene 
 
6.1 
 
Class I 
B3: Intake below threshold, 
B4: No adequate NOAEL 
Additional data required   
01.031 
 
1,2-Dihydro-1,1,6-
trimethylnaphthalene 
0.0012 
 
Class II 
B3: Intake below threshold, 
B4: No adequate NOAEL 
Additional data required   
01.058 
 
1,2,3,4-Tetrahydro-1,1,6-
trimethylnaphthalene 
0.12 
 
Class II 
B3: Intake below threshold, 
B4: No adequate NOAEL 
Additional data required   
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Table 2: Summary of Safety Evaluation Applying the Procedure (based on intakes calculated by the MSDI approach) 
FL-no EU Register name Structural formula MSDI 1) 
(μg/capita/day
) 
Class 2) 
Evaluation procedure path 
3) 
Outcome on the named 
compound 
[ 4) or 5] 
Outcome on the 
material of 
commerce [6), 7), 
or 8)] 
Evaluation remarks 
01.021 
 
delta-Cadinene 0.15 
 
Class III 
B3: Intake below threshold, 
B4: No adequate NOAEL 
Additional data required   
01.036 
 
Diphenylmethane 1.2 
 
Class III 
B3: Intake below threshold, 
B4: No adequate NOAEL 
Additional data required   
01.051 
 
2-Methylnaphthalene 0.0012 
 
Class III 
B3: Intake below threshold, 
B4: No adequate NOAEL 
Additional data required   
01.053 
 
Naphthalene 0.013 
 
Class III 
B3: Intake below threshold, 
B4: No adequate NOAEL 
Additional data required   
1) EU MSDI: Amount added to food as flavour in (kg / year) x 10E9 / (0.1 x population in Europe (= 375 x 10E6) x 0.6 x 365)  =  µg/capita/day. 
2) Thresholds of concern: Class I = 1800 µg/person/day, Class II = 540 µg/person/day, Class III = 90 µg/person/day. 
3) Procedure path A substances can be predicted to be metabolised to innocuous products.  Procedure path B substances cannot. 
4) No safety concern based on intake calculated by the MSDI approach of the named compound. 
5) Data must be available on the substance or closely related substances to perform a safety evaluation. 
6) No safety concern at estimated level of intake of the material of commerce meeting the specification of Table 1 (based on intake calculated by the MSDI approach). 
7) Tentatively regarded as presenting no safety concern (based on intake calculated by the MSDI approach) pending further information on the purity of the material of commerce and/or information on stereoisomerism. 
8) No conclusion can be drawn due to lack of information on the purity of the material of commerce. 
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TABLE 3: SUPPORTING SUBSTANCES SUMMARY (JECFA, 2005C) 
Table 3: Supporting Substances Summary (JECFA, 2005c) 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
JECFA no  
Specification available 
MSDI (EU) 1) 
(μg/capita/day) 
SCF status 2) 
JECFA status 3) 
CoE status 4) 
Comments 
01.003 Pin-2(10)-ene 2903 
2114 
127-91-3 
1330 
JECFA specification (JECFA, 
2005b) 
1300  
No safety concern a) 
Category B b) 
JECFA name: beta-
Pinene. 
EFSA conclusion: 
Additional data required 
(EFSA, 2011j). 
01.004 Pin-2(3)-ene 2902 
2113 
80-56-8 
1329 
JECFA specification (JECFA, 
2005b) 
1800  
No safety concern a) 
Category B b) 
JECFA name: alpha-
Pinene. 
EFSA conclusion: 
Additional data required 
(EFSA, 2011j). 
01.005 Terpinolene 
 
3046 
2115 
586-62-9 
1331 
JECFA specification (JECFA, 
2005b) 
660  
No safety concern a) 
Category B b) 
 
01.006 alpha-Phellandrene 
 
2856 
2117 
99-83-2 
1328 
JECFA specification (JECFA, 
2005b) 
79  
No safety concern a) 
Category B b) 
 
01.007 beta-Caryophyllene 2252 
2118 
87-44-5 
1324 
JECFA specification (JECFA, 
2005b) 
330  
No safety concern a) 
Category B b) 
EFSA conclusion: 
Additional data required 
(EFSA, 2011j). 
01.008 Myrcene 2762 
2197 
123-35-3 
1327 
JECFA specification (JECFA, 
2005b) 
290  
No safety concern a) 
Category B b) 
EFSA conclusion: 
Additional data required 
(EFSA, 2011j). 
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Table 3: Supporting Substances Summary (JECFA, 2005c) 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
JECFA no  
Specification available 
MSDI (EU) 1) 
(μg/capita/day) 
SCF status 2) 
JECFA status 3) 
CoE status 4) 
Comments 
01.009 Camphene 2229 
2227 
79-92-5 
1323 
JECFA specification (JECFA, 
2005b) 
13  
No safety concern a) 
Category B b) 
EFSA conclusion: 
Additional data required 
(EFSA, 2011j). 
01.014 1-Methylnaphthalene 3193 
11009 
90-12-0 
1335 
JECFA specification (JECFA, 
2005b) 
0.73  
No safety concern a) 
 
EFSA conclusion: 
Additional data required 
(EFSA, 2011j). 
01.016 1,4(8),12-Bisabolatriene 3331 
10979 
495-62-5 
1336 
JECFA specification (JECFA, 
2005b) 
13  
No safety concern a) 
 
JECFA name: 
Bisabolene. 
01.017 Valencene 3443 
11030 
4630-07-3 
1337 
JECFA specification (JECFA, 
2005b) 
53  
No safety concern a) 
 
EFSA conclusion: 
Additional data required 
(EFSA, 2011j). 
01.018 beta-Ocimene 
(E, E)- isomer shown
 
3539 
11015 
13877-91-3 
1338 
JECFA specification (JECFA, 
2005b). 
55  
No safety concern a) 
 
JECFA name: 3,7-
Dimethyl-1,3,6-
octatriene. 
EFSA conclusion: 
Additional data required 
(EFSA, 2011j). 
01.019 alpha-Terpinene 
 
3558 
11023 
99-86-5 
1339 
JECFA specification (JECFA, 
2005b) 
28  
No safety concern a) 
 
JECFA name: p-
Mentha-1,3-diene. 
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Table 3: Supporting Substances Summary (JECFA, 2005c) 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
JECFA no  
Specification available 
MSDI (EU) 1) 
(μg/capita/day) 
SCF status 2) 
JECFA status 3) 
CoE status 4) 
Comments 
01.020 gamma-Terpinene 
 
3559 
11025 
99-85-4 
1340 
JECFA specification (JECFA, 
2005b). 
1200  
No safety concern a) 
 
JECFA name: p-
Mentha-1,4-diene. 
01.024 beta-Bourbonene H
H H
 
11931 
5208-59-3 
1345 
JECFA specification (JECFA, 
2005b) 
ND  
No safety concern a) 
 
EFSA conclusion: 
Additional data required 
(EFSA, 2011j). 
MSDI based on USA 
production figure. 
01.026 1(5),7(11)-Guaiadiene 
S
S
 
 
88-84-6 
1347 
JECFA specification (JECFA, 
2005b) 
0.012  
No safety concern a) 
 
JECFA name: Guaiene. 
EFSA conclusion: 
Additional data required 
(EFSA, 2011j). 
01.029 delta-3-Carene 3821 
10983 
13466-78-9 
1342 
JECFA specification (JECFA, 
2005b) 
290  
No safety concern a) 
 
EFSA conclusion: 
Additional data required 
(EFSA, 2011j). 
01.040 alpha-Farnesene 
 
3839 
10998 
502-61-4 
1343 
JECFA specification (JECFA, 
2005b) 
0.61  
No safety concern a) 
 
EFSA conclusion: 
Additional data required 
(EFSA, 2011j). 
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Table 3: Supporting Substances Summary (JECFA, 2005c) 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
JECFA no  
Specification available 
MSDI (EU) 1) 
(μg/capita/day) 
SCF status 2) 
JECFA status 3) 
CoE status 4) 
Comments 
01.045 d-Limonene 
 
2633 
491 
5989-27-5 
1326 
JECFA specification (JECFA, 
2005b) 
34000  
No safety concern a) 
 
ADI not specified 
(JECFA, 2006a). 
01.061 Undeca-1,3,5-triene 
 
3795 
 
16356-11-9 
1341 
JECFA specification (JECFA, 
2005b) 
0.24  
No safety concern a) 
 
JECFA name: 1,3,5-
Undecatriene. 
EFSA conclusion: 
Additional data required 
(EFSA, 2011j). 
1) EU MSDI: Amount added to food as flavouring substance in (kg / year) x 10E9 / (0.1 x population in Europe (= 375 x 10E6) x 0.6 x 365)  =  µg/capita/day. 
2) Category 1: Considered safe in use, Category 2: Temporarily considered safe in use, Category 3: Insufficient data to provide assurance of safety in use, Category 4: Not acceptable due to evidence of toxicity. 
3) No safety concern at estimated levels of intake. 
4) Category A: Flavouring substance, which may be used in foodstuffs, Category B: Flavouring substance which can be used provisionally in foodstuffs. 
a) (JECFA, 2005c). 
b) (CoE, 1992). 
ND)  No intake data reported. 
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ANNEX I: PROCEDURE FOR THE SAFETY EVALUATION 
The approach for a safety evaluation of chemically defined flavouring substances as referred to in 
Commission Regulation (EC) No 1565/2000 (EC, 2000a), named the "Procedure", is shown in schematic 
form in Figure I.1. The Procedure is based on the Opinion of the Scientific Committee on Food expressed on 
2 December 1999 (SCF, 1999a), which is derived from the evaluation Procedure developed by the Joint 
FAO/WHO Expert Committee on Food Additives at its 44th, 46th and 49th meetings (JECFA, 1995; JECFA, 
1996a; JECFA, 1997a; JECFA, 1999b). 
The Procedure is a stepwise approach that integrates information on intake from current uses, structure-
activity relationships, metabolism and, when needed, toxicity. One of the key elements in the Procedure is 
the subdivision of flavourings into three structural classes (I, II, III) for which thresholds of concern (human 
exposure thresholds) have been specified. Exposures below these thresholds are not considered to present a 
safety concern. 
Class I contains flavourings that have simple chemical structures and efficient modes of metabolism, which 
would suggest a low order of oral toxicity. Class II contains flavourings that have structural features that are 
less innocuous, but are not suggestive of toxicity. Class III comprises flavourings that have structural 
features that permit no strong initial presumption of safety, or may even suggest significant toxicity (Cramer 
et al., 1978). The thresholds of concern for these structural classes of 1800, 540 or 90 microgram/person/day, 
respectively, are derived from a large database containing data on subchronic and chronic animal studies 
(JECFA, 1996a). 
In Step 1 of the Procedure, the flavourings are assigned to one of the structural classes. The further steps 
address the following questions: 
• can the flavourings be predicted to be metabolised to innocuous products8 (Step 2)?  
• do their exposures exceed the threshold of concern for the structural class (Step A3 and B3)? 
• are the flavourings or their metabolites endogenous9 (Step A4)?  
• does a NOAEL exist on the flavourings or on structurally related substances (Step A5 and B4)? 
In addition to the data provided for the flavouring substances to be evaluated (candidate substances), 
toxicological background information available for compounds structurally related to the candidate 
substances is considered (supporting substances), in order to assure that these data are consistent with the 
results obtained after application of the Procedure.  
The Procedure is not to be applied to flavourings with existing unresolved problems of toxicity. Therefore, 
the right is reserved to use alternative approaches if data on specific flavourings warranted such actions.  
                                                     
 
8 “Innocuous metabolic products”: Products that are known or readily predicted to be harmless to humans at the estimated intakes of 
the flavouring agent” (JECFA, 1997a). 
 
9 “Endogenous substances”: Intermediary metabolites normally present in human tissues and fluids, whether free or conjugated; 
hormones and other substances with biochemical or physiological regulatory functions are not included (JECFA, 1997a). 
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Decision tree structural class 
Can the substance be predicted to be metabolised to innocuous products?
Procedure for Safety Evaluation of Chemically Defined Flavouring Substances 
Do the conditions of use result in an intake greater than the 
threshold of concern for the structural class?
Do the conditions of use result in an intake greater than the  
threshold of concern for the structural class? 
Data must be available on the  
substance or closely related  
substances to perform a safety 
evaluation
Does a NOAEL exist for the substance which provides an adequate 
margin of safety under conditions of intended use, or does a NOAEL 
exist for structurally related substances which is high enough to 
accommodate any perceived difference in toxicity between the 
substance and the related substances? 
Does a NOAEL exist for the substance which provides an adequate 
margin of safety under conditions of intended use, or does a NOAEL 
exist for structurally related substances which is  high enough to 
accommodate any perceived difference in toxicity between the 
substance and the related substances? 
  Substance would not be    
expected to be of safety concern
Is the substance or are its metabolites endogenous?
Additional data required 
Step 1. 
Step 2. 
Step A3. 
Step A4. 
Step A5. 
Step B3. 
Step B4.
 Yes No
 Yes 
 No 
No
No
Yes
No
Yes
Yes
Yes
 No
Figure I.1 Procedure for Safety Evaluation of Chemically Defined Flavouring Substances
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ANNEX II: USE LEVELS / MTAMDI 
II.1 Normal and Maximum Use Levels 
For each of the 18 Food categories (Table II.1.1) in which the candidate substances are used, Flavour 
Industry reports a “normal use level” and a “maximum use level” (EC, 2000a). According to the Industry the 
”normal use” is defined as the average of reported usages and ”maximum use” is defined as the 95th 
percentile of reported usages (EFFA, 2002i). The normal and maximum use levels in different food 
categories (EC, 2000a) have been extrapolated from figures derived from 12 model flavouring substances 
(EFFA, 2004e). 
Table II.1.1 Food categories according to Commission Regulation (EC) No 1565/2000 (EC, 2000a) 
Food category Description 
01.0 Dairy products, excluding products of category 02.0 
02.0 Fats and oils, and fat emulsions (type water-in-oil) 
03.0 Edible ices, including sherbet and sorbet 
04.1 Processed fruit 
04.2 Processed vegetables (incl. mushrooms & fungi, roots & tubers, pulses and legumes), and nuts & seeds 
05.0 Confectionery 
06.0 Cereals and cereal products, incl. flours & starches from roots & tubers, pulses & legumes, excluding bakery 
07.0 Bakery wares 
08.0 Meat and meat products, including poultry and game 
09.0 Fish and fish products, including molluscs, crustaceans and echinoderms  
10.0 Eggs and egg products 
11.0 Sweeteners, including honey 
12.0 Salts, spices, soups, sauces, salads, protein products, etc. 
13.0 Foodstuffs intended for particular nutritional uses 
14.1 Non-alcoholic ("soft") beverages, excl. dairy products 
14.2 Alcoholic beverages, incl. alcohol-free and low-alcoholic counterparts 
15.0 Ready-to-eat savouries 
16.0 Composite foods (e.g. casseroles, meat pies, mincemeat) - foods that could not be placed in categories 01.0 - 15.0 
 
The “normal and maximum use levels” are provided by Industry for the 33 of the 37 candidate substances in 
the present flavouring group (Table II.1.2). 
Table II.1.2 Normal and Maximum use levels (mg/kg) for the candidate substances in FGE.25Rev2 (EFFA, 
2005a; EFFA, 2006o; EFFA, 2007a). 
FL-no Food Categories 
Normal use levels (mg/kg) 
Maximum use levels (mg/kg) 
01.0 02.0 03.0 04.1 04.2 05.0 06.0 07.0 08.0 09.0 10.0 11.0 12.0 13.0 14.1 14.2 15.0 16.0 
01.021 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
01.022 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
01.023 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
01.027 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
01.028 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
01.030 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
01.031 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
01.032 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
01.033 7 5 10 7 - 10 5 10 2 2 - - 5 10 5 10 20 5 
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Table II.1.2 Normal and Maximum use levels (mg/kg) for the candidate substances in FGE.25Rev2 (EFFA, 
2005a; EFFA, 2006o; EFFA, 2007a). 
FL-no Food Categories 
Normal use levels (mg/kg) 
Maximum use levels (mg/kg) 
01.0 02.0 03.0 04.1 04.2 05.0 06.0 07.0 08.0 09.0 10.0 11.0 12.0 13.0 14.1 14.2 15.0 16.0 
35 25 50 35 - 50 25 50 10 10 - - 25 50 25 50 100 25 
01.034 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
01.035 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
01.036 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
01.037 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
01.038 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
01.039 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
4 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
01.042 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
01.043 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
01.044 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
- 
- 
5 
25 
01.047 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
01.050 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
01.051 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
01.052 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
01.053 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
01.054 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
01.055 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
01.056 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
01.057 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
01.058 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
01.059 3 
15 
2 
10 
3 
15 
2 
10 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
3 
15 
5 
8 
15 
75 
5 
25 
01.060 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
01.064 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
01.066 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
01.067 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
II.2 mTAMDI Calculations 
The method for calculation of modified Theoretical Added Maximum Daily Intake (mTAMDI) values is 
based on the approach used by SCF up to 1995 (SCF, 1995). The assumption is that a person may consume 
the amount of flavourable foods and beverages listed in Table II.2.1. These consumption estimates are then 
multiplied by the reported use levels in the different food categories and summed up.  
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Table II.2.1 Estimated amount of flavourable foods, beverages, and exceptions assumed to be consumed per 
person per day (SCF, 1995) 
Class of product category Intake estimate (g/day) 
Beverages (non-alcoholic) 324.0 
Foods 133.4 
Exception a: Candy, confectionery 27.0 
Exception b: Condiments, seasonings 20.0 
Exception c: Alcoholic beverages 20.0 
Exception d: Soups, savouries 20.0 
Exception e: Others, e.g. chewing gum e.g. 2.0 (chewing gum) 
 
The mTAMDI calculations are based on the normal use levels reported by Industry. The seven food 
categories used in the SCF TAMDI approach (SCF, 1995) correspond to the 18 food categories as outlined in 
Commission Regulation (EC) No 1565/2000 (EC, 2000a) and reported by the Flavour Industry in the 
following way (see Table II.2.2): 
• Beverages (SCF, 1995) correspond to food category 14.1 (EC, 2000a) 
• Foods (SCF, 1995) correspond to the food categories 1, 2, 3, 4.1, 4.2, 6, 7, 8, 9, 10, 13, and/or 16 
(EC, 2000a) 
• Exception a (SCF, 1995) corresponds to food category 5 and 11 (EC, 2000a) 
• Exception b (SCF, 1995) corresponds to food category 15 (EC, 2000a) 
• Exception c (SCF, 1995) corresponds to food category 14.2 (EC, 2000a) 
• Exception d (SCF, 1995) corresponds to food category 12 (EC, 2000a) 
• Exception e (SCF, 1995) corresponds to others, e.g. chewing gum. 
Table II.2.2 Distribution of the 18 food categories listed in Commission Regulation (EC) No 1565/2000 (EC, 
2000a) into the seven SCF food categories used for TAMDI calculation (SCF, 1995) 
 Food categories according to Commission Regulation 1565/2000 Distribution of the seven SCF food categories 
Key Food category Food Beverages Exceptions 
01.0 Dairy products, excluding products of category 02.0 Food   
02.0 Fats and oils, and fat emulsions (type water-in-oil) Food   
03.0 Edible ices, including sherbet and sorbet Food   
04.1 Processed fruit Food   
04.2 Processed vegetables (incl. mushrooms & fungi, roots & tubers, pulses and legumes), 
and nuts & seeds 
Food   
05.0 Confectionery   Exception a 
06.0 Cereals and cereal products, incl. flours & starches from roots & tubers, pulses & 
legumes, excluding bakery 
Food   
07.0 Bakery wares Food   
08.0 Meat and meat products, including poultry and game Food   
09.0 Fish and fish products, including molluscs, crustaceans and echinoderms  Food   
10.0 Eggs and egg products Food   
11.0 Sweeteners, including honey   Exception a 
12.0 Salts, spices, soups, sauces, salads, protein products, etc.    Exception d 
13.0 Foodstuffs intended for particular nutritional uses Food   
14.1 Non-alcoholic ("soft") beverages, excl. dairy products  Beverages  
14.2 Alcoholic beverages, incl. alcohol-free and low-alcoholic counterparts   Exception c 
15.0 Ready-to-eat savouries   Exception b 
16.0 Composite foods (e.g. casseroles, meat pies, mincemeat) - foods that could not be Food   
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Table II.2.2 Distribution of the 18 food categories listed in Commission Regulation (EC) No 1565/2000 (EC, 
2000a) into the seven SCF food categories used for TAMDI calculation (SCF, 1995) 
 Food categories according to Commission Regulation 1565/2000 Distribution of the seven SCF food categories 
placed in categories 01.0 - 15.0 
 
The mTAMDI values (see Table II.2.3) are presented for each of the 33 flavouring substances in the present 
flavouring group, for which Industry has provided use and use levels (EFFA, 2005a; EFFA, 2006o; EFFA, 
2007a). The mTAMDI values are only given for the highest reported normal use levels. 
TableII.2.3 Estimated intakes based on the mTAMDI approach 
FL-no EU Register name mTAMDI 
(μg/person/day) 
Structural class Threshold of concern 
(µg/person/day) 
01.001 Limonene  Class I 1800 
01.027 Bisabola-1,8,12-triene 3900 Class I 1800 
01.028 beta-Bisabolene 3900 Class I 1800 
01.033 2,2-Dimethylhexane 3900 Class I 1800 
01.034 2,4-Dimethylhexane 3900 Class I 1800 
01.038 Dodecane 3900 Class I 1800 
01.039 delta-Elemene 3900 Class I 1800 
01.046 l-Limonene  Class I 1800 
01.054 Pentadecane 3900 Class I 1800 
01.057 Tetradecane 3900 Class I 1800 
01.022 alpha-Cedrene 3900 Class I 1800 
01.023 1(5),11-Guaiadiene 3900 Class I 1800 
01.030 beta-Cubebene 3900 Class I 1800 
01.032 2,3-Dihydrofarnesene 3900 Class I 1800 
01.035 2,6-Dimethylocta-2,4,6-triene 3900 Class I 1800 
01.037 Dodec-1-ene 3900 Class I 1800 
01.042 Germacra-1(10),4(14),5-triene 3900 Class I 1800 
01.043 3,7,10-Humulatriene 3900 Class I 1800 
01.044 Isolongifolene 3500 Class I 1800 
01.047 Longifolene 3900 Class I 1800 
01.050 3-Methylhexane 3900 Class I 1800 
01.052 alpha-Muurolene 3900 Class I 1800 
01.055 beta-Phellandrene 3900 Class I 1800 
01.056 alpha-Santalene 3900 Class I 1800 
01.059 4(10)-Thujene 3100 Class I 1800 
01.060 1,1,7-Trimethyltricyclo[2.2.1.0.(2.6)]heptane 3900 Class I 1800 
01.064 cis-3,7-Dimethyl-1,3,6-octatriene 3900 Class I 1800 
01.066 2-Cedrene 3900 Class I 1800 
01.067 8(14)-Cedrene 3900 Class I 1800 
01.070 1-Octene  Class I 1800 
01.078 2,4-Nonadiene  Class I 1800 
01.031 1,2-Dihydro-1,1,6-trimethylnaphthalene 3900 Class II 540 
01.058 1,2,3,4-Tetrahydro-1,1,6-trimethylnaphthalene 3900 Class II 540 
01.021 delta-Cadinene 3900 Class III 90 
01.036 Diphenylmethane 3900 Class III 90 
01.051 2-Methylnaphthalene 3900 Class III 90 
01.053 Naphthalene 3900 Class III 90 
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ANNEX III: METABOLISM 
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III.1. Introduction 
This group of flavouring substances is very diverse with respect to the chemical structures. In order to 
facilitate the evaluation of the metabolism aspects of the individual substances, the candidate substances in 
the group have been divided into eight subgroups: I) acyclic saturated hydrocarbons [FL-no: 01.033, 01.034, 
01.038, 01.050, 01.054 and 01.057], II) acyclic unsaturated hydrocarbons [FL-no: 01.032, 01.035, 01.037, 
01.064, 01.070 and 01.078], III) cyclohexene hydrocarbons [FL-no: 01.001, 01.027, 01.028, 01.039, 01.046, 
and 01.055], IVa) benzene hydrocarbons [FL-no: 01.031 and 01.058], IVb) naphthalene hydrocarbons [FL-
no: 01.051 and 01.053], IVc) diphenylmethane [FL-no: 01.036], V) bi- and tricyclic, non-aromatic 
hydrocarbons [FL-no: 01.021, 01.022, 01.023, 01.030, 01.044, 01.047, 01.052, 01.056, 01.059, 01.060, 
01.066 and 01.067] and VI) macrocyclic, non-aromatic hydrocarbons [FL-no: 01.042 and 01.043]. From the 
evaluation of flavouring substances as carried out by the JECFA in 2004, a group of supporting substances 
has been identified. These supporting substances have also been allocated to subgroups in the same way as 
has been indicated for the candidate substances. The allocation of the candidate and supporting substances is 
shown in Table III.1. 
Table III.1 Subgroups. The supporting substances are listed in brackets. 
FL-no EU Register name Structural formula Structural class 
I:  ACYCLIC ALKANES 
01.033 2,2-Dimethylhexane    I 
01.034 2,4-Dimethylhexane   I 
01.038 Dodecane    I 
01.050 3-Methylhexane    I 
01.054 Pentadecane    I 
01.057 Tetradecane     I 
II:  ACYCLIC ALKENES 
01.032 2,3-Dihydrofarnesene   I 
01.035 2,6-Dimethylocta-2,4,6-triene I 
01.037 Dodec-1-ene I 
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Table III.1 Subgroups. The supporting substances are listed in brackets. 
FL-no EU Register name Structural formula Structural class 
Deleted from 
the Register 
2-Methylbuta-1,3-diene I 
01.064 cis-3,7-Dimethyl-1,3,6-octatriene I 
01.070 1-Octene I 
01.078 2,4-Nonadiene I 
(01.008) (Myrcene) I 
(01.018) (beta-Ocimene) I 
(01.040) (alpha-Farnesene) I 
(01.061) (Undeca-1,3,5-triene) I 
III:  CYCLOHEXENE HYDROCARBONS 
01.001 Limonene I 
01.046 l-Limonene I 
01.055 beta-Phellandrene I 
01.027 Bisabola-1,8,12-triene   
 
 
I 
01.028 beta-Bisabolene I 
01.039 delta-Elemene I 
(01.005) (Terpinolene) I 
(01.006) (alpha-Phellandrene) I 
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Table III.1 Subgroups. The supporting substances are listed in brackets. 
FL-no EU Register name Structural formula Structural class 
(01.016) (1,4(8),12-Bisabolatriene) I 
(01.019) (alpha-Terpinene) I 
(01.020) (gamma-Terpinene) I 
(01.045) (d-Limonene) I 
IV: AROMATIC HYDROCARBONS 
IVa:  BENZENE HYDROCARBONS 
01.031 1,2-Dihydro-1,1,6-trimethylnaphthalene II 
01.058 1,2,3,4-Tetrahydro-1,1,6-
trimethylnaphthalene    
II 
IVb:  NAPHTHALENE HYDROCARBONS 
01.051 2-Methylnaphthalene    III 
01.053 Naphthalene    III 
(01.014) (1-Methylnaphthalene) III 
IVc: DIPHENYLMETHANE 
01.036 Diphenylmethane   III 
V: BI- and TRICYCLIC, NON-AROMATIC HYDROCARBONS
01.021 Delta-Cadinene III 
01.022 alpha-Cedrene HH I 
01.023 1(5),11-Guaiadiene I 
01.030 beta-Cubebene I 
01.044 Isolongifolene I 
01.047 Longifolene 
H
H
H
I 
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Table III.1 Subgroups. The supporting substances are listed in brackets. 
FL-no EU Register name Structural formula Structural class 
01.052 alpha-Muurolene I 
01.056 alpha-Santalene   I 
01.059 4(10)-Thujene I 
01.060 1,1,7-
Trimethyltricyclo[2.2.1.0.(2.6)]heptane   
I 
01.066 2-Cedrene I 
01.067 8(14)-Cedrene I 
(01.003) (Pin-2(10)-ene) I 
(01.004) (Pin-2(3)-ene) I 
(01.007) (beta-Caryophyllene) I 
(01.009) (Camphene) I 
(01.017) (Valencene) I 
(01.024) (beta-Bourbonene) H
H H
I 
(01.026) (1(5),7(11)-Guaiadiene) I 
(01.029) (delta-3-Carene) I 
VI: MACROCYCLIC, NON-AROMATIC HYDROCARBONS
01.042 Germacra-1(10),4(14),5-triene I 
01.043 3,7,10-Humulatriene I 
For the majority of the substances no information of biotransformation had been submitted. Also data on 
structural analogues were scarce. Therefore, an additional search was carried out. The additional information 
retrieved has been included in the following text. 
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III.2. Absorption, Distribution and Elimination 
Acyclic Alkanes (Candidate and Structurally Related Supporting Substances from Subgroup I)  
No data on absorption, distribution and elimination were submitted for any of the candidate substances in 
this subgroup. Some studies on saturated alkanes were retrieved from the additional data search, but apart 
from two oral studies (Olson et al., 1986; Serve et al., 1995) and one subcutaneous study (Manini et al., 
1999), in all other studies retrieved, inhalation was the route of exposure. From these studies (Bahima et al., 
1984; Perbellini et al., 1986; Perbellini et al., 1982; Fedtke and Bolt, 1987; Holmberg et al., 1977), 
absorption through the membranes of the inhalatory tract was observed. Absorption rates and distribution 
ratios were dependent on blood/air and blood/tissue partition coefficients (Imbriani et al., 1985; Nilsen et al., 
1988). In addition, one inhalation study by (Dahl, 1989) showed that more branched isomers were less well 
absorbed than less branched or unbranched isomers. More saturated hydrocarbons were less well absorbed 
than unsaturated and more volatile substances were less well absorbed than less volatile (reversely correlated 
to chain length), but this may not be a relevant difference for oral exposure situations. The main purpose of 
these studies was however to study metabolism, but these inhalation exposure studies do in general not 
provide appropriate mass balance data. For that reason, apart from the two oral and one inhalation study 
(Dahl, 1989) which give insight in mass balance, the studies by (Bahima et al., 1984; Perbellini et al., 1986; 
Perbellini et al., 1982; Fedtke and Bolt, 1987) and (Manini et al., 1999) will be discussed in the section on 
biotransformation.  
Male and female rats were given a dose of 2 ml/kg or 1.4 g/kg n-octane by gavage and urine was collected 
for up to 48 hours. Urine samples were treated with glucuronidase/sulphatase and the liberated metabolites 
were analysed by gas chromatography. Several oxidised metabolites in the urine could be found, but 
quantitative data were not given (Olson et al., 1986). A similar study was carried out with n-nonane by Serve 
et al. (Serve et al., 1995), but again, no quantitative data were provided. 
Groups of three or four male F 344 rats were exposed to [4-14C] or [5-14C]-labelled iso-octane (= 2,2,4-
trimethyl pentane (trivial name)) and [1-14C]-octane vapours at approximately 1 and 350 ppm (~ 4.76 or 
1700 mg/m3 for both substances) by the nose for two hours. During the experiment exhalant was drawn 
through a bubbler train for sampling. Urine and faeces were collected at the same times, except that none 
were collected at one and two hours. For iso-octane, all rats exposed to 350 ppm were exposed to C4-labeled 
substance, but three of four low-exposure rats were exposed to C5-labeled iso-octane. Values for exhaled 
14CO2 were 0.36; 0.31; and 0.52 % of inhaled 14C. For the single rat exposed to C4-labeled iso-octane the 
corresponding value was 2 %10. Values for all rats were averaged regardless of position of label. The validity 
of conclusions regarding low production of 14CO2 from iso-octane would have been enhanced by exclusive 
use of C5-labeled material. 
For both n-octane and iso-octane the metabolised fraction was higher at low compared to high inhaled 
concentrations. For octane the major route of elimination was as carbon dioxide (15 % of the radioactive 
dose within 70 hours). For iso-octane the major route of excretion was urine. Half of the octane-introduced 
14C that was retained at the end of the two-hour exposure period was eliminated 5 - 10 hours post exposure 
and the exhalation of radiolabel became undetectable after 30 hours after which 75 - 85 % of the label was 
eliminated. For iso-octane the time to eliminate half of the label was 15 hours and was not completed at the 
end of the observation period. Based on a discussion of papers from other research groups, the study authors 
suggest that for straight-chain hydrocarbons, breakdown of the carbon skeleton with the release of CO2 is an 
important metabolic pathway. The route of excretion for n-octane in this study was markedly affected by the 
concentrations of the inhaled vapour. The ratio of total exhaled 14CO2: total 14C in urine was 5:1 after 
inhalation at 1 ppm but about 1:1 after inhalation of 350 ppm (Dahl, 1989). 
                                                     
 
10 In an additional study (not reported in detail), three rats were exposed to C4- or C5-labeled iso-octane at about 350 ppm. More 
14CO2 was exhaled during exposure to the C4-labeled material (0.07% of the inhaled amount) than after exposure to the C5-labeled 
material (0.03 %). This observation also confirms that C5 labelled iso-octane is less well metabolised to CO2 than C4 labelled iso-
octane. 
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Acyclic Alkenes (Candidate and Structurally Related Supporting Substances from Subgroup II) 
When given to male Japanese White rabbits by gavage at a dose of 670 mg/kg bw per day for two days, 
approximately 25 % of the total administered amount of myrcene [FL no: 01.008] (19 g to six rabbits) could 
be recovered from the urine over a period of three days following administration (Ishida et al., 1981). Only 
metabolites of myrcene were identified. The fate of the remaining part of the dose is unclear. 
Following intraperitoneal injection of 64 mg [4-14C]-2-methylbuta-1,3-diene/kg to F344 rats and B6C3F1 
mice, the majority of radioactivity (≈ 54 and 47 %, respectively) was excreted unchanged in the expired air 
or as urinary metabolites (≈ 32 and 33 %, respectively) over the 24 hours collection period. Less than 2 % of 
the radioactivity was recovered as CO2 for both species, and 0.2 and 7.2 % in rats and mice, respectively, of 
the radioactivity was recovered in the faeces over the same time period. Radioactivity remaining in the 
carcass and tissues amounted to only 3.1 and 1.7 % in rats and mice, respectively. From the tissues 
examined, the highest concentration was found in the kidneys but in both species the renal concentration of 
radioactivity was only twice as high as the concentration in blood. Total percentage of the dose recovered 
was ≈ 91 % for both rats and mice (Buckley et al., 1999). 
Cyclohexene Derivatives (Candidate and Structurally Related Supporting Substances from Subgroup 
III)  
Data were only available for one supporting substance in subgroup III, namely d-limonene [FL-no: 01.045].  
Following the oral administration of [9-14C]-d-limonene to male Wistar rats by stomach tube at a dose of 800 
mg/kg bw, radioactivity was determined in blood, tissues (fat not included), excreta, bile and expired air. The 
animals were sacrificed at 48 hours post dosing. Radioactivity reached a peak plasma level at two hours post 
dosing, and after maintaining high levels for 10 hours, declined to negligible levels at 48 hours. In most 
tissues, peak levels of radioactivity were reached within two hours post dosing indicating rapid distribution. 
The liver, kidney and adrenals contained the highest levels of radioactivity (higher than blood or serum); 
other tissues (including brain) contained less than 0.2 % of the administered radioactivity. Hardly any 
radioactivity could be detected at 48 hours post dosing. Whole body autoradiography confirmed these 
findings. At 48 hours post-dosing, about 60 % of the administered radioactivity was recovered from the 
urine, 5 % from faeces and 2 % from exhaled air as CO2. Approximately 25 % of the administered 
radioactivity was excreted in the bile during 24 hours after administration. Total recovery of radioactivity 
was less than 100 % and as there was hardly any radioactivity present in the tissues at 48 hours, this could 
point to loss of volatile 14C from the excreta or to the elimination of volatile 14C-compounds other than CO2 
(Igimi et al., 1974). When a similar radioactive dose of [9-14C]-d-limonene was given to male rabbits, 72 % 
and 7 % of the radioactivity was excreted in the urine and faeces during 72 hours, respectively (Kodama et 
al., 1974).  
In an additional study with several species (rats, hamsters, guinea pigs, rabbits, dogs and humans) dosed 
orally with [9-14C]-d-limonene, urinary excretion of radioactivity in rodents and rabbits comprised 82 - 96 % 
of the dose within 72 hours and faecal excretion 2 - 9 %. The total excretion rate in dogs was somewhat 
lower (77 % via urine and 9 % via faeces within 72 hours), while two human volunteers excreted 55 - 83 % 
of the administered dose in the urine. Faecal excretion in humans was not measured, but may have been 
considerable in the person with lower urinary excretion as this person developed a diarrhoea shortly after 
administration. In all species, most excretion occurred within the first 24 hours (Kodama et al., 1976). 
In vitro, the solubility of d-limonene in blood and olive oil was high, but low in water, which suggests a high 
respiratory uptake and accumulation in adipose tissues (Falk et al., 1990a). Indeed, uptake was rapid and 
high (68 %) in an experiment in which human volunteers were exposed to d-limonene in air at 225 and 450 
mg/m3 for 2 hours while doing light physical exercise. The absorbed d-limonene was metabolised rapidly. 
Elimination followed a triphasic pattern, with a short half-life in blood immediately after exposure (2.6 
minutes) but a long half-life during the late elimination phase (12.5 hours), which indicates slow elimination 
from adipose tissues. Approximately 1 % of the total uptake was eliminated unchanged in expired air, while 
approximately 0.003 % was eliminated unchanged in urine (Falk-Filipson et al., 1993). 
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Aromatic Hydrocarbons (Candidate and Structurally Related Supporting Substances from Subgroup 
IV)  
This subgroup is further divided into three groups, one with benzene derivatives (di- and 
tetrahydronaphthalenes (IVa), one with naphthalene derivatives (IVb) and one with one candidate substance, 
diphenylmethane (IVc). For the candidates of subgroup IVb only one supporting substance has been 
submitted (1-methylnaphthalene), but for both naphthalene and 2-methylnaphthalene many toxicity data are 
available, and extensive reviews on these substances have been published recently (EU-RAR, 2003; Shelby 
and Witt, 1995). 
Subgroup IVa (benzene derivatives): 
No data were available on any of the candidate substances in this group. No supporting substances were 
suggested. 
Subgroup IVb (naphthalene derivatives): 
Naphthalene [FL-no: 01.053]: 
Bock et al. (1979) reported that naphthalene was rapidly absorbed from isolated rat intestinal loops in situ, 
predominantly unchanged, into the portal blood. Approximately 84 % of the naphthalene related substances 
in the blood was naphthalene, the remainder were metabolites; mainly naphthalene-1,2-dihydrodiol and 1-
naphthol, 40 % of which was recovered as conjugates; predominantly with glucuronic acid (Bock et al., 
1979). 
Three groups of Sprague-Dawley rats were treated orally with a single administration of 2 mg 14C-
naphthalene. The dose per unit body weight was not stated (Bakke et al., 1985). One group of 16 animals 
was bile duct cannulated, the second group of four germ-free animals was uncannulated and the third group 
of 13 animals was standard uncannulated rats. Urine, faeces and bile were collected for 72 hours after 
administration of naphthalene. In the standard uncannulated rats 75.6 % of the radioactivity was recovered in 
the urine in 24 hours. At 72 hours approximately 83 % of the radioactivity had been recovered in the urine, 6 
% in the faeces and 4 % remained in the carcass with no account made for the remaining radioactivity. In the 
cannulated rats the 24 hours urine and bile contained 30 % and 66.8 % of the 14C dose, respectively (faecal 
data not presented for 24 hours time period). At 72 hours, approximately 30 % of the radioactivity had been 
recovered in the urine, 68 % was contained in the bile, less than 1 % was excreted in the faeces and 0.2 % 
remained in the carcass. 
When a single dose of 20 mg/kg bw of naphthalene-[ring-U-3H] was administered intraperitoneally in olive 
oil to outbreed male IMP:Wist rats (n = 54), urine and faeces were the main routes of elimination of the 
radioactivity with more than 88 % of the radioactivity excreted during the first 72 hours. The maximum level 
of radioactivity in plasma was observed at two hours post-dosing followed by biphasic clearance (t1/2 = 0.8 
and 99 hours for phase I and phase II, respectively). The highest concentrations during the first hour 
following dose administration were detected in fat, liver and kidneys, with a gradual decline of radioactivity 
in all tissues examined (Kilanowicz et al., 1999).  
Male Sprague-Dawley rats were given [1-14C] naphthalene (100 mg/kg) via i.p. injection. Of the 
administered dose, 20 - 30 % was excreted in the 0 - 24 hours urine, while 3-11 % was found in the 24 - 48-
hours urine. Unconjugated metabolites accounted for 5 - 20 % of the metabolites excreted, while 80 - 95 % 
of the metabolites were excreted as acidic conjugates (Horning et al., 1980).  
Urinary excretion of premercapturic acids and mercapturic acids represents a major excretory pathway for 
naphthalene in mice and rats (Chen and Dorough, 1979; Stillwell et al., 1978; Pakenham et al., 2002). Urine 
was collected for 24 hours after intraperitoneal administration of 0, 1.56, 3.12, 6.25, 12.5, 25, 50, 100 and 
200 mg/kg radiolabelled [14C]-naphthalene dissolved in corn oil to male Sprague Dawley rats and Swiss 
Webster mice, four animals in each group. The percentage of the administered dose excreted as mercapturic 
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acids in the urine for mice (25 – 34 %) and rats (24 – 35 %) did not differ with increasing dose (Pakenham et 
al., 2002). Studies with chimpanzees (Summer et al., 1979b) and with rhesus monkeys (Rozman et al., 1982) 
indicated that urinary excretion of mercapturic acids is probably less important in primates. Boyland and 
Sims reported that only traces of mercapturic acids were detected in the urine of three human subjects after 
oral administration of 500 mg naphthalene, while for rats, mice, hamsters and rabbits, 1-naphthyl-
(pre)mercapturic acid was abundantly present in the urine (Boyland and Sims, 1958).  
2-Methylnaphthalene [FL-no: 01.051]: 
Following intraperitoneal injection of C57BL/6J mice with a single 400 mg/kg dose of [8-14C]-2-
methylnaphthalene, the majority of radioactivity was distributed in fat, liver, kidney and lung, in order of 
decreasing concentration. Maximal plasma and tissue levels were achieved one (liver), two (plasma; fat) or 
four (kidneys) hours after dose administration and the t1/2 of elimination of radioactivity from blood was 
approximately three hours (Griffin et al., 1982).  
When 10 mg/kg bw 2-[1-3H]-methylnaphthalene was orally administered to guinea pigs, the highest 
concentrations of radioactivity were found in the gall bladder, kidneys and liver three hours after dosing. 
Lower concentrations were observed in the blood, brain, heart, lung and spleen. At that time the total 
gastrointestinal tract contained 27 % of the dose while the urine contained 23 %. At 24 hours only some 
retention was observed in the liver, gall bladder and kidney, with 11 % in faeces and 79 % in the urine. After 
48 hours 12 % was recovered from faeces and 72 % from the urine, and 1 % of the dose was recovered from 
the tissues investigated (Teshima et al., 1983). 
Subgroup IVc (diphenylmethane): 
After intraperitoneal administration of the candidate flavouring substance diphenylmethane [FL-no: 01.036], 
metabolites have been shown in urine and faeces. Only a small fraction of the dose (up to 6.8 %) was 
recovered after 24 hours (Deloach et al., 1978; Stocklinski et al., 1979). The studies were too incomplete to 
estimate if total elimination is slow, or that this apparently slow elimination is indicated because 
quantitatively important metabolites were not studied.  
Bi- and Tricyclic, Non-Aromatic Hydrocarbons (Candidate and Structurally Related Supporting 
Substances from Subgroup V)  
No data on absorption on candidate substances in this group were submitted. Some data were retrieved after 
database search on the candidate substance longifolene [FL-no: 01.047] and on several supporting substances 
including alpha- and beta-pinene [FL-no 01.004 and 01.003], caryophyllene [FL-no: 01.007] and delta-3-
carene [FL-no: 01.029].  
Asakawa et al. (1986) studied the metabolism of (+)-longifolene and caryophyllene in rabbits after gavage 
dosing. At two days after administration, metabolites of all of these substances could be detected in the urine, 
from which it can be concluded that these substances are absorbed. As no mass balance data were given, the 
extent of absorption cannot be assessed (Asakawa et al., 1986).  
Male albino rabbits (6/group) were administered single gavage doses of 400 - 700 mg/kg bw of (+)-alpha-
pinene, (-)-alpha-pinene, (±)-alpha-pinene, (-)-beta-pinene or delta-3-carene. Urine of individual animals was 
collected for three days. The animals excreted bicyclic terpene hydrocarbon metabolites as glucuronic acid 
conjugates or as further oxidised metabolites, notably carboxylic acids (Ishida, 1981).  
In vitro data on the solubility of alpha-pinene [FL-no: 01.004], beta-pinene [FL-no: 01.003] and delta-3-
carene [FL-no: 01.029] in blood, olive oil and water suggest a high respiratory uptake and accumulation in 
adipose tissues. For alpha-pinene this is supported by a high estimated brain/blood partition coefficient of 18 
(Falk et al., 1990a). Experiments in which human volunteers were exposed to (+)- and (-)-alpha-pinene or 
delta-3-carene in air at 225 and 450 mg/m3 for two hours while doing light physical exercise confirmed that 
uptake was rapid and high for these agents (58 – 60 % for (+)- and (-)-alpha-pinene and 70 % for delta-3-
Flavouring Group Evaluation 25, Revision 2
 
63 
carene), and that they were metabolized rapidly. Elimination followed a triphasic pattern, with (+)- and (-)-
alpha-pinene exhibiting a rapid initial (distribution) phase (4.8 and 5.6 minutes, respectively), a rapid second 
distribution phase (38 and 40 minutes, respectively), and a slow elimination phase (695 and 555 minutes, 
respectively). Triphasic elimination was also observed for delta-3-carene with half-lives of 4.5, 35 and 1800 
minutes for the initial, rapid and slow phases, respectively. It was estimated that it would require over two or 
six days to eliminate alpha-pinene or delta-3-carene, respectively, from the body. The long half-lives indicate 
slow elimination from adipose tissues. Less than 0.001 % of the total uptake of alpha-pinene or delta-3-
carene was eliminated unchanged in the urine, while 7.5 - 7.8 % and 3 % of the inhaled amount of the alpha-
pinenes and delta-3-carene were exhaled (Falk et al., 1990b; Falk et al., 1991).  
In another study, humans were exposed for four or six hours to atmospheres containing a mixture of volatile 
organic substances, which included alpha-pinene, at total concentrations of 12 or 24 mg/m3. At a 
concentration of 24 mg/m3 for the total volatiles, the air concentration of alpha-pinene was 0.775 mg/m3. The 
mean pre-exposure blood concentration of alpha-pinene of 0.035 microg/l increased to an average 
concentration of 1.9 microg/l during the 4-hours exposure (50 - 240 minutes). Thereafter (330 - 450 
minutes), the mean blood concentration decreased to 0.15 microg/l. Changes proportional to those observed 
at 24 mg/m3 were recorded at 12 mg/m3 exposure. Similar results were recorded for the 6-hours exposure. 
Plasma elimination for alpha-pinene was best described with a three-exponential curve, with half-lives 
ranging from 0.22 - 7.8 minutes, 19 - 58 minutes and > 150 minutes for the initial, mid and terminal phases, 
respectively (Ashley and Prah, 1997). 
In the urine of sawmill workers exposed to an atmosphere containing 31 - 210 mg/m3 alpha-pinene [FL-no: 
01.004], 2 - 17 mg/m3 beta-pinene [FL-no: 01.003] and 6 - 90 mg/m3 delta-3-carene [FL-no: 01.029] for 
three days, cis and trans-verbenol were identified as metabolites. They were excreted as conjugates, probably 
with glucuronic acid. The authors suggested that these metabolites were formed by hydroxylation of alpha-
pinene (Eriksson and Levin, 1990). Analysis of urinary metabolites eliminated by human volunteers within 
four hours following a 2-hours exposure to 10 - 450 mg alpha-pinene/m3 revealed that alpha-pinene is indeed 
eliminated as cis- and trans-verbenol, in a ratio of 1:10, within 20 hours following exposure (Levin et al., 
1992). In a more extensive metabolic study, urine was collected from sawmill workers at the end of an eight 
- nine hours work shift or from chamber-exposed individuals. Following hydrolysis of glucuronic acid 
conjugates, several pinene biotransformation products were found (Eriksson and Levin, 1996).  
Macrocyclic, Non-Aromatic Hydrocarbons (Candidate and Structurally Related Supporting 
Substances from Subgroup VI)  
No data were submitted on any of the two candidate substances in this subgroup [FL-no: 01.042 and 01.043]. 
No supporting substances were identified. 
III.3. Conclusions on Absorption, Distribution and Elimination 
Based on the available studies it may be concluded that the candidate alkane substances (subgroup I) will be 
absorbed after oral exposure. The extent of absorption is not known, but may be high, given their lipophilic 
character and their low molecular weight. The ease with which these substances cross the membranes of the 
respiratory tract further supports the assumption that these substances will also be absorbed after oral intake. 
Data indicate that straight-chain alkanes will predominantly be broken down to carbon dioxide at low dose 
levels. At high dose levels, biotransformation becomes saturated and other metabolites will be generated, 
which will be excreted via the urine. As illustrated by for iso-octane, metabolism of (highly) branched 
alkanes to carbon dioxide is less favourable, and their metabolites will be eliminated more slowly via the 
urine. 
For the candidate or supporting substances in subgroup II (acyclic alkenes), data were only available for the 
supporting substance beta-myrcene [FL-no: 01.008] and for the structurally related substance 2-methylbuta-
1,3-diene (former candidate substance (See “History of the evaluation”)). Given the narrow range of 
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molecular weights of the candidate substances (all between ~ 68 and 206 D) and their lipophilic nature (Log 
Kow values e.g. 2.4 (2-methylbuta-1,3-diene), 6.1 (dodec-1-ene), 4.17 (beta-myrcene) or 4.8 (cis-3,7-
dimethyl-1,3,6-octatriene)), it must be assumed that these candidate flavouring substances will be absorbed 
from the gastrointestinal tract, at least to some extent, if not completely. Mass balance data are also 
incomplete. At least for beta-myrcene it has been shown its metabolites will be excreted via urine in an 
amount of 25 % of the dose within three days after dosing. For 2-methylbuta-1,3-diene a fairly complete 
mass balance of elimination has been presented, which shows also elimination via the exhaled air (~ 50 % of 
the dose), but as this substance was administered via the intraperitoneal dose route, the elimination pattern 
may be different after oral dosing with a lower fraction of the dose exhaled, e.g. because of more efficient 
first-pass biotransformation after oral dosing. 
For the candidate or supporting substances in subgroup group III (cyclohexene derivatives), data were only 
available for d-limonene [FL-no: 01.045], which is actually a supporting substance. For this substance, data 
show a considerable absorption from the gastrointestinal tract. In humans, elimination of the substance 
followed a triphasic pattern, but still 55 - 83 % of an oral dose could be found in the urine within 72 hours 
post-dosing, with the major part excreted within 24 hours. Also in other species urinary elimination was most 
important accounting for up to 82 - 96 % of the dose within 72 hours. Hence, it may be argued that 
monocyclic cyclohexene derivatives, such as d-limonene, administered orally are absorbed and distributed 
throughout the body. Following oral administration to humans, d-limonene was distributed preferentially to 
fatty tissues, as indicated by a high oil-blood partition coefficient and a long half-life during the slow 
elimination phase. Because of the limited molecular weight of the candidate substances in this group (range 
~ 136 - 204 D) and their lipophilic character (e.g. log Kow values for beta-phellandrene, beta-bisabolene and 
d-limonene are ca. 4.7, 7.1 or 4.6, respectively) it may be assumed that all of the substances in this group 
will be absorbed to some degree, although the extent of absorption for individual substances cannot be 
accurately estimated from these physico-chemical properties. For the substances in subgroup III with 
conjugated double bonds no data are available, but based on the structural similarity with the other 
substances in subgroup III, it may be anticipated that these substances will also be absorbed. 
No data are available on the absorption, distribution and elimination of any candidate or supporting 
substance in subgroup IVa (benzene hydrocarbons). There are several data on the candidate substances in 
subgroup IVb (naphthalene hydrocarbons). The data show that naphthalene [FL-no: 01.053] will be absorbed 
after oral administration and will be eliminated predominantly via the urine, in the form of various 
metabolites, conjugated with e.g. glucuronic acid or with glutathione. In bile duct cannulated animals, 
considerable elimination into the bile was also observed, but as in intact animals urinary elimination exceeds 
by far faecal excretion, the material eliminated via the bile is reabsorbed. The glucuronide conjugate of 1-
naphthol represents a significant urinary metabolite of naphthalene. Glutathione conjugates of naphthalene 
are catabolised to (pre)mercapturic and mercapturic acids, particularly in rodents, before excretion in bile or 
urine. In primates and humans, conjugation with glutathione seems to be less important. Less data are 
available for 2-methylnaphthalene [FL-no: 01.051], but the available data show that 2-methylnaphthalene is 
also absorbed from the gastrointestinal tract and eliminated predominantly via the urine. For both substances 
the data indicate that 85 - 89 % of the dose is excreted within three days after dosing. With respect to the one 
candidate substance (diphenylmethane [FL-no: 01.036]) in subgroup IVc, it may be concluded that the 
metabolites of this substance will be eliminated from the body after intraperitoneal injection. No conclusions 
can be made on absorption from the gastrointestianl tract and the rate of elimination as any oral ADME 
studies and mass-balance data are available. 
For the substances in subgroup V (bi- and tricyclic, non-aromatic hydrocarbons), the available data from oral 
studies are few. These studies have only addressed the excretion of some supporting and one candidate 
substance (longifolene) in the form of metabolites via the urine. No mass-balance data were provided. So 
these studies only show that these substances will be absorbed to some extent. The same may be anticipated 
for the (other) candidate substances in this subgroup. For the supporting substances alpha- and beta-pinene 
and delta-carene information on kinetics is available from humans exposed via inhalation, in occupational 
settings. These studies show that these substances can be absorbed after inhalation exposure and that 
metabolites will be excreted into the urine e.g. as glucuronide conjugates. The elimination follows a triphasic 
Flavouring Group Evaluation 25, Revision 2
 
65 
pattern with rather long terminal half-lives. The absorbed amount will be eliminated within several days. 
Based on the lipophilic character of these substances it may be anticipated that they will preferentially 
distribute in the adipose tissues, which is supported by the slow terminal elimination rates. 
No data were submitted on candidate or supporting substances in subgroup VI (macrocyclic, non-aromatic 
hydrocarbons). The two substances in this group have a molecular weight of ~ 204. They are also rather 
lipophilic (estimated log Kow are 4.6 and 7.0 for [FL-no: 01.042] and [FL-no: 01.043], respectively). Based 
on these data it may be assumed that these two candidate substances will be absorbed from the 
gastrointestinal tract. For humulatriene, given the rather high Kow, the extent of absorption may be relatively 
low. 
III.4. Metabolism 
Acyclic Alkanes (Candidate and Structurally Related Supporting Substances from Subgroup I)  
Oral 
Male and female rats were given a dose of 1400 mg n-octane per kg bw by gavage and urine was collected 
for up to 48 hours. Urine samples were treated with glucuronidase/sulphatase and the liberated metabolites 
were analysed by gas chromatography. Compounds found in urine were 2-octanol, 3-octanol, 5-oxohexanoic 
acid and 6-oxoheptanoic acid. In female rats 2-octanol was found to be the major urinary metabolite and 5-
oxohexanoic acid was the major metabolite in males. The authors state that in contrast to n-hexane and n-
heptane, n-octane was not metabolised to a ketone, diketone or a diol derivative. The structures of the keto 
acids that were produced indicate that metabolic oxidation is occurring on both ends of the n-octane 
molecule. A former metabolism study of n-heptane did yield gamma-valerolactone, which was presumed to 
have been formed on the GC column from 4-hydroxy-1-pentanoic acid, which would involve a 2 carbon loss. 
The authors speculate that with n-heptane, n-octane and perhaps higher straight chain hydrocarbon 
homologues, a major metabolic pathway involves the formation of acids with loss of carbon (Olson et al., 
1986). 
The metabolism of n-nonane has been studied in rats after oral administration of 800 mg/kg bw over a 48 
hours excretion period. In the urine the following metabolites were detected: 2-, 3- and 4-nonanol, 4-
nonanone, 2,5-hexanedione, gamma-valerolactone, delta-hexanolactone and delta-heptanolactone and 5-
methyl-2-(3-oxobutyl)furane. The authors also reported the formation of 1-heptanol, but no explanation for 
this metabolite is available. Keto-acids, as observed with n-octane could not be detected after administration 
on n-nonane (Serve et al., 1995). 
Other Routes of Exposure 
Rats were exposed to n-heptane in a concentration of 8100 mg/m3 in the air for six hours/day five days/week 
for 12 weeks. After exposure the animals were kept in a metabolism cage to collect urine samples during the 
next 18 hours for the first week of the experiment and subsequently at the end of every five-day exposure 
period. Primary metabolites of n-heptane in the urine were 1-, 2-, 3,- and 4-heptanol, of which the 2- and to a 
lesser extent the 3-isomer were quantitatively the most important. Subsequent oxidations of these two 
secondary alcohols provided 2- and 3-heptanone and the diols 2,6- and 2,5-heptanediol. In follow-up 
oxidations, final products were 5-hydroxy-2-heptanone, 6-hydroxy-2-heptanone, 2,6-and 2,5-heptanedione 
and 6-hydroxy-3-heptanone, which was de-acetylated to yield 4-hydroxy-pentanoic acid. This metabolite 
was detected in the urine as gamma-valerolactone. The alcoholic metabolites were rapidly excreted as 
sulphate and glucuronide conjugates. Although 2,5-heptanedione is a gamma-diketone, no signs of 
peripheral neuropathy were observed. The authors speculated that the plasma levels of this ketone did not 
become high enough to trigger this effect because of the rapid conjugation of the precursor alcohols which 
was supported by the minute amounts in which they were present in the urine, although their (conjugated) 
precursors reached much higher concentrations (Bahima et al., 1984). 
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In Sprague-Dawley rats exposed to vapours (7680 mg/m3) of n-heptane for six hours, main urinary 
metabolites were 2- and 3-heptanol. Other metabolites detected were 2- and 3- heptanone, 4-heptanol, 2,5-
heptanedione, gamma-valerolactone, 2,6-dimethyl-2,3-dihydropyrane and 2-ethyl-5-methyl-2,3,-
dihydrofurane. In humans, occupationally exposed to n-heptane (5 - 196 mg/m3) 2- and 3-heptanol were 
found in the urine. Other metabolites detected were 2- and 4-heptanone and 2,5-heptanedione. In human 
urinary samples no ring-closure products could be detected, but it is noted that the human exposure was less 
than that of the rats. In rat tissues (blood, muscle, kidney, nervous tissue, liver), levels of 2-heptanol were 
between 0.2 and 2 mg/l. Levels of n-heptane in the same tissues were around 20 mg/l (Perbellini et al., 
1986). 
After oral administration of n-octane (1400 mg/kg bw) to rats in the urine the following metabolites could be 
detected within 48 hours after dosing: 2- and 3-octanol and 5-keto-hexanoic and 6-keto-heptanoic acid. In 
contrast to heptane, n-octane was not converted into mono- or diketones or into diols (Olson et al., 1986). 
Based on this study and the data for n-heptane, the authors argued that for n-heptane and higher straight-
chain alkanes, formation of carboxylic acids and subsequent loss of carbon may be a major metabolic 
pathway. However, the quantitative contribution of de-carboxylation was not thoroughly studied (e.g. no 
studies with radioactive material) and no mass balances were provided. It has been proposed that n-octane is 
also converted into 1-octanol and further into octanoic acid, but no detailed information on these studies was 
submitted (Low et al., 1987).  
Groups of three or six rats (Sprague-Dawley, 300 - 600 g), groups of two male rabbits (New Zealand, 1600 - 
2000 g) and one male monkey (Maccaca mulatta, 1600 - 2000 g) were subjected to single inhalatory 
treatments of 5000 ppm (~ 18 000 mg/m3) n-hexane for 6, 12 and 24 hours. After treatment animals were 
kept in metabolic cages for the following 72 hours. Urine from treated and control animals were collected 
during treatment and at various intervals thereafter. For rats blood was collected during and after treatment. 
Urine samples were subjected to enzymatic and then acid hydrolysis and analysed by gas chromatography. In 
urine of rats, 2-hexanol, 3-hexanol, 2,5-dimethylfurane, gamma-valerolactone and 2,5-hexanedione along 
with methyl n-butylketone were found. The metabolites detected in urine from rabbit and monkey were 2-
hexanol, 3-hexanol, methyl n-butylketone and 2,5-hexanedione. 1-hexanol and 2,5-hexanediol were not 
detectable in any of the species. In rats peaks of 2,5-hexanedione and 2,5-dimethylfurane in urine were 
preceded by analogous peaks in blood, while blood concentrations of n-hexane, methyl n-butylketone and 2-
hexanol “peaked” immediately after termination of exposure (Perbellini et al., 1982). 
Male rats were exposed to n-hexane by inhalation at concentrations ranging from approximately 180 to 
approximately 11000 mg/m3 for 8 hours in an all-glass exposure system. Urinary kinetics for the metabolites 
1-hexanol, 2-hexanol, 3-hexanol, 2 hexanone, 2,5-hexanedione and 4,5-dihydroxy-2-hexanone were 
assessed. Urine samples were collected up to 48 hours following the start of exposure. Amounts of 
metabolites were linearly dependent on the exposure concentrations, up to an exposure of about 1070 mg/m3. 
Above this the metabolite excretion indicated saturation kinetics in the metabolism. 2-Hexanol amounted to 
about twice the excretion of all other metabolites excreted. In quantity 4,5-dihydroxy-2-hexanone was the 
second metabolite, the amount in urine being about 10 times higher than that of excreted 2,5-hexanedione. 2-
Hexanol and 4,5-dihydroxy-2-hexanone accounted for 90 % of the total excretion (Fedtke and Bolt, 1987). 
A male volunteer was exposed to a mean n-hexane atmosphere of 217 ppm (~ 800 mg/m3) for 4 hours. The 
occurrence of 4,5-dihydroxy-2-hexanone as a metabolite in urine of the man was confirmed. Twenty-six 
hours after exposure the excretion of 4,5-dihydroxy-2-hexanone reached a level that was four times higher 
than the excretion of 2,5-hexanedione. The authors conclude that formation of 4,5-dihydroxy-2-hexanone 
may be viewed as a route of detoxification, and also state that it is clear that 4,5-dihydroxy-2-hexanone is 
responsible for an artificial appearance of 2,5-hexanedione after drastic acid treatment of human urine, 
presumably via 2,5-dimethylfuran as intermediate (Fedtke and Bolt, 1987). 
Groups of three or four male F 344 rats were exposed to [4-14C]-labelled iso-octane (2,2,4-trimethyl pentane) 
and [1-14C]-octane vapours at approximately 1 and 350 ppm (~ 4.76 or 1700 mg/m3 for both substances) for 
two hours. During the experiment, exhalant was drawn through a bubbler train for sampling. Urine and 
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faeces were collected at the same times, except that none were collected at one or two hours. Exhalation of 
14CO2 appeared to be much more important for n-octane than for iso-octane, from which a larger part of the 
radioactivity is eliminated via urine. Based on this observation and on a discussion of papers from other 
research groups, the study authors suggest that for straight-chain hydrocarbons, breakdown of the carbon 
skeleton with the release of CO2 is an important metabolic pathway. The route of excretion for n-octane in 
this study was markedly affected by the concentrations of the inhaled vapour. The ratio of 14CO2: 14C in urine 
was 5:1 after inhalation at 1 ppm but 1:1 after inhalation of 350 ppm (Dahl, 1989). The radioactivity 
eliminated via the urine was not identified.  
Hexane was given to rats via subcutaneous injections during three consecutive days. Urinary metabolites 
were various hexanols, 5-hydroxy-2-hexanone, 4,5-dihydroxy-2-hexanone, 2,5-hexanedione, 2-hexanone 
and the ring closure products gamma-valerolactone and 2,5-dimethylfurane. It was noted that most of the 
alcoholic metabolites were excreted as conjugates (in particular glucuronide) (Manini et al., 1999). Such 
conjugation has also been reported in the other alkane biotransformation studies discussed in this Annex. The 
study authors (Manini et al., 1999) further demonstrated that the cyclization products (i.e. the lactones and 
furans) may be formed under the acidic conditions during deconjugation procedures for sample treatment. 
Conclusions on the metabolism of subgroup I substances 
The substances in subgroup I can be expected to be metabolised through omega-oxidation, which will lead to 
the formation of alcohols, and after subsequent oxidation to carboxylic acids, which may be further oxidised 
via beta-oxidation to yield carbon dioxide. Extensive mass balance data are not available, but in some of the 
studies described above some excretion of carboxylic acids and carbon dioxide has been reported. Formation 
of keto-acids has also been reported, and these may be formed from omega-oxidation at one end of the 
molecule and omega-1 or -2 oxidation at the other end. More interest has been put in the identification of 
metabolites which did not undergo substantial chain shortening. These metabolites will arise from oxidation 
of the non-terminal carbon atoms, e.g. via omega-1, -2, -3 or even -4 oxidations. The resulting secondary 
alcohols can be conjugated with e.g. glucuronic acid and excreted via the urine, or can be further oxidised to 
yield ketones. A subsequent introduction of another secondary hydroxyl group may result in the formation of 
diketones. With n-hexane, the resulting 2,5-hexanedione (a gamma-diketone) has been demonstrated to be 
responsible for hexane-induced neurotoxicity. Neurotoxicity is a common feature of gamma-diketones, and 
for that reason, the candidate substance 3-methylhexane [FL-no: 01.050] cannot be anticipated to be 
metabolised into innocuous compounds. In addition, it is known that methyl-branching of the carbon chain 
potentiates the neurotoxicity of the gamma-diketone (Topping et al., 1994; EFSA, 2004e). The two other 
hexane derivatives in this group [FL-no: 01.033 and 01.034] cannot be oxidised to gamma-diketone, due to 
the presence of methyl groups on the C2 or C5 carbon atoms. Therefore, these substances may be 
metabolised to innocuous metabolites. For the longer chain alkanes in this group, it would require oxidation 
of the more central carbon atoms in order to be converted into gamma-diketones. Such oxidations are less 
favourable than omega, omega-1 or -2 oxidations, and therefore it is concluded that oxidation of these higher 
alkanes will not result in toxicologically relevant levels of gamma-diketones, also because of rapid 
conjugation of the precursor alcohols. For heptane it was shown that this substance does not result in 
neurotoxicity (Bahima et al., 1984), although the gamma-diketone itself (2,5-heptanedione) is known to be 
neurotoxic (Topping et al., 1994). The remaining three candidate flavouring substances in this group i.e. [FL-
no: 01.038, 01.054 and 01.057] can be expected to be metabolised to innocuous products. 
Acyclic Alkenes (Candidate and Structurally Related Supporting Substances from Subgroup II) 
For the substances in this group, information is only available on the biotransformation of beta-myrcene 
([FL-no: 01.008]; a supporting substance) and 2-methylbuta-1,3-diene (a structurally related substance). 
Some additional information on the related industrial chemical 1,3-butadiene has also been added. Two of 
the substances in this group (dodec-1-ene; [FL-no: 01.037] and 1-octene [FL-no: 01.070) bear a terminal 
double bond without any other structural features (e.g. hydroxyl groups, methyl substituents). No further 
data for these or similar substances are available. The metabolic aspects of terminal double bond substances 
have been discussed in FGE.07 and FGE.18 (EFSA, 2004e; EFSA, 2006b). The relevant parts of these FGEs 
will also be included in the current discussion. 
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Beta-Myrcene [FL-no: 01.008] 
In the urine of rabbits, orally administered beta-myrcene via gavage (670 mg/kg bw/day for two days), 25 % 
of the total amount administered could be recovered from the urine within three days post-dosing, and > 80 
% of the myrcene-derived substances were neutral metabolites; the rest were acidic substances. The main 
metabolites identified were myrcene-3,10-glycol, myrcene-1,2-glycol and uroterpenol (as acetate) (40.7, 20.8 
and 11.8 %, respectively, of the neutral metabolites). Additionally, the glycols underwent further oxidation 
to yield 2-hydroxymyrcene-1-carboxylic acid and 3-hydroxymyrcene-10-carboxylic acid (no quantitative 
data were given for these acidic metabolites). The authors suggested that uroterpenol (or limonene-8,9-diol) 
may have been formed from limonene, which is derived from cyclization of myrcene in the acidic conditions 
of the rabbit stomach (Ishida et al., 1981). A graphic representation of beta-myrcene metabolites has been 
presented in Figure III.1. 
When rats were administered 800 mg/kg bw per day of beta-myrcene orally via gavage for 20 days, the 
principal metabolites isolated from the urine were 10-hydroxylinalool (or myrcene-3,10-glycol) and, to a 
lesser extent, 7-methyl-3-methylene-oct-6-ene-1,2-diol (or myrcene-1,2-glycol). Other minor metabolites 
included the hydroxy-acids of both the 3,10- and 1,2-glycols (10-carboxylinalool (or 3-hydroxymyrcene-10-
carboxylic acid) and 2-hydroxy-7-methyl-3-methylene-oct-6-enoic acid (or 2-hydroxymyrcene-1-carboxylic 
acid), respectively) and a cyclic diol, 1-hydroxymethyl-4-isopropenylcyclohexanol (or p-menth-8-ene-1,7-
diol), formed by intramolecular cyclization of an open chain metabolite (Madyastha & Srivatsan, 1987). It 
was demonstrated that the biotransformation of beta-myrcene was cytochrome P450 (CYP)-mediated and 
that it could be enhanced by pre-treatment of animals with phenobarbital (Madyastha & Srivatsan, 1987). 
Aside from being a substrate for CYP enzymes, myrcene has also been shown to induce these enzymes at 
high dose levels (1000 mg/kg bw/day orally for three days), especially those from the CYP2B 
(phenobarbital-inducible) subfamily (De-Oliveira et al., 1997a). At lower dose levels (40 mg/kg bw/day 
intraperitoneally for three days) such induction was not observed (Austin et al., 1988).  
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Figure III.1. Metabolism of beta-myrcene in rats and rabbits.  
 
2-Methylbuta-1,3-diene 
In a sequence of inhalation exposure studies in which rats and mice were exposed to 2-methylbuta-1,3-diene 
in the air in concentration of 13 - 11 000 mg/m3, the metabolism of isoprene became saturated at a level of 
ca. 700 mg/m3 in the rat and ca. 840 mg/m3 in the mouse. Maximal rates of metabolism were 130 
micromole/kg bw/hour in the rat and 400 micromole/kg bw/hour in the mouse. It was demonstrated that 2-
methylbuta-1,3-diene is also produced endogenously at rates of 1.9 micromole/(hour × kg) in rats and 0.4 
micromole/(hour × kg) in mice. Part of the endogenous 2-methylbuta-1,3-diene is exhaled by animals, but it 
is metabolised extensively. The rate of metabolism of endogenously produced and systemically available 2-
methylbuta-1,3-diene is 1.6 micromole/(hour × kg) in rats and 0.3 micromole/(hour × kg) in mice, 
respectively (Peter et al., 1987). The authors quoted literature demonstrating that 2-methylbuta-1,3-diene is 
also endogenously produced in humans (Gelmont et al., 1981 as cited in (Peter et al., 1987)).  
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Liver microsomes from mice, rats, rabbits and hamsters metabolise 2-methylbuta-1,3-diene to the 
corresponding monoepoxides, 1,2-epoxy-2-methyl-3-butene (major) and 3,4-epoxy-2-methyl-1-butene 
(minor). Both monoepoxides are hydrolysed to their respective diols (for chemical structures, see Figure 
III.2). The main metabolite of 2-methylbuta-1,3-diene (i.e. 1,2-epoxy-2-methyl-3-butene) exhibited a half-
life of 75 minutes in aqueous environments; whereas the minor metabolite, 3,4-epoxy-2-methyl-1-butene (14 
- 25 % with respect to the main metabolite) is more stable (half-life not specified). The kinetic constants for 
the formation of the major epoxide metabolite (trans-2-methyl-3-butene-1,2-diol) of 2- methylbuta-1,3-diene 
were determined in the four test species as apparent Km = 0.06 – 0.2 mM and Vmax = 0.24 – 1.79 nmol trans-
2-methyl-3-butene-1,2-diol/mg protein × min. The minor metabolite, 3,4-epoxy-2-methyl-1-butene, was 
further epoxidised to the diepoxide, 2-methyl-1,2:3,4-diepoxybutane, by microsomes of all rodents studied. 
The authors argued that the latter diepoxide metabolite could be responsible for the genotoxic and 
carcinogenic activity of 2-methylbuta-1,3-diene, as the two mono-epoxies were not reported to be genotoxic 
(Del Monte et al., 1985; Longo et al., 1985).  
The in vitro metabolism of 2-methylbuta-1,3-diene was investigated in rat, mouse and human liver 
microsomes and in microsomes derived from cell lines expressing eight different human cytochrome P-450 
enzymes. Human CYP2E1 showed the highest rates for formation of the monoepoxides, 1,2-epoxy-2-
methyl-3-butene and 3,4-epoxy-2-methyl-1-butene, and CYP2B6 showed the second highest rate. Only 
CYP2E1 catalysed formation of the diepoxide, 2-methyl-1,2:3,4-diepoxybutane. With human liver 
microsomes in the presence of an epoxide hydrolase inhibitor, the formation of 1,2-epoxy-2-methyl-3-butene 
was four times faster than the formation of the 3,4-epoxy-2-methyl-1-butene, which is comparable to the 
results in rats and mice obtained by others (e.g. Del Monte et al., 1985; Longo et al., 1985). The rates of 
monoepoxide formation from isoprene and diepoxide formation from either monoepoxide intermediate were 
strongly correlated with the microsomal activity of CYP2E1, rather than with the activities of the other CYP 
enzymes, and both monoepoxides were equally good substrates for the formation of the diepoxide.  
Also, species differences with regard to the role of epoxide hydrolase were investigated by comparing the 
epoxidation of 2-methylbuta-1,3-diene by rat, mouse and human liver microsomes. When an epoxide 
hydrolase inhibitor was used, similar rates of monoepoxide formation in mouse, rat and human liver 
microsome systems were measured. However, without epoxide hydrolase inhibition, the total amount of 1,2-
epoxy-2-methyl-3-butene measured at the end of the incubation period was twice as high for mouse as for rat 
liver microsomes and 30 times as high for mouse as for human liver microsomes in which formation of this 
epoxide was reduced to 4 % of the rate in presence of the inhibitor. For the 3,4-epoxy 2-methyl-1-butene 
metabolite the effect of epoxide hydrolase inhibition was less dramatic. While hardly any effect was 
observed in mouse or rat microsomes, in the human microsomes, the rate was reduced to approximately 25 
%. The effect of epoxide inhibition on the rate of formation of the diepoxide was not studied. The authors 
concluded that differences in epoxide hydrolase activity between species may be of crucial importance for 
the toxicity of 2-methylbuta-1,3-diene in various species (Bogaards et al., 1996).  
Following intraperitoneal injection of 64 mg [4-14C]-2-methylbuta-1,3-diene per kg to F344 rats, the parent 
compound was excreted unchanged in the breath (> 50 % of the dose together with < 4 % unidentified 
material) or via the urine in the form of metabolites (≈ 32 %) over the 24-hours collection period. Only 1.7 % 
was expired as CO2 and 0.2 % was eliminated via faeces. 3 % Remained in the carcass. In the urine, 2-
methylbuta-1,3-diene was excreted primarily as 2-hydroxy-2-methyl-3-butenoic acid (53 % of total urinary 
metabolites excreted), 2-methyl-3-buten-1,2-diol (23 %), and the C-1 glucuronide conjugate of 2-methyl-3-
buten-1,2-diol (13 %). A fraction of 7 % of the radioactivity in the urine was (an) unidentified polar material. 
The principal urinary acidic metabolite forms via oxidation of the corresponding 1,2-diol. These metabolites 
indicate a preferential epoxidation of the methyl-substituted vinyl group of 2-methylbuta-1,3-diene (see 
Figure III.2) in the rat (Buckley et al., 1999).  
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Figure III.2. Major metabolic pathways for 2-methylbuta-1,3-diene (after Del Monte et al. (1985) and Buckley et al. 
(1999)).  
Following intraperitoneal injection of 64 mg [4-14C]-2-methylbuta-1,3-diene/kg to B6C3F1 mice, the parent 
compound was excreted unchanged in the breath (≈ 44 % of the dose and < 3 % unidentified material) or as 
urinary metabolites (≈ 33 %) over the 24-hours collection period. Only 1.9 % was expired as CO2 and 7 % 
was eliminated via faeces. 2 % remained in the carcass. In comparison with rat urine (see above), the urine of 
the mice contained several other metabolites, including an unidentified polar fraction which comprised 25 % 
of the total urinary radioactivity as compared to 7 % in rat urine. The major identified metabolite in mouse 
urine, 2-hydroxy-2-methyl-3-butenoic acid, accounted for ≈ 15 % of the total urinary radioactivity, whereas 
2-methyl-3-buten-1,2-diol and its glucuronide conjugate accounted for ≈ 3.5 and 2.5 %, respectively 
(Buckley et al., 1999). The authors speculated that the unidentified metabolite in the urine of rats and mice 
could be related to glutathione conjugates. They concluded that if this were the case, in rats glutathione 
conjugation of 2-methylbuta-1,3-diene is less important than in mice.  
Special features of terminal double bond oxidation 
Double bonds are usually oxidised by P450 to the corresponding epoxides, which are highly reactive 
molecules. Due to the large strain associated with the three membered ring structure, epoxides easily react 
with nucleophilic sites of cellular macromolecules; conversely they are readily detoxified either 
spontaneously or by the action of epoxide hydrolase to diols or conjugated with reduced glutathione by 
glutathione-S-transferases. 1-Alkenes are metabolised by cytochrome P450, through double bond oxidation, 
to the corresponding epoxide or alternatively allylic oxidation (Chiappe et al., 1998). The rates of the two 
reactions measured with different cytochrome P450 isoforms indicate that epoxide formation is generally 
favoured (Chiappe et al., 1998) and this may also apply in particular to the candidate substances dodec-1-ene 
[FL-no: 01.037] and 1-octene [FL-no: 01.070]. 
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Based on this information and the data available for beta-myrcene and 2-methylbuta-1,3-diene, it cannot be 
excluded that the candidate substances with these terminal double bonds [FL-no: 01.037, 01.064 and 01.070] 
may be metabolised to epoxides.  
Conclusions on the metabolism of subgroup II substances 
The data available on the metabolism of one supporting and one structurally related substance in subgroup II 
show that metabolic options for the substances in this group are epoxidation of double bonds ultimately 
resulting in diols, which can be further conjugated. With the supporting substance beta-myrcene also further 
metabolism of the diols into carboxylic acids has been reported. Both in rats and rabbits, the principal 
urinary metabolite following gavage administration of beta-myrcene is myrcene-3,10-glycol, formed from 
the hydration of the epoxide intermediate in both species. Epoxidation of the 3,10-double bond was favoured 
over epoxidation of the 1,2-double bond. 
The studies indicate that the formation of diols from the myrcene-epoxides is very efficient. It is noted, 
however, that the diols and the related carboxylic acids are all the result of epoxidation of double bonds in 
which one of the carbon atoms has only hydrogen substituents, but no further carbon chains. In this respect, 
the candidate substance cis-3,7-dimethyl-1,3,6-octatriene [FL-no: 01.064] is most similar to beta-myrcene. 
With beta-myrcene no diepoxide metabolites or further reaction products thereof have been reported, but it is 
noted that mass balance data are incomplete, so some metabolites may have been overlooked. 
With the structurally related substance 2-methyl-buta-1,3-diene, epoxidation of the 1,2-double bond is 
favoured over epoxidation of the 3,4-double bond. While the 1,2-epoxide is readily hydrolysed, the 3,4-
epoxide is far more stable. Both metabolites can be converted to the corresponding diols and at least one 
hydroxy-carboxylic acid (2-hydroxy-2-methyl-3-butenoic acid) has been identified. In addition, in particular 
the 3,4-epoxide metabolite can be oxidised a second time, resulting in the formation of a diepoxide 
metabolite, which is known to be reactive and has been suggested to be responsible for 2-methylbuta-1,3-
diene-induced DNA damage. For candidate substance dodec-1-ene [FL-no: 01.037], diol- and alpha-
hydroxy-carboxylic acid formation may also be expected. In addition, this substance may also undergo 
omega and omega-1 or -2 oxidation at the other (saturated) end of the carbon chain (similar to the candidate 
substances in subgroup I). 
Apart from beta-myrcene and 2-methylbuta-1,3-diene, terminal double bonds appear in candidate substances 
[FL-no: 01.037, 01.064 and 01.070]. In contrast to corresponding substances in FGE.07 and FGE.18 there is 
no other functional group in the molecule (e.g. hydroxyl- or keto-group) that could provide a more direct 
option for detoxication e.g. via conjugation with glucuronide or sulphate. In the two FGEs mentioned above 
the presence of such groups was an argument to consider that the metabolism of the particular candidate 
substances would go via innocuous products. It would not be possible to conclude similarly for the candidate 
substances in FGE.25. The other candidate substances in this subgroup (II) might also be oxidised in the 
various methyl groups but no data are available to substantiate this. Because of these considerations, it 
cannot be concluded that the candidate substances in this subgroup [FL-no: 01.032, 01.035, 01.037, 01.064, 
01.070 and 01.078] will be metabolised to innocuous products.  
 
Cyclohexene derivatives (Candidate and structurally related supporting substances from subgroup 
III) 
For the candidate substances in this group, data for one supporting substance (d-limonene; [FL-no: 01.045]) 
were submitted.  
More than 10 metabolites were found in the urine of rats given an oral gavage dose of 800 mg/kg bw d-
limonene (or p-mentha-1,8-diene). Four of the metabolites were identified as perillic acid, p-menth-1-ene-
8,9-diol (= limonene-8,9-diol), perillic acid-8,9-diol and 8-hydroxy-p-menth-1-en-9-yl-glucuronic acid. The 
bile of these rats contained three metabolites, the most important of which was 8-hydroxy-p-menth-1-en-9-
yl-beta-D-glucuronic acid (Igimi et al., 1974). Six metabolites were identified in the urine of rabbits given 
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the same oral dose. In addition to the four metabolites identified in rat urine, the rabbit urine contained p-
mentha-1,8-dien-10-ol (= limonene-10-ol) and p-mentha-1,8-dien-10-yl-glucuronic acid (= p-mentha-1,8-
dien-10-ol-glucuronide). Although not determined quantitatively, perillic acid, perillic acid-8,9-diol and both 
glucuronic acid conjugates were the major metabolites in rabbit urine, and no unchanged d-limonene was 
detected (Kodama et al., 1974). The same authors identified five additional metabolites in the urine of rats 
and dogs treated orally with d-limonene. These were characterised as 2-hydroxy-p-menth-8-en-7-oic acid, 
perillylglycine, perillyl-glucuronide, p-mentha-1,8-dien-6-ol (or limonene-6-ol) and p-menth-1-ene-6,8,9-
triol. They also found some species differences in the nature of the major metabolites in urine. Perillic acid-
8,9-diol was the main metabolite in rats and rabbits, perillyl-glucuronide in hamsters, limonene-8,9-diol in 
dogs and limonene-8,9-diol-glucuronide in guinea pigs and humans. It should be noted that the fate of only 
40 - 65 % of the d-limonene dose administered orally to these animals and humans was accounted for 
(Kodama et al., 1976). The metabolites of d-limonene are shown in Figure III.3. 
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FigureIII. 3. Metabolism of d-limonene.  
Perillic acid, dihydroperillic acid and limonene-1,2-diol were the major metabolites identified in the plasma 
of humans given an oral dose of d-limonene. Minor metabolites were the methyl esters of perillic acid and 
dihydroperillic acid, and d-limonene itself (Crowell et al., 1994a). Apart from the parent compound (Poon et 
al., 1996) and (Vigushin et al., 1998) also identified perillic acid, dihydroperillic acid and limonene-1,2-diol 
as major metabolites in human plasma. However, they also found two other metabolites, i.e. p-mentha-1,8-
diene-10-carboxylic acid and limonene-8,9-diol, whereas they did not detect the methyl esters of perillic acid 
and dihydroperillic acid. Peak plasma levels for all metabolites were achieved four to six hours after 
administration, with the exception of limonene-8,9-diol which reached its peak level one hour after 
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administration (Poon et al., 1996). Metabolites in human urine comprised the glucuronic acid conjugates of 
perillic acid, dihydroperillic acid, p-mentha-1,8-diene-10-carboxylic acid, limonene-8,9-diol and limonene-
10-ol (Poon et al., 1996).  
Experiments with rat liver microsomes have shown that epoxidation of the C8 double bond (in the vinyl 
substituent) of d-limonene is favoured over epoxidation of the C1 double bond (the one in the ring), due to 
steric hindrance by the 1-methyl group, which was demonstrated by comparison of the metabolism of d-
limonene with that of 4-vinylcyclohex-1-ene. Upon incubation with rat liver microsomes, the majority of d-
limonene was converted to the 8,9-epoxide and the 8,9-diol, and to a much lesser extent to the 1,2-epoxide 
and the 1,2-diol (ratio of 8,9- vs. 1,2-epoxidation = 4:1). In contrast, with 4-vinylcyclohex-1-ene the 
epoxidation rate of the ring double bond was about four times as fast as the epoxidation rate of the vinyl 
double bond. Because the 1,2-epoxide of d-limonene is a very poor substrate for microsomal epoxide 
hydrolase, the 1,2-diol could not be found in microsomal incubates, whereas the 8,9-diol could be found 
(Watabe et al., 1981). Both epoxides of d-limonene were tested for mutagenicity in several Salmonella 
strains and showed to be inactive. The mono-epoxides of 4-vinylcyclohex-1-ene were inactive in Salmonella 
strain TA100, but were not tested in the other strains. However, the diepoxide of 4-vinylcyclohex-1-ene was 
mutagenic in this bacterial strain, but this diepoxide was not detected in the microsomal metabolism studies 
with 4-vinylcyclohex-1-ene as starting material (Watabe et al., 1981). 
Other in vitro experiments have shown that male rats can convert d- and l-limonene into the corresponding 
trans-perillyl alcohol (by hydroxylation of the methyl group at C7) and carveol (or limonene-6-ol; by ring 
C6-hydroxylation). These reactions are catalysed by CYP2C11 and, when pretreated with phenobarbital, 
CYP2B1. In female rats, the activity for conversion to either alcohol is much lower. Apparently, the female-
specific CYP2C12 has no activity with respect to d- and l-limonene hydroxylation. In males, the 
hydroxylation activities were not detectable with foetal liver microsomes, but they increased after birth, 
closely related to the developmental increase in CYP2C11. This study also investigated whether the d- and l-
limonene enantiomers are differently metabolised by liver microsomes. Both in liver microsomes from 
untreated and treated with phenobarbital, approximately the same amounts of carveol and perillyl alcohol 
were formed from the two limonene enantiomers. Ratios over the two routes of metabolism were 
carveol/perillyl alcohol: 0.87/1.23 for d-limonene and 0.61/1.03 for l-limonene. Also the rate of formation of 
carveol and perillyl alcohol from d- and l-limonene is similar using either liver microsomes or recombinant 
P450 enzymes (Miyazawa et al., 2002). 
In male rats orally administered 3 mmol/kg (408 mg/kg) of [14C]-d-limonene radioactivity was detected in 
the renal cytosol. Forty percent of the total cytosolic radioactivity was reversibly associated with the protein 
fraction and further analysis showed that > 97 % of this activity was associated with one single protein, 
which was identified as α-2µ-globulin. 1,2-Limonene epoxide, 1,2-limonene-diol and d-limonene comprised 
82, 5 or 13 %, respectively, of the radioactivity associated with this protein (Lehman-McKeeman et al., 
1989). 
d-Limonene has been shown to induce P450 enzymes of the CYP2B and CYP2C subfamilies and epoxide 
hydrolase in rats (Austin et al., 1988; Maltzman et al., 1991). 
Conclusions on the metabolism of subgroup III substances 
In the subgroup III there are only metabolism data available for one supporting substance, d-limonene, which 
in several animal species and humans has been demonstrated to be oxidised in both side chains and at the 
cyclohexene ring, resulting in alcohols and/or carboxylic acids. Ring and side chain hydroxylation has also 
been described for its structural isomer l-limonene (a constituent of candidate substance [FL no: 01.001] and 
a candidate substance on its own [FL-no: 01.046]) in rat liver microsomes. The metabolites of these 
limonenes are, at least partly, conjugated and eliminated with the urine. It is anticipated that three out of the 
six candidate substances [FL-no: 01.027, 01.028 and 01.039] in subgroup III are metabolised in a similar 
way to innocuous products. It cannot be anticipated based on the data available that beta-phellandrene [FL-
no: 01.055] with a double bond directly on the ring and in conjugation with double bond in the cyclohexene 
ring can be metabolised to innocuous products. 
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Aromatic Hydrocarbons (Candidate and Structurally Related Supporting Substances from Subgroup 
IV) 
Subgroup IVa: Benzene Hydrocarbons 
No data are available for the candidate substances in this group. Some information was available on the 
biotransformation of p-cymene ([FL-no: 01.002]; p-isopropyl toluene). Given the structure of this substance, 
which deviates considerably from the candidate substances in this subgroup, the information provided was 
considered to be only of limited relevance for the evaluation of the benzene hydrocarbons in this group. In 
general, the studies indicate that in various animal species p-cymene undergoes extensive oxidation of the 
methyl and isopropyl side chain to yield polar oxygenated metabolites. These metabolites are either excreted 
unchanged in the urine or undergo phase II conjugation with glucuronic acid and/or glycine, followed by 
excretion in the urine (Bakke and Scheline, 1970; Walde et al., 1983; Matsumoto et al., 1992; Boyle et al., 
1999). Only in the guinea pig,  ring hydroxylation products (carvacrol and hydroxycarvacrol) were found in 
minute amounts. Ring hydroxylation in guinea pigs only occurred ortho to the methyl group (Walde et al., 
1983). 
Subgroup IVb: Naphthalene Hydrocarbons 
Naphthalene [FL-no: 01.053] 
Metabolism of naphthalene (0.031, 0.062, 0.125, 0.25, 0.50 and 1.0 mM) was studied in lung and liver 
microsomal preparations from Swiss Webster mice, Sprague-Dawley rats, Sprague-Dawley hamsters and 
rhesus macaque monkeys. Naphthalene metabolism to glutathione conjugates and diols was 4 to 8-fold 
higher in mouse lung microsomal incubations than in corresponding incubations from hamster and rat lung. 
Mice lung had a high degree of stereoselectivity in metabolism of naphthalene to naphthalene epoxide, 
where the ratio of 1R,2S- to 1S,2R-naphthalene epoxide was 11 to 14:1. Little or no stereoselectivity in the 
metabolism of naphthalene was found in the mouse liver or in the lung and liver from the rat, hamster and 
monkey. The mouse liver metabolises more of the naphthalene to diol than the mouse lung, 12 % and 5 % of 
the total metabolites, respectively. Naphthalene is metabolised in lung tissue microsomal incubations of 
rhesus monkeys at a rate 100-fold less than mice and 10-fold less than rats. Naphthalene is metabolised in 
lung tissue microsomal incubations of rhesus monkeys at a rate 100-fold less than mice and 10-fold less than 
rats. In the primate liver microsomes naphthalene diols comprise 80 % of the total metabolites produced 
(Buckpitt et al., 1992). The olfactory epithelium contained the greatest amount of CYP protein of all tissues 
investigated in the rat. However, CYP2F expression levels in primate nasal tissues demonstrate that only the 
nasal ethmoturbinates contained quantifiable amounts of CYP2F with the levels in primates roughly 10- and 
20-fold less than the corresponding tissues in rats and mice, respectively (Baldwin et al., 2004). Clearly, 
humans would produce less naphthalene-1,2-oxide or produce it at a slower rate than rats or mice in 
respiratory tract tissues. An overview of naphthalene metabolism is presented in Figure III.4. 
Three groups of Sprague-Dawley rats were treated orally with a single administration of 2 mg 14C-
naphthalene. The dose/unit body weight was not stated (Bakke et al., 1985). One group of 16 animals were 
bile duct cannulated, the second group of four germ-free animals were uncannulated, and the third group of 
13 animals were standard uncannulated rats. Urine, faeces and bile were collected for 72 hours after 
administration of naphthalene and the metabolites were identified and quantified. In the standard 
uncannulated rats the urinary metabolites identified at 24 hours were an N-acetyl cysteinyl naphthalene 
conjugate (38.1 % of the administered radioactivity), 1,2-dihydro 1,2-dihydroxynaphthalene (dihydrodiol) 
glucuronide (23.9 %), dihydroxynaphthalene (4.9 %), naphthols and naphthol glucuronides (4.6 %) and 1,2-
dihydro-1-hydroxy-2-thionaphthalene glucuronide [CH3S-metabolite] (4.6 %). At 24 hours in cannulated 
rats, 14.4 % of the administered dose was present in the urine as N-acetyl cysteinyl naphthalene conjugate, 
and 14.5 % as the dihydroxynaphthalene glucuronide conjugate. Naphthols, thionaphthols, CH3S-metabolites 
or their respective glucuronides and sulphates were not detected in either the 24-hours urine or bile. The 
major urinary metabolites of germ-free rats were N-acetyl cysteinyl naphthalene (89 %) and 
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dihydroxynaphthalene glucuronide (4 %). Only trace amounts of naphthols and no CH3S-metabolites could 
be detected indicating that intestinal microflora are probably involved in production of these metabolites 
followed by enterohepatic recirculation. In vitro experiments showed that 1,2-dihydroxy-1,2-
dihydronaphthalene may be transformed by isolated rat liver dihydrodiol dehydrogenase to form the 1,2-
naphthoquinone, which reacts rapidly with glutathione or cysteine (Smithgall et al., 1986; Smithgall et al., 
1988). Naphthalene-1,2-dihydrodiol may be oxidised further by CYP enzymes, resulting in an epoxide, 1,2-
dihydroxy-3,4-epoxy-1,2,3,4-tetrahydronaphthalene. Several urinary metabolites, including a number of 
trihydroxytetrahydromethylthio-derivatives (Horning et al., 1980) and trihydroxytetrahydromercapturic acid 
(Pakenham et al., 2002) provide support for the in vivo formation of 1,2-dihydroxy-3,4-epoxy-1,2,3,4-
tetrahydronaphthalene. Initially, naphthalene metabolism involves epoxidation of the aromatic ring by 
cytochrome (CYP) enzymes yielding naphthalene-1,2-oxide. Several studies have shown that a number of 
CYP isozymes catalyse this reaction, including CYP2E1 (Wilson et al., 1996) and CYP2F (Buckpitt et al., 
2002; Shultz et al., 1999).  
Limited information is available regarding the metabolism of naphthalene in humans. Incubation of human 
lung microsomal fractions demonstrated naphthalene metabolism to naphthalene dihydrodiol and glutathione 
conjugates (Buckpitt and Bahnson, 1986). Human and mouse liver microsomes exposed to naphthalene 
produced the 1-naphthol and naphthalene-1,2-dihydrodiol metabolites in the ratio 8.6 and 0.4 in human and 
in phenobarbital-induced mouse microsomes, respectively (Tingle et al., 1993). In human liver microsomes 
naphthalene-1,2-dihydrodiol is formed following epoxidation and hydrolysis, whereas rearrangement of the 
1,2-epoxide leads to the formation of 1-naphthol (Tingle et al., 1993). Preferential formation of the 1S,2R-
naphthalene oxide enantiomer in human and rat microsomes provides evidence that human metabolism of 
naphthalene may be more similar to rats than mice (Lanza et al., 1999). Naphthalene metabolising enzymes 
have been demonstrated in nasal respiratory epithelial and olfactory epithelial tissue from rodents and 
humans (Buckpitt et al., 1992; Buckpitt et al., 2002; Plopper et al., 1992; Thornton-Manning & Dahl, 1997). 
Waidyanatha et al. (2002) have studied covalent binding of naphthalene metabolites to haemoglobin and 
albumin in vivo. They measured cysteinyl adducts of naphthalene-1,2-oxide and 1,2- and 1,4-
naphthoquinone in rats, 24 hours after dosing them with 100 - 800 mg naphthalene/kg bw. Cysteinyl adducts 
with all three metabolites were produced in a dose-dependent manner. Naphthalene-1,2-oxide produced 
adducts with both proteins and at dose levels > 200 mg/kg bw the formation of adducts became saturated. 
For 1,2-naphthoquinone-albumin adducts were more abundant than for 1,4-naphthoquinone. Differences for 
the haemoglobin adducts were much less pronounced. Total naphthoquinone adducts with albumin were also 
produced in larger amounts than with haemoglobin. Naphthoquinone, but not naphthalene-1,2-oxide adducts, 
could also be detected in albumin and heamoglobin of control animals (Waidyanatha et al., 2002).  
Urine samples were collected from an infant hospitalised because of haemolytic anaemia following ingestion 
of unknown quantities of naphthalene mothballs. 1- and 2-naphthol and 1,2- and 1,4-naphthoquinone were 
identified in the samples for up to eight days of hospitalisation. 1-Naphthol was present in the largest, 
unspecified quantities (Mackell et al 1951, as cited in (EU-RAR, 2003)).  
It can be concluded that naphthalene [FL-no: 01.053] is metabolised by cytochrome P450 enzymes, yielding 
naphthalene-1,2-oxide. This epoxide may be metabolised by glutathione S-transferase enzymes to a 
glutathione conjugate that is subsequently converted into a mercapturic acid conjugate and excreted in the 
urine. Naphthalene-1,2-oxide may also rearrange to yield 1- or 2-naphthol, which are excreted as 
glucuronide or sulphate conjugates in the urine. In addition, 1-naphthol may be further metabolised by CYP 
enzymes to 1,2- or 1,4-naphthoquinone, and 2-naphthol may be further oxidised to give also 1,2-naphtho-
quinone. Naphthalene-1,2-oxide may be hydrated by epoxide hydrolase, yielding 1,2-dihydroxy-1,2-
dihydronaphthalene, which is oxidised by dihydrodiol dehydrogenase also to form 1,2-naphthoquinone. CYP 
enzymes may oxidise naphthalene-1,2-dihydrodiol to yield 1,2-dihydroxy-3,4-epoxy-1,2,3,4-
tetrahydronaphthalene, which can be further metabolised by a number of conjugation pathways. 
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Figure III.4. Pathways for metabolism of naphthalene (adapted from ATSDR, 2005). 
 
2-methylnaphthalene [FL-no: 01.051] 
The oxidative metabolism of 2-methylnaphthalene was investigated using rat liver microsome suspensions. 
One monohydroxylated (2-hydroxymethylnaphthalene) and three isomeric dihydrodiol (3,4-dihydrodiol, 5,6-
dihydrodiol and 7,8-dihydrodiol) metabolites of 2-methylnaphthalene were identified (Breger et al., 1983). 
Melancon et al. (1985) confirmed that one 2-hydroxymethyl- and three isomeric dihydrodiol metabolites of 
2-methylnaphthalene are formed in vitro by rat hepatic microsomes and purified cytochromes (Melancon et 
al., 1985).  
Four female rats were dosed with two subcutaneous injections of 300 mg 2-methyl-[8-14C]-naphthalene/kg 
bw and urine was collected for three days. Of the radioactivity injected, 55 % was found in the urine and 
only 3 - 5 % (ca. 2.2 % of the dose) appeared to be unchanged parent compound. Three isomeric dihydrodiol 
metabolites of 2-methylnaphthalene represented 6 - 8 % of urine 14C (ca. 3.8 % of the dose). More polar 
metabolites were identified as 2-naphthoic acid and 2-naphthoylglycine, the latter of which accounted for 30 
- 35 % of urine 14C (ca. 17.5 % of the dose). The remainder of the urinary radioactivity was not fully 
elucidated but 6 - 8 % were other conjugates of naphthoic acid (ca 3.8 % of the dose), and some were 
identified as hydrolysable with beta-glucuronidase (not yielding naphthoic acid) (Melancon et al., 1982). 
In guinea pigs, when 10 mg/kg bw 2-[1-3H]-methylnaphthalene was orally administered the major 
metabolites excreted in the urine at 24 hours (in total 23 % of the dose) were oxidation products of the 
methyl group (i.e. 2-naphthoic acid (4 %), 2-naphthoylglucuronic acid (11 %), and 2-naphthoylglycine (61 
%)) which in total accounted for 76 % of the total urinary radioactivity. Dihydrodiols could not be detected, 
but S-(7-methyl-1-naphthyl)cysteine (10 %), and glucuronic acid and sulphate conjugates of 7-methyl-1-
naphthol (each 4 %) were also identified as minor metabolites accounting together for 18 % of the total 
urinary radioactivity. In incubations of 2-methylnaphthalene with guinea pig liver S9, formation of S-(7-
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methyl-1-naphthyl)-glutathione could be demonstrated, and four hours after oral administration of 500 mg 2-
methylnaphthalene/kg bw, GSH depletion in the liver was observed, but no mercapturic acids could be found 
in the urine. It was speculated that the cysteine conjugate might be an artificial break-down product of 
mercapturic acid derivatives (Teshima et al., 1983). Other authors have also demonstrated that 2-
methylnaphthalene can deplete liver GSH stores, e.g. (Griffin et al., 1982). This depletion has been brought 
into connection with the toxicity of 2-methylnaphthalene (Shelby and Witt, 1995). 
Griffin et al. (1982) have studied the relationship between 2-methylnaphthalene (400 mg/kg bw 
intraperitoneally) induced lung toxicity and GSH depletion in the lung, liver and kidneys in the mouse in 
relationship to 2-methylnaphthalene covalent tissue binding and metabolic conversion into dihydrodiol 
metabolites, using age at onset modifiers of cytochrome P450 activity. Both phenobarbital (PB) and 3-
methylcholanthrene (3MC) reduced lung toxicity of 2-methylnaphthalene, but only PB reduced pulmonary 
covalent binding. In the liver neither PB nor 3MC had an effect on covalent binding of 2-methylnaphthalene. 
In liver microsomes, PB increased formation of dihydrodiols, but it had no effect in the lung, whereas 3MC 
reduced formation of dihydrodiols in lung but not in liver microsomes. Piperonyl butoxide decreased 
covalent binding in the lung, liver and kidney, but did not affect lung toxicity. SKF-525A had also no effect 
on pulmonary necrosis. Diethyl maleate had no effect on binding in the liver, but it decreased binding in the 
lung and kidney. It also did not affect the severity of the pulmonary toxicity, but it enhanced the lethality of 
2-methylnaphthalene. Pretreatment of mice with piperonyl butoxide or diethyl maleate did not affect the 
hepatic or pulmonary microsomal conversion of 2-methylnaphthalene into dihydrodiols. It was also shown 
that 2-methylnaphthalene strongly decreases liver GSH levels, but not GSH levels in the lung or kidney. The 
authors concluded that the pulmonary toxicity of 2-methylnaphthalene may be related to metabolism, but that 
the role of the dihydrodiols or covalent binding as indicators of activity of epoxide intermediates in vivo is as 
yet uncertain (Griffin et al., 1982). 
Subgroup IVc: Diphenylmethane 
The biotransformation of diphenylmethane [FL-no: 01.036] was studied in microsomal fractions prepared 
from rat liver homogenate. It was determined that diphenylmethane is hydroxylated at both the aromatic 
(para-) and aliphatic positions of the molecule. If hydroxylation of the methylene group occurs, the resulting 
diphenylmethanol is further oxidised to diphenylketone (Sípal & Zelingerová, 1978). 
Four male rats were administered 900 mg/kg bw of diphenylmethane via intraperitoneal injection. Animals 
were housed in individual metabolism cages and provided food and water ad libitum. Urine and faecal 
samples were collected after 24 hours and analysed immediately. The urine and faecal samples indicated that 
both free and conjugated forms of p-hydroxydiphenylmethane are eliminated with 88 % of the recovered 
material (in total ca. 6.8 % of the dose) being found in the urine (Deloach et al., 1978). The major part of the 
urinary p-hydroxyphenylmethane was excreted as unconjugated material. In a subsequent experiment by the 
same investigators, six male rats were administered 500 mg/kg bw of diphenylmethane via intraperitoneal 
injection. Animals were housed in individual metabolism cages and provided food and water ad libitum. 
Urine samples were collected after 24 hours and analysed immediately. The urine samples indicated that 
conjugated benzhydrol (= diphenylmethanol) is eliminated by rats at 0.6 % of the total dose of 
diphenylmethane administered, free benzhydrol is not eliminated. The authors indicated that others have 
found that benzhydrol is excreted as glucuronide (Stocklinski et al., 1979). 
Conclusions on the metabolism of subgroup IV substances 
No data are available for the two substances in subgroup IVa [FL-no: 01.031 and 01.058]. Based on 
information available on p-cymene, it may be anticipated that these substances may be oxidised at the ring-
substituent methyl groups (resulting in the formation of hydroxymethyl groups). These products may 
subsequently be excreted after conjugation. Also epoxidation of the 3,4-double bond in [FL-no: 01.031] may 
be expected. Oxidative attack on the aromatic ring seems less likely. Nevertheless, due to the lack of 
experimental data it would be impossible to conclude that these substances are metabolised into innocuous 
products. 
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Several data are available on the biotransformation of the naphthalene [FL-no: 01.053] and its 2-methyl 
derivative [FL-no: 01.051] in subgroup IVb. With naphthalene, the primary products resulting from 
epoxidation can be further metabolised to naphtoquinones and other metabolites, which have been brought 
into connection with the toxicity of this substance. Whereas epoxidation is the main metabolic option for 
naphthalene, methyl group oxidation is the major metabolic pathway in the case of 2-methylnaphthalene. 
However, also with 2-methylnaphthalene, epoxidation may occur to some extent, and 2-methylnaphthalene-
induced depletion of glutathione stores, possibly as a result of conjugation, has been suggested to be related 
to epoxidation reactions. However, although biotransformation does play a role in the toxicity of 2-
methylnaphthalene, the exact mechanism of toxicity and the metabolites which are involved have not been 
clearly identified. Hence, neither for naphthalene [FL-no: 01.053] nor for 2-methylnaphthalene [FL-no: 
01.051] can it be concluded that these are metabolised into innocuous substances. 
For the one candidate substance in subgroup IVc (diphenylmethane [FL-no: 01.036]) only a very limited 
amount of metabolites have been identified in the urine. One of these is an aromatic hydroxylation product 
(i.e. a phenol derivative), which may be generated from epoxidation. Because of lack of further data it cannot 
be concluded that diphenylmethane [FL-no: 01.036] is metabolised to innocuous products. 
Bi- and Tricyclic Non-Aromatic Hydrocarbons (Candidate and Structurally Related Supporting 
Substances from Subgroup V) 
Analysis of urinary metabolites eliminated by human volunteers within four hours following a 2hours 
inhalation exposure to 10 - 450 mg (+)-alpha-pinene/m3 [FL-no: 01.004] in a pharmacokinetic study (Falk et 
al., 1990b) revealed cis- and trans-verbenol in a ratio of 1:10, with 3.8 and 1.7 % being eliminated at 10 and 
450 mg/m3, respectively. Most of the verbenols were eliminated within 20 hours. In a more extensive 
metabolic study, urine was collected from sawmill workers at the end of an 8 - 9 hours work shift or from 
chamber-exposed individuals. Following hydrolysis of glucuronic acid conjugates, cis- and trans-verbenol 
were identified in the urine along with two diols, cis- and trans-4-hydroxymyrtenol, formed by methyl group 
hydroxylation of cis- and trans-verbenol. trans-4-Hydroxymyrtenal was also detected (see Figure III.5) 
(Eriksson and Levin, 1990).  
Analysis of the urinary metabolites of a patient attempting suicide with 400 - 500 ml pine oil containing 57 
% alpha-pinene showed the presence of myrtenol, verbenol and borneol. Renal excretion reached a peak 
level five days after ingestion (Koppel et al., 1981).  
Male albino rabbits (six/group) administered single gavage doses of 400 - 700 mg/kg bw of (+)-alpha-
pinene, (-)-alpha-pinene, (+/-)-alpha-pinene, (-)-beta-pinene or delta-3-carene, excreted bicyclic terpene 
hydrocarbon metabolites as (glucuronic acid) conjugates or as further oxidised metabolites, notably 
carboxylic acids. Animals were housed individually and urine was collected daily for three days.  
The principal neutral metabolite formed by oxidation at the C4 position in the alicyclic ring of each of the 
three alpha stereochemical forms of pinene was trans-verbenol (see Figure III.5). As a minor pathway, allylic 
oxidation of the exocyclic methyl group to yield myrtenol was observed for all three alpha-pinene 
stereoisomers, with also myrtenic acid as minor metabolite (Ishida et al., 1981). 
The presence of an exocyclic alkene function in (-)-beta-pinene provided additional metabolic options, and 
four neutral and one acidic metabolites were identified. Allylic oxidation of the methyl group at the C2 
position yields (+)-trans-pinocarveol, while epoxidation of the exocyclic alkene followed by hydration or 
rearrangement yields (-)-trans-10-pinanol and (-)-1-p-menthene-7,8-diol, respectively. Ring cleavage yields 
(-)-alpha-terpineol. These metabolites comprised 11, 39, 30 or 5 % of the total urinary neutral metabolite 
fraction, respectively. The acidic metabolite identified was identical to the one identified for the alpha-
pinenes (i.e. myrtenic acid), which was suggested to be formed via double bond epoxidation and subsequent 
rearrangement to give myrtenol and further oxidation to the carboxylic acid (Ishida et al., 1981).  
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Figure III.5. Metabolism of α-pinene and β-pinene in animals.  
 
Trans-verbenol and myrtenic acid have also been found in faeces or urine of brushtail possum fed alpha-
pinene. When the same species was fed beta-pinene, only myrtenic acid was found in the excreta (Southwell 
et al., 1980).  
It has been stated in a limited review paper that in rabbits, alpha- and beta-pinenes can be excreted as 
glucuronide conjugates of undetermined nature, which can release cymene upon heating in diluted acids 
(Williams, 1959 as cited in (Opdyke, 1978c)).  
Delta-3-Carene [FL-no: 01.029] undergoes stereoselective hydroxylation at the gem-methyl group (yielding 
3-caren-9-ol) followed by carboxylation, allylic oxidation of the C10 methyl group followed by 
carboxylation or, as the main route, allylic ring opening and hydroxylation at a secondary carbon atom, 
yielding (-)-m-mentha-4,6-dien-8-ol (72 % of the total urinary neutral metabolite fraction) and m-cymen-8-ol 
(Ishida et al., 1981). 
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In addition to the terpenoids pinene and carene, the group of Ishida has also studied the metabolism of the 
saturated analogues pinane and carane11 (Ishida et al., 1981). Only a relatively small part of the dose (in total 
18 g given to six rabbits) was identified, among which were 3- and 4-pinalol, alpha-terpineol, trans-sobrerol, 
trans-carveol, and verbenol (some of the structures have been shown in Figure III.5). In short, these products 
result from hydroxylations of secondary carbon atoms in the 6-membered ring, or cleavage of the 4-
membered ring in combination with hydroxylation in the remaining 6-membered ring. In addition, 
desaturation of the 6-membered ring was also observed and hence, some of the metabolites may be 
considered as cyclohexene derivatives. No hydroxylation of the primary carbon atom (i.e. the methyl ring 
substituent) in pinane was observed. With carane, however, the hydroxylation of one of the gem-methyl 
groups and hydroxylation of the C10 exocyclic carbon atom was observed, ultimately resulting in the 
formation of carane-9,10-dicarboxylic acid. 
In rabbits, beta-caryophyllene [FL-no: 01.007] undergoes epoxidation of the endocylic 5,6-double bond to 
yield a stable epoxide metabolite and hydroxylation at the gem-dimethyl group. The resulting metabolite 14-
hydroxycaryophyllene-5,6-epoxide and its C14-acetylated conjugate could be detected in the urine. A second 
epoxidation of the 5,6-epoxide’s exocyclic 2,12-double bond, ultimately resulting in the 14-
hydroxycaryophyllene-5,6-epoxide-2,12-diol, was also reported (Asakawa et al., 1981; Asakawa et al., 
1986).  
Data were also found on the metabolism of camphene12. Ishida et al. (1979) administered dl-camphene [FL-
no: 01.009] to five starved male rabbits at a dose level of 800 mg/kg bw via stomach tube. In total 8 g of the 
substance was given. Urinary metabolites, collected over three days post-dosing were examined. The 
following metabolites were identified in urine samples after treatment with beta-glucuronidase/sulphatase: 
camphene-2,10-glycol (after epoxidation of the double bond), 6-exo-hydroxycamphene, 7-
hydroxycamphene, 10-hydroxytricyclene and 3-hydroxytricyclene. Quantitative information was provided 
only for the diol which was found in a total amount of 260 mg, which corresponds to ca. 3 % of the dose 
(Ishida et al., 1979a). 
In a human volunteer and in a young pig, camphene was eliminated from the body by exhalation and via bile 
as unchanged substance or as glucuronide conjugate via the urine (Opdyke, 1975).  
(+)-Longifolene [FL-no: 01.047] metabolism was studied following the oral administration of about 2 
g/animal as a suspension in 0.02 % Tween80 aqueous solution to six male rabbits. Urine samples were 
collected daily for three days and treated with beta-glucuronidase / sulphatase. Due to imprecise description 
of dose and amounts recovered, it is not possible to indicate the extent of metabolism and excretion as 
percentage of the dose. Deconjugated metabolites were extracted in a neutral and an acidic fraction. In the 
neutral fraction (10 % of the dose), many peaks were observed but only one was further characterised to be 
(2S, 7S)-(+)-14-hydroxyisolongifolaldehyde (35 % of the neutral metabolite fraction). It was concluded that 
(+)-longifolene is metabolised at two sites in two subsequent steps: 1) oxidation of the exo-methylene group 
to form its epoxide with subsequent isomerisation to form a stable aldehyde, and 2) hydroxylation of the 
gem-dimethyl group to form a primary alcohol (Ishida et al., 1982; Asakawa et al., 1986; Ford et al., 1992b).  
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An in vitro study with rat liver microsomes demonstrated the involvement of cytochrome P450 enzymes in 
the metabolism of alpha-pinene. Metabolites present were beta-pinene and d-limonene together with smaller 
amounts of trans-verbenol, myrtenol, verbenone, and pinene oxide (White & Agrosin, 1980). 
alpha-Pinene and cadinene, have been shown to induce cytochrome P450 enzymes, especially those from the 
CYP2B subfamily, and to a lesser extent also CYP3A2 (cadinene) and CYP4A2 (alpha-pinene) (Austin et 
al., 1988; Hiroi et al., 1995). Based on similarity with beta-pinene it may be speculated that the candidate 
substance 4(10)-thujene [FL-no: 01.059] may be hydroxylated to thujyl alcohol, which is known to be 
conjugated with glucuronic acid and eliminated via urine (Hämäläinen, 1912; EFSA, 2009ah). However, 
based on the same similarity, epoxidation of the exocyclic double bond may also be expected, and it is not 
clear what other reactions might occur. No indications of the relevance of the various routes are available. 
Conclusions on the metabolism of subgroup V substances 
Metabolism data for subgroup V are available for some supporting substances (pinenes, camphene, 
caryophyllene, delta-3-carene, pinane and carane) and the candidate substance longifolene [Fl no: 01.047]. In 
general, the metabolic options for these substances include oxidation of methyl ring substituent groups to 
give the corresponding alcohol and further oxidation products. For the substances studied, double bond 
epoxidation has also been demonstrated. In addition, ring cleavage has also been observed, e.g. for beta-
pinene, resulting in the formation of monocyclic terpenoid derivatives like alpha-terpineol. Hydroxylated 
metabolites (i.e. alcohols) or further metabolic products may be eliminated as conjugates e.g. with glucuronic 
acid. However, given the diversity of this group, the lack of data on any of the candidate substances, except 
longifolene for which the mass balance is incomplete, it cannot be concluded that the candidate substances in 
this subgroup  [FL-no: 01.021, 01.022, 01.023, 01.030, 01.044, 01.047, 01.052, 01.056, 01.059, 01.060, 
01.066 and 01.067] can be metabolised to innocuous products. 
Macrocyclic, Non-Aromatic Hydrocarbons (Candidate and Structurally Related Supporting 
Substances from Subgroup VI) 
No data are available for the two substances in subgroup VI [FL-no: 01.042 and 01.043] or for any 
supporting substance. Due to the lack of experimental data it cannot be concluded that these substances are 
metabolised to innocuous products.  
III.5. Summary on Absorption, Distribution, Metabolism and Excretion 
Given the diverse nature of the chemical structures of the candidate flavouring substances in this FGE, it is 
impossible to draw conclusions which are applicable to all substances. The amount on information on 
kinetics of either candidate or supporting substances is very limited. For these reasons, the available 
information is presented here in a subgroup-wise manner. 
III.5.1. Absorption, Distribution and Elimination 
Subgroup I 
From the available studies it may be concluded that the candidate alkane substances in subgroup 1 will be 
absorbed after oral exposure. The extent of absorption is not known, but may be high, given their lipophilic 
character and their low molecular weight. The ease with which these substances cross the membranes of the 
respiratory tract further supports the assumption that these substances will also be absorbed after oral intake. 
Data indicate that straight-chain alkanes will predominantly be broken down to carbon dioxide at low dose 
levels. At high dose levels, biotransformation becomes saturated and other metabolites will be generated 
which will be excreted via the urine. 
Subgroup II 
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For the candidate and supporting substances in subgroup II, the acyclic alkenes, data were only available for 
beta-myrcene [FL-no: 01.008] and 2-methylbuta-1,3-diene (a structurally related substance). Given the 
narrow range of molecular weights of the candidate substances (between ~ 68 and 206 D) and their lipophilic 
nature (estimated or measured Log Kow values e.g. 2.4 (2-methylbuta-1,3-diene), 6.1 (dodec-1-ene), 4.17 
(beta-myrcene) or 4.8 (cis-3,7-dimethyl-1,3,6-octatriene)), it is assumed that these candidate flavouring 
substances may be absorbed from the gastrointestinal tract. Mass balance data for beta-myrcene are 
incomplete. For 2-methylbuta-1,3-diene a mass balance of elimination has been presented, which also shows 
elimination via the exhaled air (~ 50 % of the dose), but as this substance was administered via the 
intraperitoneal route, the elimination pattern may be different after oral dosing with a lower fraction of the 
dose exhaled, e.g. because of more efficient first-pass biotransformation after oral dosing. 
Subgroup III 
For the candidate and supporting substances in subgroup III (cyclohexene derivatives), data were only 
available for d-limonene [FL-no: 01.045]. For this substance, data show a considerable absorption from the 
gastrointestinal tract. In humans, elimination of the substance followed a triphasic pattern, but still 55 - 83 % 
of an oral dose could be found in the urine within 72 hours post dosing, with the major part excreted within 
24 hours. Also in other species urinary elimination was most important accounting for up to 82 - 96 % of the 
dose within 72 hours. Hence, it may be anticipated that monocyclic cyclohexene derivatives, such as d-
limonene, administered orally, are absorbed and distributed throughout the body. Following oral 
administration to humans, d-limonene was distributed preferentially to fatty tissues, as indicated by a high 
oil-blood partition coefficient and a long half-life during the slow elimination phase. Because of the limited 
molecular weight of the candidate substances in this group (range ~ 136 - 204 D) and their lipophilic 
character (e.g. estimated or measured log Kow values for beta-phellandrene, beta-bisabolene and d-limonene 
are approximately 4.7, 7.1 or 4.6, respectively) it may be assumed that all of the substances in this group may 
be absorbed, although the extent of absorption for individual substances cannot be accurately estimated from 
these physico-chemical properties. 
Subgroup IV 
No data are available on the absorption, distribution and elimination of any candidate or supporting 
substance in subgroup IVa (benzene hydrocarbons). But there are several data available on the candidate 
substances in subgroup IVb (naphthalene hydrocarbons). The data show that naphthalene [FL-no: 01.053] 
will be absorbed after oral administration and will be eliminated predominantly via the urine, in the form of 
various metabolites, conjugated with e.g. glucuronic acid or with glutathione. In bile duct cannulated 
animals, considerable elimination into the bile was also observed, but as in intact animals urinary elimination 
exceeds by far faecal excretion, the material eliminated via the bile is reabsorbed. The glucuronide conjugate 
of 1-naphthol represents a significant urinary metabolite of naphthalene. Glutathione conjugates of 
naphthalene are catabolized to (pre)mercapturic and mercapturic acids, particularly in rodents, before 
excretion in bile or urine. In primates and humans, conjugation with glutathione seems to be less important. 
Less data are available for 2-methylnaphthalene [FL-no: 01.051], but the available data show that 2-
methylnaphthalene is also absorbed from the gastrointestinal tract and eliminated predominantly via the 
urine. For both substances the data indicate that 85 - 89 % of the dose is excreted within three days after 
dosing. With respect to the one candidate substance (diphenylmethane [FL-no: 01.036]) in subgroup IVc, it 
may be concluded that the metabolites of this substance will be eliminated from the body after intraperitoneal 
injection. No conclusions can be made on absorption from the gastrointestinal tract and the rate of 
elimination as no oral ADME studies and mass-balance data are available. 
Subgroup V 
For the substances in subgroup V (bi- and tricyclic, non-aromatic hydrocarbons), the available data from oral 
studies are incomplete. These studies have only addressed the excretion of some supporting and one 
candidate substance (longifolene) in the form of metabolites via the urine. No mass-balance data were 
provided. So, these studies only show that these substances will be absorbed to some extent. The same may 
be anticipated for the other candidate substances in this subgroup. For the supporting substances alpha- and 
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beta-pinene and delta-carene information on kinetics is available from humans exposed via inhalation, in 
occupational settings. These studies show that these substances can be absorbed after inhalation exposure 
and that metabolites will be excreted into the urine e.g. as glucuronide conjugates. The elimination follows a 
triphasic pattern with rather long terminal half-lives and the absorbed amount will be eliminated within 
several days. Based on the lipophilic character of these substances it may be anticipated that they will 
preferentially distribute in the adipose tissues, which is supported by the slow terminal elimination rates. 
Subgroup VI 
No data were available on candidate or supporting substances in subgroup VI (macrocyclic, non-aromatic 
hydrocarbons). The two substances in this group have a molecular weight of ~ 204. They are also rather 
lipophilic (estimated log Kow are 4.6 and 7.0 for [FL-no: 01.042] and [FL-no: 01.043], respectively). Based 
on these data it may be assumed that these two candidate chemicals will be absorbed from the 
gastrointestinal tract. For humulatriene, given the rather high Kow, the extent of absorption may be relatively 
low. 
III.5.2. Metabolism 
Subgroup I 
The substances in subgroup I can be expected to be metabolised through omega-oxidation, which will lead to 
the formation of alcohols, and after subsequent further oxidation to carboxylic acids, which may be further 
oxidised via beta-oxidation to yield carbon dioxide. Extensive mass balance data are not available, but in 
some of the available studies excretion of carboxylic acids and carbon dioxide has been reported. Formation 
of keto-acids has also been reported, and these may be thought to be formed from omega-oxidation at one 
end of the molecule and omega-1 or -2 oxidation at the other end. More interest has been put in the 
identification of metabolites, which did not undergo substantial chain shortening. These metabolites will 
arise from oxidation of the non-terminal carbon atoms, e.g. via omega-1, -2, -3 or even -4 oxidation. The 
resulting secondary alcohols can be conjugated with e.g. glucuronic acid and excreted via the urine, or can be 
further oxidised to yield ketones. A subsequent introduction of another secondary hydroxyl group may result 
in the formation of diketones. With n-hexane, the resulting 2,5-hexanedione (a gamma-diketone) has been 
demonstrated to be responsible for hexane-induced neurotoxicity. Neurotoxicity is a common feature of 
gamma-diketones, and for that reason, candidate substance 3-methylhexane [FL-no: 01.050] cannot be 
anticipated to be metabolised into innocuous compounds. In addition, it is known that methyl-branching of 
the carbon chain potentiates the neurotoxicity of the gamma-diketone (Topping et al., 1994; EFSA, 2004e). 
The two other hexane derivatives in this group [FL-no: 01.033 and 01.034] cannot be oxidised to give a 
gamma-diketone, due to the presence of methyl groups on the C2 or C5 carbon atoms. Therefore, these 
substances may be considered as being metabolised to innocuous metabolites. For the longer chain alkanes in 
this group it would require oxidation of the more central carbon atoms in order to be converted into gamma-
diketones. Such oxidations are less favourable than omega, omega-1 or -2 oxidations, and therefore it is 
concluded that oxidation of these higher alkanes will not result in toxicologically relevant levels of gamma-
diketones, also because of rapid conjugation of the precursor alcohols. For heptane it was shown that this 
substance does not result in neurotoxicity (Bahima et al., 1984), although the gamma-diketone itself (2,5-
heptanedione) is known to be neurotoxic (Topping et al., 1994). The remaining three candidate flavouring 
substances in this group (i.e. [FL-no: 01.038, 01.054 and 01.057]) can be expected to be metabolised to 
innocuous products. 
Subgroup II 
The data available on the metabolism of one supporting and one structurally related substance in subgroup II 
show that metabolic options for the chemicals in this group are epoxidation of double bonds, ultimately 
resulting in diols, which can be further conjugated. With the supporting substance beta-myrcene, further 
metabolism of the diols into carboxylic acids has also been reported. Both in rats and rabbits, the principal 
urinary metabolite following gavage administration of beta-myrcene is myrcene-3,10-glycol, formed from 
Flavouring Group Evaluation 25, Revision 2
 
85 
the hydration of the epoxide intermediate in both species. Epoxidation of the 3,10-double bond was favoured 
over epoxidation of the 1,2-double bond. 
The studies indicate that the formation of diols from the myrcene-epoxides is very efficient. It is noted, 
however, that the diols and the related carboxylic acids are all the result of epoxidation of double bonds in 
which one of the carbon atoms has only hydrogen substituents, but no further carbon chains. In this respect, 
the candidate substance cis-3,7-dimethyl-1,3,6-octatriene [FL-no: 01.064] is most similar to beta-myrcene. 
With beta-myrcene, no diepoxide metabolites or further reaction products thereof have been reported, but it 
is noted that mass balance data are highly incomplete, so some metabolites may have been overlooked. 
With the structurally related substance, 2-methyl-buta-1,3-diene, epoxidation of the 1,2-double bond is 
favoured over epoxidation of the 3,4-double bond. While the 1,2-epoxide is readily hydrolysed, the 3,4-
epoxide is far more stable. Both metabolites can be converted to the corresponding diols and at least one 
hydroxy-carboxylic acid (2-hydroxy-2-methyl-3-butenoic acid) has been identified. In addition, in particular 
the 3,4-epoxide metabolite can be oxidised for a second time, resulting in the formation of a diepoxide 
metabolite, which is known to be reactive and has been suggested to be responsible for 2-methylbuta-1,3-
diene-induced DNA damage. For candidate substance dodec-1-ene [FL-no: 01.037], diol- and alpha-
hydroxy-carboxylic acid formation may also be expected. In addition this substance may also undergo 
omega and omega-1 or -2 oxidation at the other (saturated) end of the carbon chain (similar to the candidate 
substances in subgroup I). 
Apart from beta-myrcene and 2-methylbuta-1,3-diene, terminal double bonds appear in candidate substances 
[FL-no: 01.037, 01.064 and 01.070]. In contrast to corresponding substances in FGE.07 and FGE.18 there 
are no other functional groups in the molecule (e.g. hydroxyl- or keto-group) that could provide a more 
direct option for detoxication e.g. via conjugation with glucuronide or sulphate. In the two FGEs mentioned 
above, the presence of such groups was an argument to conclude that the metabolism of the particular 
candidate substances would give rise to innocuous products. It would not be possible to conclude similarly 
for the candidate substances in FGE.25. The other candidate substances in this subgroup (II) might also be 
oxidised in the various methyl groups but no data are available to substantiate this. Because of these 
considerations, it cannot be concluded that the candidate substances in this subgroup [FL-no: 01.032, 01.035, 
01.037, 01.064, 01.070 and 01.078] will be metabolised to innocuous products.  
Subgroup III 
Hardly any data are available on the metabolism of the candidate substances in subgroup III. Only for l-
limonene a very limited amount of data was available on biotransformation in incubations with rat liver 
microsomes. In comparison with the structures of the candidate substances in subgroup III, the structure of 
the one supporting chemical d-limonene is comparatively simple. Major differences between d-limonene and 
the candidate substances are the length of the ring substituents and the number of double bonds. In addition, 
based on the data available for one of the candidate substances, beta-phellandrene [FL-no: 01.055], with a 
double bond directly on the ring and in conjugation with double bond in the cyclohexene ring, it cannot be 
anticipated that it can be metabolised to innocuous products. 
Allylic oxidation is by far the major pathway for metabolism of limonene in humans. Minor pathways in 
limonene metabolism reported for the rat include epoxidation of either the 1,2- or the 8,9-double bond and 
subsequent hydrolysis to the diol. Given the many metabolic options for this substance, a myriad of 
metabolites has been found, including conjugates, and for a change mass balance data are available, which 
show that in various animal species the substance is completely eliminated within three days, predominantly 
via the urine. No genotoxicity of limonene epoxides could be detected, and it may well be concluded that d-
limonene is metabolised to innocuous substances. However, although it is very likely that the candidate 
substances may undergo the same metabolic conversions (allylic oxidations and double bond epoxidation) 
the conclusion for d-limonene cannot be extrapolated to all of the candidate substances because of the 
structural dissimilarities and the absence of any further data on molecules with closer resemblance to the 
candidate substances. The data available for l-limonene do not indicate that major differences are to be 
anticipated between the metabolism of d-limonene and l-limonene. For bisabola-1,8,12-triene [FL-no: 
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01.027], beta-bisabolene [FL-no: 01.028] and delta-elemene [FL-no: 01.039] it may be concluded that these 
are metabolised to innocuous products. 
It is noted that d-limonene (metabolites) causes α-2µ-globulin accumulation in male kidneys, an event 
known to be associated with male rat specific nephropathy13, and irrelevant for human toxicological risk 
assessment. 
Subgroup IV 
No data are available for the two substances in subgroup IVa [FL-no: 01.031 and 01.058]. Based on 
information available on p-cymene, it may be anticipated that these substances may be oxidised at the ring-
substituent methyl groups (resulting in the formation of hydroxymethyl groups). These metabolites may 
subsequently be excreted after conjugation. Also epoxidation of the 3,4-double bond in [FL-no: 01.031] may 
be expected. Oxidative attack on the aromatic ring seems less likely. Due to the lack of experimental data it 
cannot be concluded that these substances are metabolised into innocuous products. 
Data are available on the biotransformation of naphthalene [FL-no: 01.053] and its 2-methyl derivative [FL-
no: 01.051] in subgroup IVb. With naphthalene, the primary products resulting from epoxidation can be 
further metabolised to naphtoquinones and other metabolites, which have been brought into connection with 
the toxicity of this substance. Whereas epoxidation is the main metabolic option for naphthalene, methyl 
group oxidation is the major metabolic pathway in the case of 2-methylnaphthalene. However, also with 2-
methylnaphthalene, epoxidation may occur to some extent, and 2-methylnaphthalene-induced depletion of 
glutathione stores, possibly as a result of conjugation, has been suggested to be related to epoxidation 
reactions. However, although biotransformation does play a role in the toxicity of 2-methylnaphthalene, the 
exact mechanism of toxiciy and the metabolites which are involved have not been clearly identified. Hence, 
neither for naphthalene [FL-no: 01.053] nor for 2-methylnaphthalene [FL-no: 01.051] can it be concluded 
that they are metabolised into innocuous substances. 
For the one candidate substance in subgroup IVc (diphenylmethane [FL-no: 01.036]) only a very limited 
amount of metabolites have been identified in the urine. One of these is an aromatic hydroxylation product, 
which may be generated from epoxidation. Because of lack of further data it cannot be concluded that 
diphenylmethane [FL-no: 01.036] is metabolised to innocuous products. 
Subgroup V 
Metabolism data for subgroup V are available for the supporting substances pinenes, camphene, 
caryophyllene, delta-3-carene, pinane and carane and the candidate substance longifolene [FL-no: 01.047]. 
In general, the metabolic options for these substances include oxidation of methyl ring substituent groups to 
give the corresponding alcohol and further oxidation products. For the substances studied, double bond 
epoxidation has also been demonstrated. In addition, ring cleavage has also been observed, e.g. for beta-
pinene resulting in the formation of monocyclic terpenoid derivatives like alpha-terpineol. Hydroxylated 
metabolites or further metabolised products may be eliminated as conjugates e.g. with glucuronic acid. 
However, given the diversity of this group, the lack of data on any of the candidate substances, except 
longifolene for which the mass balance is incomplete, it cannot be concluded that the candidate substances in 
this subgroup [FL-no: 01.021, 01.022, 01.023, 01.030, 01.044, 01.047, 01.052, 01.056, 01.059, 01.060, 
01.066 and 01.067] can be metabolised to innocuous products. 
Based on similarity with beta-pinene it may be speculated that the candidate substance 4(10)-thujene [FL-no: 
01.059] may be hydroxylated to thujyl alcohol, which is known to be conjugated with glucuronic acid and 
eliminated via urine (Hämäläinen, 1912; EFSA, 2009ah). However, based on the same similarity, 
epoxidation of the exocyclic double bond may also be expected, and it is not clear what other reactions might 
occur. No indications of the relevance of these various routes are available. Hence, despite the knowledge of 
                                                     
 
13 For introduction into this area see e.g. the referred paper by Lehman-McKeeman et al. (1989) 
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the fate of thujyl alcohol, also for thujene it cannot be concluded that it will be metabolised to innocuous 
products. 
Subgroup VI 
No data are available for the two candidate substances in subgroup VI [FL-no: 01.042 and 01.043] or for any 
supporting substance. Due to the lack of experimental data it cannot be concluded that these substances are 
metabolised to innocuous products.  
III.1 Overal Conclusion on Absorption, Distribution, Metabolism and Elimination. 
Generally, the available data indicate that the aliphatic and aromatic hydrocarbons participate in similar 
pathways of metabolic detoxication. Being lipophilic and of low molecular weight, these hydrocarbons may 
be assumed to be absorbed by the gastrointestinal tract. Subsequently, they are oxidised to more polar 
oxygenated metabolites e.g. by CYP-450 enzymes. The phase I metabolites are then conjugated and 
excreted, mainly in the urine. The candidate substances and supporting substances are oxidised either by side 
chain oxidation or epoxidation of the exocyclic or endocyclic double bond. Oxidation initially yields 
hydroxylated metabolites that may be excreted in conjugated form or undergo further oxidation, yielding 
more polar metabolites that are also excreted. If a double bond is present, epoxide metabolites may form that 
are further metabolised either by hydrolysis to yield diols or by conjugation with glutathione to yield 
mercapturic acid derivatives. The aromatic hydrocarbons that do not contain alkyl substituents may undergo 
ring hydroxylation to form phenolic metabolites that are subsequently conjugated with sulphate or 
glucuronic acid and excreted in the urine. The saturated alkanes in this group may be metabolised via omega 
and omega-1, -2, -3 or -4 oxidation. Whereas omega oxidation would ultimately lead to the formation of 
carboxylic acids, the other oxidations would give rise to secondary alcohols and ketones. The carboxylic 
acids may be expected to participate in the endogenous fatty acid metabolism. However, for most of the 
subgroups the information was incomplete and the similarity between supporting and candidate substances 
was limited. In addition, proper mass balance data were not available. Some mass balance data available 
indicated slow elimination. For several subgroups no data were available at all. In Table III.2 the final 
conclusions for each of the candidate substances has been presented, together with a brief explanatory 
statement, about the conclusion reached. It is noted that the subgroup III supporting substance d-limonene 
causes α-2µ-globulin accumulation in male kidneys, an event known to be associated with male rat specific 
nephropathy, and irrelevant for human toxicological risk assessment.  
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Table III.2 Can innocuous metabolites be expected to be formed based on available data? 
FL-no: Substance name Innocuous metabolites? 
Subgroup I:  ACYCLIC ALKANES 
01.033 2,2-Dimethylhexane Yes 
01.034 2,4-Dimethylhexane Yes 
01.038 Dodecane Yes 
01.050 3-Methylhexane No (potential formation of neurotoxic gamma-diketone) 
01.054 Pentadecane Yes 
01.057 Tetradecane Yes 
Subgroup II:  ACYCLIC ALKENES 
01.032 2,3-Dihydrofarnesene No (lack of supporting data) 
01.035 2,6-Dimethylocta-2,4,6-triene No (lack of supporting data) 
01.037 Dodec-1-ene No (presence of terminal double bond which may give rise 
to reactive metabolites without counteracting metabolic 
options) 
Deleted 
from the 
Register 
2-Methylbuta-1,3-diene No (known biotransformation to reactive metabolite 
responsible for toxicity and genotoxicity) 
01.064 cis-3,7-Dimethyl-1,3,6-octatriene No (presence of terminal double bond which may give rise 
to reactive metabolites without counteracting metabolic 
options)  
01.070 1-Octene No (presence of terminal double bond which may give rise 
to reactive metabolites without counteracting metabolic 
options) 
01.078 2,4-Nonadiene No (lack of supporting data) 
Subgroup III:  CYCLOHEXENE HYDROCARBONS 
01.055 beta-Phellandrene No (lack of supporting data) 
01.027 Bisabola-1,8,12-triene Yes 
01.028 beta-Bisabolene Yes 
01.039 delta-Elemene Yes  
01.001 Limonene Yes 
01.046 l-Limonene Yes 
Subgroup IV: AROMATIC HYDROCARBONS 
Subgroup IVa:  BENZENE HYDROCARBONS 
01.031 1,2-Dihydro-1,1,6-trimethylnaphthalene No (lack of supporting data) 
01.058 1,2,3,4-Tetrahydro-1,1,6-trimethylnaphthalene No (lack of supporting dat) 
Subgroup IVb:  NAPHTHALENE HYDROCARBONS  
01.051 2-Methylnaphthalene No (known metabolism to toxic metabolites) 
01.053 Naphthalene No (known metabolism to toxic metabolites) 
Subgroup IVc: DIPHENYLMETHANE  
01.036 Diphenylmethane No (lack of supporting data) 
Subgroup V: BI- and TRICYCLIC, NON-AROMATIC HYDROCARBONS 
01.021 Delta-Cadinene No (lack of supporting data) 
01.022 alpha-Cedrene No (lack of supporting data) 
01.023 1(5),11-Guaiadiene No (lack of supporting data) 
01.030 beta-Cubebene No (lack of supporting data) 
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Table III.2 Can innocuous metabolites be expected to be formed based on available data? 
FL-no: Substance name Innocuous metabolites? 
01.044 Isolongifolene No (lack of supporting data) 
01.047 Longifolene No (lack of supporting data) 
01.052 alpha-Muurolene No (lack of supporting data) 
01.056 alpha-Santalene No (lack of supporting data) 
01.059 4(10)-Thujene No (lack of supporting data) 
01.060 1,1,7-Trimethyltricyclo[2.2.1.0.(2.6)]heptane No (lack of supporting data) 
01.066 2-Cedrene No (lack of supporting data) 
01.067 8(14)-Cedrene No (lack of supporting data) 
Subgroup VI: MACROCYCLIC, NON-AROMATIC HYDROCARBONS 
01.042 Germacra-1(10),4(14),5-triene No (lack of supporting data) 
01.043 3,7,10-Humulatriene No (lack of supporting data) 
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ANNEX IV: TOXICITY 
Oral acute toxicity data are available for seven candidate substances of the present Flavouring Group Evaluation, and for 16 supporting substances evaluated 
by the JECFA at the 63rd meeting and one structurally related substance (1-methyl-1,3-cyclohexadiene [FL-no: 01.077]). The supporting substances are listed 
in brackets. 
Table IV.1: ACUTE TOXICITY 
Chemical Name [FL-no]  Species  Sex  Route  LD50 
(mg/kg bw)  
Reference  Comments 
Tetradecane [01.057] Rat NR Oral > 5000 (Enichem Augusta Ind., 1987) Study not available 
Rat NR Oral > 5000 (PETRESA, 19??b) Study not available 
(Undeca-1,3,5-triene [01.061])  Rat M, F Oral > 8000 (Pellmont, 1973c) Data not possible to interprete 
Mouse M, F Oral 2000 - 4000 (Pellmont, 1973c) Data not possible to interprete 
Dodec-1-ene [01.037] Rat NR Oral > 3200 (Jones, 1969) No information given on study design 
Rat NR Oral > 1000 (Ethyl Corporation, 1973) Study not available 
(Myrcene [01.008]) Rat M Oral > 5000 (Moreno, 1972j) Identity of compound not stated as other than 
code number 
(beta-Ocimene [01.018])  Rat NR Oral 5000 (Moreno, 1976z) One dose tested 
(d-Limonene [01.045])  Rat M Oral > 5000 (Moreno, 1972m) Identity of compound not stated as other than 
code number 
Rat M, F Oral M: 4400 
F: 5100 
(Tsuji et al., 1975a) Study is on dogs, rats not mentioned in English 
text. Study in Japanese 
Mouse M, F Oral M: 5600  
F: 6600 
(Tsuji et al., 1975a) Study is on dogs, mice not mentioned in English 
text. Study in Japanese 
(Terpinolene [01.005]) Rat NR Oral 4.39 ml/kg (3784) (Levenstein, 1975o) Observation period not given. 
(alpha-Terpinene [01.019])  Rat NR Oral 1680 (Moreno, 1973ah)  
(gamma-Terpinene [01.020])  Rat M, F Oral 3650 (Moreno, 1973ag)  
(alpha–Phellandrene [01.006]) Rat M, F Oral > 5700 (Moreno, 1972k) Submitted study is on dermal toxicity. 
Rat M, F Oral 1.87 ml/kg 
(1590) 
(Brownlee, 1940) Substance mixed with acacia.  6 animals per dose 
group 
beta-Bisabolene [01.028] Rat NR Oral > 5000 (Moreno, 1974l) One dose tested 
Mouse M, F Oral > 13,360 (Hoffman-LaRoche, Inc., 1967b) No of dose levels not given. 
(delta-3-Carene [01.029])  Rat M Oral 4800 (Moreno, 1972l) Identity of compound not stated 
(Pin-2(3)-ene [01.004])  Rat M, F Oral 3700 (Moreno, 1972n) Identity of compound not stated 
(Pin-2(10)-ene [01.003])  Rat NR Oral > 5000 (Moreno, 1975q) One dose tested. 
(Camphene [01.009])  Rat NR Oral > 5000 (Moreno, 1974m) One dose tested  
(Valencene [01.017]) Rat M Oral > 5000 (Moreno, 1980m) One dose tested 
(beta–Caryophyllene [01.007]) Rat M, F Oral > 5000 (Hart and Wong, 1971) One dose tested 
(1(5),7(11)-Guaiadiene [01.026])  Rat NR Oral > 5000 (Moreno, 1976aa) One dose tested 
Longifolene [01.047] Rat NR Oral > 5000 (Moreno, 1977ai) One dose tested 
Diphenylmethane [01.036] Rat NR Oral 2250 (Moreno, 1973ai)  
Naphthalene [01.053] Rat NR Oral > 2000 (Hazleton France, 1990a; Hazleton 
France, 1990b) 
Study not available 
Rat NR Oral > 2000 (Vaughn & Keeler, 1976) No information on study design 
Rat M, F Oral 2400 (Birch, 1978d)  5 animals per dose group 
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Table IV.1: ACUTE TOXICITY 
Chemical Name [FL-no]  Species  Sex  Route  LD50 
(mg/kg bw)  
Reference  Comments 
Rat M, F Oral 2800 (Birch, 1978b) 5 animals per dose group 
Rat M, F Oral 19004 (Birch, 1978c) 5 animals per dose group 
Rat NR Oral 2000 (Hazleton France, 1990c) Study not available 
Rat F Gavage 9430 (Carpenter et al., 1949)  
Mouse M, F Gavage M: 533  
F: 710 
(Shopp et al., 1984)  
(1-Methylnaphthalene [01.014]) Rat NR Oral 1840 (Izmerov et al., 1982b)  Study not available 
2-Methylnaphthalene [01.051] Rat NR Oral 1630 (Izmerov et al., 1982b) Study not available 
(1-methyl-1,3-cyclohexadiene [01.077]) Rat M, F Oral > 2000 (Felice, 2005) Acute toxic class method. 2000 mg/kg is only 
dose tested, no death was observed. 
1 Administered as a 25 % solution in olive oil. 
2 Dowtherm A, which was a mixture of biphenyl (26 %) and diphenyl oxide (72 %), was tested. 
3 Administered as a 20 % solution in corn oil. 
4 Administered as a 10 % solution in corn oil. 
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Subacute / Subchronic / Chronic / Carcinogenic toxicity data are available for two candidate substances of the present Flavouring Group Evaluation and for 
six supporting substances evaluated by the JECFA at the 63rd meeting. The supporting substances are listed in brackets. 
Table IV.2: Subacute / Subchronic / Chronic / Carcinogenicity Studies 
Chemical Name [FL-no]  Species; Sex 
No./Group 
Route  Dose levels Duration NOAEL 
(mg/kg bw/day) 
Reference Comments 
(Undeca-1,3,5-triene [01.061])  Rat; M, F 
10 
Diet Calculated to provide 10 mg 
Galbelica/kg bw/day corresponding to 2 
mg undecatriene, 8 mg pinene and the 
rest dodecene.   
14 days Corresponding to 2 mg 
undecatriene1 
(Shapiro, 1988) Not valid. See footnote1. 
. 
(d-Limonene [01.045])  Rat; M 
5 
Gavage 0, 75, 150 or 300 mg/kg bw/day 5 days a 
week 
6 or 27 days  
(5 or 25 doses) 
75 (Kanerva et al., 1987) Study is on kidney toxicity specifically.  
Rat; M 
5 – 10 
Gavage 0, 2, 5, 10, 30 or 75 mg/kg bw/day, 5 
days/week 
13 weeks 5 (Webb et al., 1989) Study is on kidney toxicity specifically. 
Dog; M, F 
6 
Gavage 0, 0.4, 1.2 or 3.6 ml/kg bw/day 
corresponding to 0, 340, 1000 or 3000 
mg/kg bw/day 
180 days M: 340  
F:  340 
(Tsuji et al., 1975a) Study is in Japanese, only summary 
and tables in English. Quality of study 
not possible to assess.  
Dog; M, F 
10 
Gavage 
(divided 
doses) 
0, 0.12 or 1.2 ml/kg bw/day 
corresponding to 0, 100 or 1000 mg/kg 
bw/day.  
180 days 100 (Webb et al., 1990)  
Mouse; M, F 
10 
Gavage 0, 413, 825, 1650, 3300 or 6600 mg/kg 
bw/day for 12 days over 16-day period 
16 days 1650  (NTP, 1990e)  
Mouse; M, F 
20 
Gavage 0, 125, 250, 500, 1000 or 2000 mg/kg 
bw/day 5 days per week 
13 weeks M: 500  
F: 500  
(NTP, 1990e) Clinical signs of rough hair coat and 
decrased activity were observed at the 
two highest doses.  
Mouse; M, F 
M:50 F:50 
Gavage M: 0, 250 or 500 mg/kg bw/day 
F: 0, 500, 1000 mg/kg bw/day 
5 days per week 
103 weeks M: 250  
F: 500 
(NTP, 1990e)  
Rat; M, F 
10 
Gavage 0, 413, 825, 1650, 3300 or 6600 mg/kg 
bw/day for 12 days over 16-day period 
16 days 1650 (NTP, 1990e)  
Rat; M, F 
20 
Gavage 0, 150, 300, 600, 1200 or 2400 mg/kg 
bw/day 5 days per week 
13 weeks M: None 
F: 1200 
(NTP, 1990e) Dose-dependent nephropathy in all 
treated males.  
Rat; M, F 
M:50 F:50 
Gavage M: 0, 75 or 150 mg/kg bw/day 
F: 0, 300 or 600 mg/kg bw/day 
5 days per week 
103 weeks M: None  
F: 300 
(NTP, 1990e)  
(Pin-2(10)-ene [01.003])  Rat; M, F 
10 
Diet Calculated to provide 10 mg 
Galbelica/kg bw/day corresponding to 8 
mg pin-2(10)-ene 
14 days Corresponding to 8 mg 
pin-2(10)-ene1 
(Shapiro, 1988) Not valid. See footnote1. 
(Camphene [01.009]) Rat; M, F 
10 
Gavage 0, 62.5, 250, 1000 mg/ kg bw/day 28 days M: None 
F: 250 
(Hoechst, 1991b) Study report very limited in details. 
Study according to OECD Guideline 
407.   
Naphthalene [01.053] Rat; M, F 
20 
Gavage 0, 25, 50, 100, 200 or 400 mg/kg 
bw/day, 5 days/week 
13 weeks 100 
(LOAEL 200) 
(Battelle Columbus 
Laboratory, 1980a)  
Unpublished study that is not 
submitted. It is therefore not possible 
to assess the quality of the study. Study 
is referred to in US EPA 1998.   
Rat; NR 
28 
Diet 10-20 mg/kg bw/day 700 days 422 (Schmähl, 1955) Study not considered valid. 
Mouse; M, F 
116 – 156 
Gavage 0, 5.3, 53, 133 mg/kg bw/day 90 days 53 (Shopp et al., 1984) No histopathology was conducted, 
study not considered valid. 
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Table IV.2: Subacute / Subchronic / Chronic / Carcinogenicity Studies 
Chemical Name [FL-no]  Species; Sex 
No./Group 
Route  Dose levels Duration NOAEL 
(mg/kg bw/day) 
Reference Comments 
B6C3F1 
Mouse, M,F 
Inhalation 0, 10, 30 ppm, 5 days/week 
estimated to be 0, 3.6-3.9, 10.7-11.4 
mg/kg bw/day 
105 weeks None (NTP, 1992g) Valid study.  
F344/N rat, 
M, F 
Inhalation 0, 10, 30, 60 ppm, 5 days/week 
estimated to be 0, 3.6-3.9, 10.7-11.4, 
20.1-20.7 mg/kg bw/day 
105 weeks None (NTP, 2000d) Valid study.  
Mouse; M, F 
20 
Gavage 0, 12.5, 25, 50, 100 or 200 mg/kg 
bw/day, 5 days/week 
13 weeks 200 
(LOAEL 200) 
(Battelle Columbus 
Laboratory, 1980b)  
Unpublished study that is not 
submitted. It is therefore not possible 
to assess the quality of the study. Study 
is referred to in US EPA 1998. 
(1-Methylnaphthalene [01.014]) Mouse; M, F 
20 
Diet 0, 0,0163, 0.049, 0.147, 0.44 or 1.33 % 
in diet calculated to correspond to 0, 16, 
47, 142, 425 or 1259 mg/kg bw/day 
13 weeks 0.147% (142) (Murata et al., 1993) Dose-finding study.  
Mouse; M, F 
100 
Diet 0, 0.075 or 0.15 % in diet, average daily 
doses calculated to correspond to 0, 73 
or 142 mg/kg bw/day  
81 weeks None3 (Murata et al., 1993) Exposure related increase in incidence 
of pulmonary alveolar proteinosis.  
2-Methylnaphthalene [01.051] Mouse; M, F 
100 
Diet 0, 0.075 or 0.15 %. Average daily doses 
calculated by the authors to correspond 
to 50.3-54.3 resp. 107.6-113.8 mg/kg 
bw/day 
81 weeks No NOAEL derived4.  (Murata et al., 1997) Study considered valid. Pulmonary 
alveolar proteinosis developed in all 
treated animals. 
Mixture of (1-Methylnaphthalene 
[01.014]) and 2-Methylnaphthalene 
[01.051] 
B6C3F1 
Mouse; F 
4, 11, 32 
Cutaneous 
application 
0, 29.7, 118.8 mg/kg bw twice a week 61 weeks No NOAEL derived. (Emi and Konishi, 1985) The lesions were diagnosed as 
endogenous lipid pneumonia. 
Frequency of animals with these 
lesions were 0/4 control, 3/11 low dose 
and 31/32 high dose animals. 
(Myrcene [01.008]) Mouse; M,F 
5/20 
Gavage  3 months <250 (NTP, 2010b) As a significant dose-dependent 
increase in the relative kidney weight 
was observed for female mice at all 
treatment doses, no NOAEL for this 
study could be allocated. 
Mouse; M, F 
3/100 
Gavage  2 years 250 (NTP, 2010b) A NOAEL of 250 mg/kg bw for beta-
myrcene was allocated, based on the 
increase in bone marrow atrophy and 
lymph node atrophy observed in both 
males and females at 500 mg/kg bw 
dose. 
Rat; M, F 
5/20 
Gavage  3 months <250 (NTP, 2010b) Based on the presence of renal tubular 
nephrosis and necrosis in all test 
groups, a NOAEL could not be 
assigned. 
Rat; M, F 
3/100 
Gavage  2 years <250 (NTP, 2010b) Due to the observation of renal tubular 
adenomas and carcinomas in all dose 
groups in male rats, accompanied by an 
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Table IV.2: Subacute / Subchronic / Chronic / Carcinogenicity Studies 
Chemical Name [FL-no]  Species; Sex 
No./Group 
Route  Dose levels Duration NOAEL 
(mg/kg bw/day) 
Reference Comments 
increased incidence and severity of 
nephrosis in both sexes, a NOAEL for 
beta-myrcene from this study could not 
be allocated. 
1 Study performed using a dose of 10 mg/kg body weight per day of Galbelica, which is a solution composed of 80 % beta-pinene and 20 % 1,3,5-undecatriene and dodecene.  
2 True NOEL not determined. Only a single dose level was selected for a lifetime carcinogenicity study. Naphthalene was considered not to be carcinogenic. 
3 Study evaluated the carcinogenicity of 1-methylnaphthalene. The results were negative in the females. The males in both treatment groups showed a statistically significant increase in the number of lung adenomas from the control group; 
however, it may be concluded that because of a lack of tumours in females and at other sites (particularly the liver), it is unlikely that 1-methylnaphthalene is a carcinogen or promoter. 
4 Study evaluated the carcinogenicity of 2-methylnaphthalene. The results were negative, with the exception of the males in the 0.075 % dose group. It was concluded that although the total number of lung adenomas and adenocarcinomas was 
statistically significant in the 0.075 % dose group, they were in the range of spontaneous tumours.
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Developmental and reproductive toxicity data are available for one candidate substance of the present flavouring group evaluation and for three supporting 
substances evaluated by the JECFA at the 63rd meeting. Supporting substances listed in brackets. 
Table IV.3: Developmental and Reproductive Toxicity Studies 
Chemical Name [FL-no]  Study type 
Durations  
Species/Se
x 
No / group 
Route  Dose levels NOAEL  (mg/kg bw/day),  
Including information of possible 
maternal toxicity 
Reference  Comments 
(Myrcene [01.008]) Developmental Toxicity:  
Gestation Days 6 - 15 
Rat; F 
16 - 29 
Gavage 250, 500 or 1200 
mg/kg bw/day 
Maternal: 5002  
Foetal: 500 
(Delgado et al., 1993a) Study considered valid.  
Peri- and Postnatal 
Developmental Toxicity:  
Gestation Day 15 to Postnatal 
Day 21 
Rat; F 
12 - 18 
Gavage 0, 250, 500, 1000, 
1500 mg/kg bw/day 
Maternal: 5003 
Peri- and  
Post-natal: 250 
(Delgado et al., 1993b) Study considered valid.  
Reproductive and 
developmental toxicity: Prior 
to mating until postnatal day 
21 
Rat; M, F 
60 
Gavage 0, 100, 300, 500 
mg/kg bw/day 
Maternal/paternal: 500 mg/kg 
bw/day 
Foetal: 300 mg/kg bw/day 
(Paumgartten et al., 1998) Study considered valid.  
(d-Limonene [01.045]) Developmental Toxicity:  
Gestation Days 9 - 15 
Rat; F 
20 
Oral 0, 591 or 2869 mg/kg 
bw/day 
Maternal: 591  
Foetal: 591 
(Tsuji et al., 1975b) Study in Japanese, only summary and tables in 
English. Quality of study not possible to assess. 
Developmental Toxicity: 
Gestation Days 7 - 12 
Mouse; F 
15 
Oral 0, 591 or 2363 mg/kg 
bw/day 
Maternal: 591  
Foetal: 591 
(Kodama et al., 1977b) Study in Japanese, only summary and tables in 
English. Quality of study not possible to assess. 
Developmental toxicity: 
gestation days 6 - 18 
Rabbit; F  
10, 18 in 
highest 
dose group 
Oral 0, 250, 500 or 1000 
mg/kg bw/day 
Maternal: 250 
Foetal: 1000 
(Kodama et al., 1977c) Study in Japanese, only summary and tables in 
English. Quality of study not possible to assess.  
(Pin-2(3)-ene [01.004]) Developmental toxicity:  
Gestation days 9 - 14 
Rat; F 
12 - 17 
Oral Not relevant Not relevant (Hasegawa and Toda, 
1978) 
Study is not considered valid.  
Study is on a mixture of menthol, menthone, 
pinene, borneol cineol, camphene rheochrysin in 
olive oil. Pin-2(3)-ene content is 17 %. Study in 
Japanese.  
Developmental toxicity:  
Gestation Days 6 - 15 
Rat; F 
20 
Gavage  Maternal: 2504 
Foetal: 1000 
(Leuschner, 1992; LPT 
Research, 1992) 
Study not submitted.  
Naphthalene [01.053] 
 
Developmental toxicity:  
Gestation Days 6 - 15 
Rat; F 
25 - 26 
Gavage 0, 50, 150 or 450 
mg/kg bw/day 
Maternal LOAEL:  50 
Foetal NOAEL: 450 
(Navarro et al., 1991) Study considered valid.  
Developmental toxicity:  
Gestation days 7 - 14 
Mouse; F 
33 
Gavage 0 or 300 mg/kg/day Not possible to derive a NOAEL1 (Booth et al., 1983; 
Plasterer et al., 1985) 
Only one dosage.  No assessment of visceral or 
skeletal foetal development.  
Developmental toxicity:  
Gestation Days 6 - 18 
Rabbit; F 
18 
Gavage 0, 40, 200 or 400 
mg/kg bw/day 
Maternal: Not determined  
Foetal: 400 
(Naismith & Matthews, 
1986) 
Study is considered valid, although only code 
number is given as identity of test substance.  
Developmental toxicity:  
Gestation days 6 - 19 
Rabbit; F 
25 - 27 
Gavage 0, 20, 80 or 120 
mg/kg bw/day 
Maternal: 120  
Foetal: 120 
(Navarro et al., 1992) Study considered valid.  
1NOEL not determined; only a single dose level was tested.  Naphthalene decreased the number of surviving dams, maternal body weight, number of live pups and litter weights, but not the weight per pup.  However, it was concluded by the authors 
that maternal toxicity would manifest before high levels of developmental toxicity would occur.  
2Test substance was beta-myrcene.  
3Study performed using a dose of 10 mg/kg body weight per day of Galbelica, which is a solution composed of 80 % beta-pinene and 20 % 1,3,5-undecatriene. 
4Test substance was 78 % pure. 
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In vitro mutagenicity/genotoxicity data are available for six candidate substances of the present flavouring group evaluation, for 11 supporting substances 
evaluated by the JECFA at the 63rd meeting and for two separate stereoisomers and for one structurally related non-Register substance (2-Methylbuta-1,3-
diene). Supporting substances are listed in brackets. 
Table IV.4: GENOTOXICITY (in vitro) 
Chemical Name [FL-no]  Test System Test Object  Concentration Result  Reference  Comments 
Cedrene washed6 
[CAS no 11028-42-5] 
Ames test S. typhimurium  
TA97, TA98; TA100; TA1535; TA102 
8-50004 Negative1 (Gocke, 1999b) Validity cannot be evaluated as substance is not 
specified. 
Cedarwood oil terpenes and tertonoids. 
Ames test S. typhimurium  
TA97, TA98; TA100; TA1535; TA102 
1.6-10005 Negative1 (Gocke, 1999b) Validity cannot be evaluated as substance is not 
specified. 
Cedarwood oil terpenes and tertonoids. 
Longifolene [1.047] Ames test S. typhimurium  
TA98; TA100; TA1535; TA1537, 
TA102 
1-5000 Negative1 (Sokolowski, 2001)  
Dodecane [01.038] Ames test S. typhimurium  
TA98; TA100 
NR Negative1 (Tummey et al., 1992) 
 
Only part of abstract available. Validity of the study 
cannot be evaluated due to insufficient report of 
experimental details and results. 
Mammalian cell gene mutation test 
(mouse lymphoma assay) 
Mouse lymphocytes NR Negative1 (Tummey et al., 1992) 
 
Only part of abstract available. Validity of the study 
cannot be evaluated due to insufficient report of 
experimental details and results. 
Mammalian cell gene mutation test V79 Chinese hamster ovary cells 0.12 mM (20 µg/ml) Negative3 (Lankas et al., 1978) 
 
Published non-GLP study. Some important details of 
study design and results are not reported. Thus, the 
validity of the study cannot be evaluated. Study 
designed to evaluate the ability of various alkanes to 
enhance the mutagenicity induced by the chemical 
carcinogen methylazoxymethanol acetate. Dodecane 
showed no mutagenic activity per se, but increased 
the mutagenesis induced by pretreatment with the 
carcinogen. 
Tetradecane [01.057] Ames test S. typhimurium  
TA98; TA100; TA1535; TA1537; 
TA1538 
50, 150, 500, 1500, 5000 
µg/plate 
Negative1 (PETRESA, 19??a) 
 
(Study carried out by Huntingdon Research Centre, 
Report PEQ 5C/85914, sponsored by PETRESA; 
year not indicated). 
Unpublished GLP-study carried out in accordance 
with OECD guideline 471 as stated in the IUCLID 
datasheet submitted. IUCLID abstract available only. 
Validity of the study cannot be evaluated. 
Mammalian cell gene mutation test V79 Chinese hamster ovary cells 0.12 mM (23 µg/ml) Negative3 (Lankas et al., 1978) 
 
Published non-GLP study. Some important details of 
study design and results are not reported. Thus, the 
validity of the study cannot be evaluated. Study 
designed to evaluate the ability of various alkanes to 
enhance the mutagenicity induced by the chemical 
carcinogen methylazoxymethanol acetate. 
Tetradecane showed no mutagenic activity per se, 
but increased the mutagenesis induced by 
pretreatment with the carcinogen.  
Ames test  
(preincubation method) 
S. typhimurium  
TA98; TA100; UTH8414; UTH8413 
0, 50, 100, 500, 1000, 
2000 µg/plate 
Negative1 (Conner et al., 1985)  
 
Published non-GLP study with insufficient report of 
some details of method and results. Thus, the validity 
of the study cannot be evaluated. Cytotoxicity not 
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Table IV.4: GENOTOXICITY (in vitro) 
Chemical Name [FL-no]  Test System Test Object  Concentration Result  Reference  Comments 
reported. 
Dodec-1-ene [01.037] Ames test S. typhimurium  
TA98; TA100; TA1535; TA1537; 
TA1538  
E. coli WP2uvrA 
0.2 to 2000 µg/plate Negative1 (Dean, 1980) 
 
Unpublished GLP-study. IUCLID abstract available 
only. Details of study design and results are not 
reported. Thus, the validity of the study cannot be 
evaluated. 
(2-Methylbuta-1,3-diene) Ames test S. typhimurium  
TA98; TA100; TA1530; TA1535; 
TA1538 
25% atmosphere 
concentration 
Negative1 (De Meester et al., 1981) 
 
Published non-GLP study not in accordance with 
OECD guideline 471. Part of a larger study 
evaluating the effects of various experimental 
conditions (different liver cell preparations and 
concentrations) on the mutagenic activity of 
butadiene, hexachlorobutadiene and isoprene. Some 
important details of study design and results are not 
reported. Thus, the validity of the study cannot be 
evaluated. Plates were exposed to a 25 % 2-
methylbuta-1,3-diene atmosphere for 24 hours.  
Ames test 
(preincubation method) 
S. typhimurium   
TA98; TA100; TA1535; TA1537 
0, 100, 333, 1000, 3333, 
10000 µg/plate 
Negative1 (Mortelmans et al., 1986) 
(NTP, 1999d) 
Published summary report including detailed results 
from studies on 270 compounds tested in various 
laboratories within the NTP to a large extent in 
accordance with OECD guideline 471. 
Ames test S. typhimurium   
TA102; TA104 
NR Negative (Kushi et al., 1985) 
 
Published abstract only, of which part of the text 
including results is missing. No information on the 
use of a metabolic activation system. Validity of the 
study cannot be evaluated. 
Ames test 
(preincubation method) 
S. typhimurium  
TA98; TA100; TA1535 
E. coli WP2uvrA/pKM101 
0, 500, 1000, 2000, 5000 
μg/plate 
Negative1 (Madhusree et al., 2002) Published non-GLP study with limited report of 
experimental details and results. Thus, the validity of 
the study cannot be evaluated. 
Sister chromatid exchange test Chinese hamster ovary cells 0, 50, 160, 500, 1600 
μg/ml (-S9)  
0, 160, 500, 1600, 5000 
μg/ml (+S9). 
Negative1 (NTP, 1999d; Galloway et al., 
1987a) 
Published summary report including detailed results 
from studies on 108 chemicals tested within the NTP 
to a large extent in accordance with OECD guideline 
479. 
Chromosomal aberration assay Chinese hamster ovary cells 0, 1600, 3000, 5000 
μg/ml 
Negative1 (NTP, 1999d; Galloway et al., 
1987a) 
 
Published summary report including detailed results 
from studies on 108 chemicals tested within the NTP 
to a large extent in accordance with OECD guideline 
473. 
(Myrcene [01.008]) Chromosomal aberration assay Human lymphocytes 100 - 1000 µg/ml Negative1 (Kauderer et al., 1991) 
 
Abstracted by JECFA at their 63rd meeting (JECFA, 
2006a). 
Mammalian cell gene mutation 
assay 
Chinese hamster ovary V79 cells 100 - 1000 µg/ml Negative1 (Kauderer et al., 1991) 
 
Abstracted by JECFA at their 63rd meeting (JECFA, 
2006a). 
Sister chromatid exchange test Human lymphocytes 100 - 1000 µg/ml Negative1 (Kauderer et al., 1991) 
 
Abstracted by JECFA at their 63rd meeting (JECFA, 
2006a). 
Sister chromatid exchange test Chinese hamster ovary cells and hepatic 
tumour cell line 
100 - 500 µg/ml Negative1 (Röscheisen et al., 1991) 
 
Abstracted by JECFA at their 63rd meeting (JECFA, 
2006a). 
Ames test 
(plate incorporation method) 
S. typhimurium TA97a ; TA98; TA100; 
TA1535 
Up to 1500 µg/plate 
(16 concentrations) 
Negative (Gomes-Carneiro et al., 2005a) Valid studies which were carried out with a selection 
of 6 of the concentrations mentioned. In the first run, 
concentrations up to cytotoxicity were studied; in a 
second run only non-toxic concentrations were 
tested. 
Ames S. typhimurium TA97; TA98; TA100; 10 – 10 000 µg/plate Negative1 (NTP, 2010b)  
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Table IV.4: GENOTOXICITY (in vitro) 
Chemical Name [FL-no]  Test System Test Object  Concentration Result  Reference  Comments 
TA1535 
Reverse mutation E. coli WP2uvrA/pKM101 50 – 10 000 µg/plate Negative1 (NTP, 2010b)  
Ames S. typhimurium TA97a; TA98; TA100; 
TA1535 
10 - 5000 Negative1 (Gomes-Carneiro et al., 2005a)  
Ames S. typhimurium TA97a; TA98; TA100; 
TA1535 
1 - 1500 Negative1 (Gomes-Carneiro et al., 2005a)  
(d-Limonene [01.045]) Ames test 
(preincubation method) 
S. typhimurium  
TA98; TA100; TA1535; TA1537 
0.03, 0.3, 3, 30 µM/plate 
(4.1, 41, 410, 4100 
µg/plate) 
Negative1 (Florin et al., 1980) 
 
Abstracted by JECFA at their 63rd meeting (JECFA, 
2006a). 
Ames test S. typhimurium  
TA98; TA100; TA1535; TA1537; 
TA1538 
Up to 150,000 µg/plate Negative1 (Heck et al., 1989) Abstracted by JECFA at their 63rd meeting (JECFA, 
2006a). 
Ames test S. typhimurium TA102 Up to 5000 µg/plate Negative2 (Müller et al., 1993) Abstracted by JECFA at their 63rd meeting (JECFA, 
2006a). 
Ames test S. typhimurium TA98; TA100; TA1535; 
TA1537 
Up to 3333 µg/plate Negative1 (Haworth et al., 1983) Abstracted by JECFA at their 63rd meeting (JECFA, 
2006a). 
Ames test 
(preincubation method)  
S. typhimurium   
TA98; TA100, UTH8413 and UTH8414 
0, 10 to 500 µg/plate  
(5 concentrations) 
Negative1 (Conner et al., 1985) Abstracted by JECFA at their 63rd meeting (JECFA, 
2006a). 
Forward mutation assay L5178Y Mouse  
lymphoma 
Up to 100 µg/ml Negative1 (Heck et al., 1989) Abstracted by JECFA at their 63rd meeting (JECFA, 
2006a). 
Forward mutation assay L5178Y Mouse Lymphoma Up to 100 µg /ml  Negative1 (Myhr et al., 1990) Abstracted by JECFA at their 63rd meeting (JECFA, 
2006a). 
Chromosomal aberration assay Chinese hamster  
ovary cells 
Up to 500 µg/ml Negative1 (Anderson et al., 1990) Abstracted by JECFA at their 63rd meeting (JECFA, 
2006a). 
Sister chromatid exchange test Chinese hamster ovary cells Up to 162 µg/ml Negative1 (Anderson et al., 1990) Abstracted by JECFA at their 63rd meeting (JECFA, 
2006a). 
Sister chromatid exchange test Chinese hamster ovary cells 10 - 333 µmol/ml 
(1.4 - 45.4 µg/ml). 
Negative (Sasaki et al., 1989) Abstracted by JECFA at their 63rd meeting (JECFA, 
2006a). 
(gamma-Terpinene [01.020]) Ames test S. typhimurium TA98; TA100; TA1535; 
TA1537; TA1538 
Up to 50,000 µg/plate Negative1 (Heck et al., 1989) Abstracted by JECFA at their 63rd meeting (JECFA, 
2006a). 
Unscheduled DNA synthesis Rat hepatocytes Up to 30 µg/ml Negative (Heck et al., 1989) Abstracted by JECFA at their 63rd meeting (JECFA, 
2006a). 
(alpha-Terpinene [01.019]) Ames test 
(plate incorporation method) 
S. typhimurium TA97a ; TA98; TA100; 
TA1535 
Up to 1500 µg/plate 
(13 concentrations) 
Negative (Gomes-Carneiro et al., 2005a) Valid studies which were carried out with a selection 
of 6 of the the concentrations mentioned. In the first 
run concentrations up to cytotoxicity were studied; in 
a second run only non-toxic concentrations were 
tested. 
(alpha–Phellandrene [01.006]) Sister chromatid exchange test Chinese hamster ovary cells Up to 1000 µM (136.2 
µg/ml) 
Negative3 (Sasaki et al., 1989) Abstracted by JECFA at their 63rd meeting (JECFA, 
2006a). 
(delta-3-Carene [01.029])  Ames test 
(plate incorporation method) 
S. typhimurium TA98; TA100; TA102 Up to 5 µl/plate  
(up to 4300 µg/plate; 5 
concentrations) 
Positive3 
Negative2 
(Kurttio et al., 1990) Published non-GLP study with insufficiently 
reported results. Limited validity. Positive without 
metabolic activation in TA100 and TA102 and at 
doses of 2.5 μl/plate and higher. 
(Pin-2(3)-ene [01.004]) 
 
 
Ames test S. typhimurium  
TA98; TA100 
Up to 100 µl/plate 
(Up to 85,800 µg/ plate) 
Negative2 (Rockwell and Raw, 1979) Abstracted by JECFA at their 63rd meeting (JECFA, 
2006a). 
Ames test S. typhimurium TA98; TA100; TA1535; 
TA1537 
0.03, 0.3, 3, 30 µM/plate  
(4.1, 41, 410, 4100 µg/ 
plate) 
Negative1 (Florin et al., 1980) Abstracted by JECFA at their 63rd meeting (JECFA, 
2006a). 
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Table IV.4: GENOTOXICITY (in vitro) 
Chemical Name [FL-no]  Test System Test Object  Concentration Result  Reference  Comments 
Ames test S. typhimurium TA98; TA100; TA1535; 
TA1537; TA1538 
Up to 25000 µg/plate Negative1 (Heck et al., 1989) Abstracted by JECFA at their 63rd meeting (JECFA, 
2006a). 
Ames test S. typhimurium TA98; TA100; TA1535; 
TA1537; TA1538 
Up to 25 µl/plate 
(Up to 21,450 µg/ plate) 
Negative1 (Jagannath, 1984) Abstracted by JECFA at their 63rd meeting (JECFA, 
2006a). 
Ames test S. typhimurium TA98; TA100; 
UTH8413; UTH8414 
0, 10 to 500 µg/plate  
(5 concentrations) 
Negative1 (Conner et al., 1985) Abstracted by JECFA at their 63rd meeting (JECFA, 
2006a). 
Unscheduled DNA synthesis Rat hepatocytes Up to 10000 µg/ml Negative (Heck et al., 1989) Abstracted by JECFA at their 63rd meeting (JECFA, 
2006a). 
(+)-alpha-pinene (pin-2(3)-ene) 
(isomer of [01.004]) 
Ames test 
(plate incorporation method) 
S. typhimurium TA97a ; TA98; TA100; 
TA1535 
Up to 1000 µg/plate 
(18 concentrations) 
Negative (Gomes-Carneiro et al., 2005a) Valid studies. 
(-)-alpha-pinene (pin-2(3)-ene) 
(isomer of [01.004]) 
Ames test 
(plate incorporation method) 
S. typhimurium TA97a ; TA98; TA100; 
TA1535 
Up to 4000 µg/plate 
(19 concentrations) 
Negative (Gomes-Carneiro et al., 2005a) Valid studies. 
(Pin-2(10)-ene [01.003]) Ames test S. typhimurium TA98; TA100; TA1535; 
TA1537; TA1538 
Up to 5000 µg/plate Negative1 (Heck et al., 1989) Abstracted by JECFA at their 63rd meeting (JECFA, 
2006a). 
Ames test 
(preincubation method) 
S. typhimurium  
TA98; TA100; TA1535; TA1537 
0.03, 0.3, 3, 30 µM/plate  
(4.1, 41, 410, 4100 
µg/plate) 
Negative1 (Florin et al., 1980) Abstracted by JECFA at their 63rd meeting (JECFA, 
2006a). 
Ames test S. typhimurium TA98; TA100; TA1535; 
TA1537; TA1538 
5 µl/plate  
(4290 µg/plate) 
Negative1 (DeGraff, 1983a) Abstracted by JECFA at their 63rd meeting (JECFA, 
2006a). 
Sister chromatid exchange Chinese hamster ovary cells Up to 1000 µM (136.2 
µg/ml) 
Negative (Sasaki et al., 1989) Abstracted by JECFA at their 63rd meeting (JECFA, 
2006a). 
(Camphene [01.009]) Ames test S. typhimurium  
TA98; TA100 
0.05 - 100 µl/plate  
(42.1 - 84,500 µg/ plate) 
Negative2 (Rockwell and Raw, 1979) Abstracted by JECFA at their 63rd meeting (JECFA, 
2006a). 
Ames test S. typhimurium TA98; TA100; 
UTH8414; UTH8413 
0, 10 to 1000 µg/plate (5 
concentrations) 
Negative1 (Conner et al., 1985) Abstracted by JECFA at their 63rd meeting (JECFA, 
2006a). 
Sister chromatid exchange test Chinese hamster ovary cells 10 - 1000 µM  
(1.4 - 136.2 µg/ml) 
Negative3 (Sasaki et al., 1989) Abstracted by JECFA at their 63rd meeting (JECFA, 
2006a). 
(beta–Caryophyllene [01.007]) Ames test S. typhimurium TA98; TA100; TA1535; 
TA1537; TA1538 
Up to 150,000 µg/plate Negative1 (Heck et al., 1989) Abstracted by JECFA at their 63rd meeting (JECFA, 
2006a). 
Ames test S. typhimurium TA98; TA100; TA1535; 
TA1537; TA1538 
0.1 - 150 µl/plate 
(90.4 – 135 525 µg/plate) 
Negative1 (Lorillard, 1984) Abstracted by JECFA at their 63rd meeting (JECFA, 
2006a). 
Ames test  
(plate incorporation method) 
S. typhimurium TA98; TA100; TA102; 
TA1535; TA1537 
Up to 10,000 µg/plate Negative1 (NTP, 2010b) Abstracted by JECFA at their 63rd meeting (JECFA, 
2006a). 
Sister chromatid exchange test Chinese hamster ovary cells 10 - 1000 µM  
(2.0 - 204.4 µg/ml) 
Negative (Sasaki et al., 1989) Abstracted by JECFA at their 63rd meeting (JECFA, 
2006a). 
Naphthalene [01.053] Ames test 
(preincubation method) 
S. typhimurium  
TA98; TA100; TA1535; TA1537 
0.03, 0.3, 3, 30 µM/plate 
(3.9, 39, 385, 3850 
g/plate) 
Negative1 (Florin et al., 1980) Published non-GLP study. Part of a larger 
mutagenicity screening study evaluating 239 
compounds. Due to the limited report of 
experimental details and results the validity of the 
study cannot be evaluated. Cytotoxicity observed at 
doses >3 µM/plate.  
Ames test  
(plate incorporation method) 
S. typhimurium  
TA98; TA100; TA1535; TA1537; 
TA1538 
0, 3, 10, 30, 100, 300 
µg/plate 
Negative1 (Godek et al., 1985) Unpublished GLP study carried out according to 
OECD guideline 471. 
Ames test  
(plate incorporation method) 
S. typhimurium  
TA98; TA100; TA1535; TA1537; 
TA1538 
0, 3, 10, 30, 100, 300 
µg/plate 
Negative1 (Stankowski, 1987) Unpublished GLP study carried out according to 
OECD guideline 471. Repeat confirmation of Ames 
test by Godek et al, 1985. 
Ames test  S. typhimurium  0, 1, 2 mM (0, 128, 256 Negative2 (Kaden et al., 1979) Published non-GLP study of limited validity (only 
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Table IV.4: GENOTOXICITY (in vitro) 
Chemical Name [FL-no]  Test System Test Object  Concentration Result  Reference  Comments 
(preincubation method) TM677 µg/ml) one strain, concentrations used were cytotoxic, 
insufficient report of experimental details and 
results). 
Ames test  
(plate incorporation method) 
S. typhimurium  
TA98; TA100; TA1535; TA1537 
Up to 100 µg/plate Negative2 (McCann et al., 1975) Published summary report of a large study evaluating 
the mutagenic potential of 300 chemicals. Due to the 
limited report of experimental details and results the 
validity of the study cannot be evaluated. 
Ames test  
(preincubation method) 
S. typhimurium  
TA98; TA100; TA1535; TA1537 
0, (0.3), 1, 3.3, 10, 33, 
100 µg/plate 
Negative1 (Mortelmans et al., 1986)  
(NTP, 1992g) 
Published summary report including detailed results 
from studies on 270 compounds tested in various 
laboratories within the NTP to a large extent in 
accordance with OECD guideline 471. Study design 
and detailed results on naphthalene also included in 
NTP, 1992g. In the absence of metabolic activation 
the concentration of 100 microgram/plate was 
completely toxic and not tested any more in the 
second trial when 0.3 microgram/plate was used as 
additional concentration. In the presence of 
metabolic activation the highest concentration was 
slightly toxic. 
Ames test  
(plate incorporation method) 
S. typhimurium  
TA98; TA100; TA1535; TA1537; 
TA1538 
0, 5, 10, 25, 50, 100, 300 
µg/plate (-S9) 
0, 10, 25, 50, 100, 300, 
900 µg/plate (+ S9) 
Negative1 (Lawlor, 1994) Unpublished GLP study carried out in accordance 
with OECD guideline 471. Cytotoxicity was 
observed in a preliminary study at 66.7 
microgram/plate and above in the absence of S9 mix 
and at 333 microgram/plate and above in the 
presence of S9 mix. 
Ames test  
(preincubation method) 
S. typhimurium  
TA98; TA100; UTH8414; UTH8413 
0, 100, 500, 1000, 2000 
µg/plate 
Negative1 (Conner et al., 1985) Published non-GLP study with insufficient report of 
some details of method and results. Thus, the validity 
of the study cannot be evaluated. Cytotoxicity not 
reported. 
Ames test  
(plate incorporation method) 
S. typhimurium  
TA97; TA98; TA100 
0, 5, 10, 50, 250 µg/plate Negative1 (Sakai et al., 1985) Published non-GLP study of acceptable quality. 
Cytotoxicity was observed at the highest 
concentration with complete toxicity in TA97 (+/-S9) 
and in TA100 (-S9) and a reduced number of mutants 
in TA100 (+S9) and in TA98 (+/-S9). 
Ames test  
(plate incorporation) 
S. typhimurium 
TA98; TA100; TA1535; TA1537; 
TA1538 
0, 3.3 to 10,000 µg/plate  Negative1 (Longfellow, 1991) Only summary from CCRIS database available. 
Validity of the study cannot be evaluated. 
Ames test  
(preincubation method) 
S. typhimurium  
TA98; TA100; TA1535; TA1537  
E. coli WP2uvrA 
1 to 100 µg/plate 
 
10 to 10,000 μg/plate 
Negative1 (Japan Chemical Industry) Only summary from CCRIS database available. 
Validity of the study cannot be evaluated. 
Rec assay E. coli  
WP2 and WP100 uvrA- recA- 
0 to 2000 µg/plate 
(≥ 4 concentrations) 
Negative2 (Mamber et al., 1984) Published non-GLP study with adequate study 
design, however, deficient in the report of some 
details on method and results (no single doses, no 
detailed results, no data on cytotoxicity reported). 
Inductest  
(prophage induction test) 
E. coli  
GY5027 envA- uvrB- (λ ); GY4015 ampR 
0 to 2000 µg/plate 
(≥ 4 concentrations) 
Negative2 (Mamber et al., 1984) Published non-GLP study with adequate study 
design, however, deficient in the report of some 
details on method and results (no single doses, no 
detailed results, no data on cytotoxicity reported). 
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Table IV.4: GENOTOXICITY (in vitro) 
Chemical Name [FL-no]  Test System Test Object  Concentration Result  Reference  Comments 
Unscheduled DNA synthesis test Primary rat hepatocytes 0, 0.16, 0.5, 1.6, 5, 16, 50, 
166, 500, 1666, 5000 
µg/ml 
Negative (Barfknecht et al., 1985) Unpublished GLP-study according to OECD 
guideline 482. Excessive cytotoxicity observed at 50 
to 5000 microgram/ml. 
Sister chromatid exchange test Chinese hamster ovary cells 0, 2.7, 9, 27, 45, 90 µg/ml 
(-S9) 
0, 9. 15, 27, 90 µg/ml 
(+S9) 
Positive1 (NTP, 1992g) Valid study in accordance with OECD guideline 479. 
No data on cytotoxicity reported. According to the 
study protocol the highest dose chosen was limited 
by cytotoxicity. 
Significant dose-related increase in frequency of 
SCE at concentrations from 27 - 90 µg/ml (without 
metabolic activation) and 15 - 27 µg/ml (with 
metabolic activation). Maximum values for the 
percent increase in SCEs/chromosome in cultures 
exposed to naphthalene relative to those exposed to 
solvent of 40 and 50 % were reached at the highest 
dose tested in the presence and absence of S9, 
respectively, whereas values of 360 - 640 % were 
reached with the positive control mitomycin C. 
Result is considered positive by NTP since the 
increase over solvent control observed is ≥ 20 % 
(NTP, 1992g; Galloway et al., 1987a). 
Results would be considered negative by UK HSE as 
the increase in SCEs per cell does not reach the 
required minimum of at least 100 %)(EU RAR, 
2003). 
Sister chromatid exchange test Human peripheral mononuclear 
leukocytes 
100 µM 
(13 µg/ml) 
Negative1 (Tingle et al., 1993; Wilson et 
al., 1995) 
Published non-GLP study of limited validity (only 
one concentration tested). Naphthalene was not 
cytotoxic to the dividing lymphocytes with and 
without metabolic activation at the concentration 
tested. 
Mammalian cell gene mutation test 
(Mouse lymphoma assay) 
Mouse lymphocytes L5178Y tk+/tk- 0, 22 to 87 µg/ml (-S9) 
0, 8 to 30 μg/ml (+S9) 
Negative3
Positive2 
(Longfellow, 1991) Only summary from CCRIS database available. 
Validity of the study cannot be evaluated. 
Chromosomal aberration assay Chinese hamster ovary cells 15 to 75 µg/ml (-S9) 
30 to 67.5 µg/ml (+S9) 
Negative3 
Positive2 
(NTP, 1992g) Study carried out in accordance with OECD 
guideline 473, except that data on cytotoxicity are 
not reported. According to the study protocol the 
highest dose chosen was limited by cytotoxicity. 
Study is considered valid. The structural aberrations 
did not include gaps. In the presence of S9 the 
percent of cells with structural aberrations was 
significantly (p ≤ 0.05) elevated at all concentrations 
tested compared to controls and the increase was 
significantly dose-related (p≤0.001). A maximum of 
32 % of cells with aberrations was reached at the 
highest concentration vs. 0 - 1.5 % in negative and 
up to 52 % in positive controls. Result is considered 
positive by NTP since a statistically significant 
difference is observed for two or more doses 
(Galloway et al., 1987a). 
(1-Methylnaphthalene [01.014]) Ames test 
(preincubation method) 
S. typhimurium  
TA98; TA100; TA1535; TA1537 
0.03, 0.3, 3, 30 µM/plate 
(4.3, 43, 427, 4266 
Negative1 (Florin et al., 1980) Abstracted by JECFA at their 63rd meeting (JECFA, 
2006a). 
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Table IV.4: GENOTOXICITY (in vitro) 
Chemical Name [FL-no]  Test System Test Object  Concentration Result  Reference  Comments 
μ g/plate) 
Ames test  
(preincubation method) 
S. typhimurium  
TM677 
0, 0.7, 3.5, 7 mM (0, 498, 
995 µg/ml) 
Negative2 (Kaden et al., 1979)  
Chromosomal aberration assay Human lymphocytes 0, 1, 2 mM (0, 142, 284 
µg/ml) (-S9) 
 
0, 0.25, 0.5, 1, 2 mM (0, 
36, 71, 142, 284 μg/ml) 
(+S9) 
Negative1 (Kulka et al., 1988) Published non-GLP study largely in accordance with 
OECD guideline 473. Even if cytotoxicity data are 
not reported, the study is considered acceptable. The 
highest dose did not impair cell proliferation. No 
evidence for differences in the incidences of 
structural chromosomal aberrations (chromatid 
breaks, no exchanges seen) and gaps between treated 
and untreated cells (p ≤ 0.05). 0.5 to 2.0 % of treated 
cells showed aberrations (gaps excluded) vs. 1 % of 
control cells. 
Sister chromatid exchange test Human lymphocytes 0, 1, 2 mM (0, 142, 284 
µg/ml) (-S9) 
 
0, 0.25, 0.5, 1, 2 mM (0, 
36, 71, 142, 284 μg/ml) 
(+S9) 
Negative3 
 
Positive2 
(limited 
evidence) 
(Kulka et al., 1988) Published non-GLP study largely in accordance with 
OECD guideline 479. Cytotoxicity data not reported. 
The highest dose did not impair cell proliferation. In 
the presence of S9 the SCE frequency was 
significantly increased at each dose. An increase of 
43 % was reported at the highest dose compared to 
the control. The effect was dose-related, but with a 
less marked increase at higher doses (saturation). 
According to OECD and NTP criteria the result in 
the presence of S9 is considered positive (significant 
increase, dose-relation, increase ≥ 20 % over solvent 
control). The authors of the study refer to the UK 
HSE guidelines on mutagenicity testing that require 
at least a doubling in SCE frequency for a positive 
response. 
2-Methylnaphthalene [01.051] Ames test 
(preincubation method) 
S. typhimurium  
TA98; TA100; TA1535; TA1537 
0.03, 0.3, 3, 30 µM/plate 
(4.3, 43, 427, 4266 
µg/plate) 
Negative1 (Florin et al., 1980) Published non-GLP study. Part of a larger 
mutagenicity screening study evaluating 239 
compounds. Due to the limited report of 
experimental details and results the validity of the 
study cannot be evaluated. Bacterial toxicity 
observed at doses >3 µM/plate. 
Chromosomal aberration assay Human lymphocytes 0, 2.0, 4.0 mM (0, 284, 
569 microgram/ml) (-S9) 
 
0, 0.25, 0.5, 1.0, 2.0, 4.0 
mM (0, 35.6, 71.1, 142, 
284 and 569 
microgram/ml) (+S9) 
Negative3 
 
 
Positive2 
(limited 
evidence) 
(Kulka et al., 1988) Published non-GLP study largely in accordance with 
OECD guideline 473. Even if cytotoxicity data are 
not reported, the study is considered acceptable. The 
highest dose did not impair cell proliferation. In the 
presence of S9 a statistically significant but weak 
increase (6.5 fold above control) of structural 
aberrations (chromatid breaks, no exchanges seen) 
was observed at the highest tolerated dose (4 mM). 
The percent of cells with structural aberrations 
(excluding gaps) showed a dose-related increase (up 
to 5 % vs. 1.0 % in negative and 40 % in positive 
controls), however, the increase was not reported as 
statistically significant. A dose-dependent weak 
increase of gaps was also noted over the 
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Table IV.4: GENOTOXICITY (in vitro) 
Chemical Name [FL-no]  Test System Test Object  Concentration Result  Reference  Comments 
concentration range tested in the presence of S9. 
According to OECD and NTP criteria there is a weak 
evidence for a positive response since a statistically 
significant difference for structural aberrations per 
cell is observed for one dose (NTP, 1992g; 
(Galloway et al., 1987a) and the effect was dose-
related (OECD guideline 473). 
Sister chromatid exchange test Human lymphocytes 0, 2.0, 4.0 mM (0, 284, 
569 microgram/ml) (-S9) 
 
0, 0.25, 0.5, 1.0, 2.0, 4.0 
mM (0, 36, 71, 142, 284 
and 569 microgram/ml) 
(+S9) 
Negative3 
 
 
Positive2 
(limited 
evidence) 
(Kulka et al., 1988) Published non-GLP study largely in accordance with 
OECD guideline 479. Even if cytotoxicity data are 
not reported, the study is considered acceptable. The 
highest dose did not impair cell proliferation. In the 
presence of S9 the SCE frequency was significantly 
increased at each dose. An increase of 80 % was 
reported at the highest dose compared to the control. 
The effect was dose-related. 
According to OECD and NTP criteria the result in 
the presence of S9 is considered positive (significant 
increase, dose-relation, increase ≥ 20 % over solvent 
control). The authors of the study refer to the UK 
HSE guidelines on mutagenicity testing that require 
at least a doubling in SCE frequency for a positive 
response. 
NR: Not Reported. 
1 With and without S9 metabolic activation.  
2 With metabolic activation. 
3 Without metabolic activation. 
4 Plate incorporation. 
5 Pre-incubation.. 
6 An Ames test with cedrene washed (unspecified cedrene) was also submitted, but an adequate identification of the substance studied was not possible. Therefore the study is not further discussed. 
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In vivo mutagenicity/genotoxicity data are available for one candidate substance of the present flavouring group evaluation, for two supporting substances 
evaluated by JECFA at the 63rd meeting and for one structurally related non-Register substance (2-Methylbuta-1,3-diene). Supporting substances are listed in 
brackets. 
Table IV.5: GENOTOXICITY (in vivo) 
Chemical Name [FL-no]  Test System Test Object  Route Dose Result  Reference  Comments 
(2-Methylbuta-1,3-diene) In vivo Chromosomal 
aberration assay 
Mouse (B6C3F1) 
bone marrow 
(male mice) 
Inhalation 0, 438, 1750, 7000 ppm for 6 
hours/day for 12 exposures over a 
period of 16 days (Trial 1) 
 
0, 70, 220, 700 ppm for 6 
hours/day for 12 exposures over a 
period of 16 days (Trial 2) 
Negativ
e 
(Tice et al., 1987; Tice, 
1988; Shelby, 1990) 
Unpublished study report and published summary report of a valid 
multiple endpoint cytogenicity study sponsered by NTP, roughly in 
accordance with OECD guideline 475 (special dosage regimen used). 
In vivo Sister chromatid 
exchange test 
Mouse (B6C3F1) 
bone marrow 
(male mice) 
Inhalation 0, 438, 1750, 7000 ppm for 6 
hours/day for 12 exposures over a 
period of 16 days (Trial 1) 
 
0, 70, 220, 700 ppm for 6 
hours/day for 12 exposures over a 
period of 16 days (Trial 2) 
Positive 
 
(Tice et al., 1987; Tice, 
1988; Shelby, 1990) 
Unpublished study report and published summary report of valid 
cytogenicity study sponsered by NTP. The study is considered valid. 
Significant (0.01 <p <0.05) increase in the frequency of SCE in the 
bone marrow cells at all concentrations. In addition, a significant 
delay in bone marrow cellular proliferation kinetics (lengthening of 
the generation time) was detected. The mitotic index was not 
significantly altered. 
In vivo Micronucleus 
test 
Mouse (B6C3F1) 
peripheral blood cells 
(male mice) 
Inhalation 0, 438, 1750, 7000 ppm for 6 
hours/day for 12 exposures over a 
period of 16 days 
Positive 
 
(Tice et al., 1987; Tice, 
1988) 
Unpublished study report and published summary report of valid 
cytogenicity study sponsored by NTP, roughly in accordance with 
OECD guideline 474 (special dosage regimen used). The study is 
considered valid.  
Significant (p < 0.001) increase in the frequency of micronucleated 
polychromatic and normochromatic erythrocytes, and percentage of 
PCE. A significant (p < 0.001) and dose-dependent decrease in the 
percentage of circulating polychromatic erythrocytes (suppression of 
erythropoiesis) was noted. 
In vivo Micronucleus 
test 
Rat lung fibroblasts 
(male and female 
rats) 
Inhalation 0, 220, 700, 7000 ppm for 13-
weeks 
Negativ
e 
(Khan and Heddle, 
1991) 
Study carried out within NTP. Only tabulated results available from 
NTP TR 486 (NTP, 1999). Unusual study protocol. Validity of the 
study cannot be evaluated.  
(Myrcene [01.008]) In vivo Chromosomal 
aberration assay 
Rat (Wistar) bone 
marrow 
Gavage 0, 100, 500, 1000 mg/kg bw 
(single exposure) 
Negativ
e 
(Zamith et al., 1993) Abstracted by JECFA at their 63rd meeting (JECFA, 2006a). 
In vivo Micronucleus 
test 
Mouse (B6C3F1)  
peripheral blood cells 
Gavage 0, 250, 500, 1000, 2000 mg/kg bw 
(single exposure) 
Negativ
e 
(NTP, 2004h) Abstracted by JECFA at their 63rd meeting (JECFA, 2006a). 
Micronucleus assay  Mouse peripheral 
blood cells  
Gavage 250, 500, 1000 mg/kg bw/ day Negativ
e 
(NTP, 2010b)  
(d-Limonene [01.045]) In vivo Comet assay Mouse (ddY) / Rat 
(Wistar). 
Oral 0, 2000 mg/kg  Negativ
e 
(Sekihashi et al., 2002)  
In vivo Mammalian spot 
test 
Mouse embryos from 
C57BL/6JHan x T 
stocks 
Intraperitoneal 
injection 
215 mg/kg bw  Negativ
e 
(Fahrig, 1984) Abstracted by JECFA at their 63rd meeting (JECFA, 2006a). 
 In vivo Comet assay Rats (Sprague-
Dawley) (males) 
(Kidneys) 
Gavage 0, 1000, 2000 mg/kg bw (single 
exposure) 
Negativ
e 
(Nesslany et al., 2007)  
 In vivo transgenic 
mutagenisity assay 
Rats (Big blue) 
(males) (liver, 
Diet 0, 525 mg/kg bw/day (10 days) Negativ
e 
(Turner et al., 2001) The author do not specify whether the tested compound is d- or l-
limonene, and the purity of the compound is not stated. However, the 
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Table IV.5: GENOTOXICITY (in vivo) 
Chemical Name [FL-no]  Test System Test Object  Route Dose Result  Reference  Comments 
kidney, bladder) stability of the limonene in the diet was measured. 
Naphthalene [01.053] In vivo Unscheduled 
DNA synthesis 
Rat hepatocytes Gavage 0, 600, 1000, 1600 mg/kg bw Negativ
e 
(Research Toxicology 
Center, 1999) 
Summarised report of unpublished study carried out in accordance 
with OECD guideline 486. Although some minor details of the 
results are not reported (viability of cells, individual slide values for 
nuclear grains and cytoplasmic grains) the study is considered valid. 
In vivo Micronucleus 
test 
Mouse (Swiss ICR) 
bone marrow 
Gavage 50, 250, 500 mg/kg bw (single 
exposure) 
Negativ
e 
(Harper et al., 1984) Published non-GLP study not fully in accordance with OECD 
guideline 474 (only males tested, sampling time not indicated, effect 
on PCE/NCE ratio not reported). Due to the limited report of 
experimental details and results the validity of the study cannot be 
evaluated. 
At the dose of 500 mg/kg bw two of 10 animals died. The dose of 
1500 mg/kg bw was toxic (lethal) to all animals. Induction of 
micronuclei in benzene-treated mice was significantly enhanced by 
co-treatment with naphthalene at 50 and 250 mg/kg bw. 
In vivo Micronucleus 
test 
Mouse (CD-1) bone 
marrow 
Intraperitoneal 
injection 
250 mg/kg bw (single exposure) Negativ
e 
(Sorg et al., 1985) Unpublished valid GLP-study carried in accordance with OECD 
guideline 474. Naphthalene was negative in the micronucleus test at 
the dose of 250 mg/kg bw at all of the time intervals tested. A 
harvest-time dependent depression in the PCE/NCE ratio was 
observed in animals treated with the test substance, which was 
statistically significant (p ≤ 0.05) at sacrifice time of 72 hours. 
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 ABBREVIATIONS 
ADI  Acceptable Daily Intake 
ADME  Absorption, Distribution, Metabolism and Excretion 
BW  Body weight 
CAS  Chemical Abstract Service 
CEF  Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids 
CHO  Chinese hamster ovary (cells) 
CoE  Council of Europe 
CPN  Chronic progressive nephropathy 
CYP  Cytochrome P450 
DNA  Deoxyribonucleic acid 
DTU-NFI Danish Technical University – National Food Institute 
EC  European Commission 
EFSA  The European Food Safety Authority 
EPA  United States Environmental Protection Agency  
EU  European Union 
FAO  Food and Agriculture Organization of the United Nations  
FEMA  Flavor and Extract Manufacturers Association 
FGE  Flavouring Group Evaluation  
FLAVIS (FL) Flavour Information System (database) 
GLP  Good laboratory practise 
GSH  Glutahione 
ID  Identity 
IOFI  International Organization of the Flavor Industry 
Ip  Intraperitoneal 
IR  Infrared spectroscopy 
ISS  Istituto Superiore di Sanita 
JECFA  The Joint FAO/WHO Expert Committee on Food Additives 
LOAEL Lowest Observed Adverse Effect Level 
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MC  Methylcholanthrene 
MSDI  Maximised Survey-derived Daily Intake 
mTAMDI Modified Theoretical Added Maximum Daily Intake 
NCE  Normochromatic erythrocyte 
No  Number 
NOAEL No observed adverse effect level 
NTP  National Toxicology Program 
OECD  Organisation for Economic Co-operation and Development 
PB  Phenobarbital 
PCE  Polychromatic erythrocyte 
SCE  Sister chromatic exchange 
SCF  Scientific Committee on Food 
UDS  Unscheduled DNA Synthesis  
US EPA United States Environmental Protection Agency 
WHO  World Health Organisation 
 
 
 
